

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

---

**THIS PAGE BLANK (USPTO)**



REC'D 06 SEP 2000

WIPO

PCT

# Kongeriget Danmark

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Patent application No.: PA 2000 00667

Date of filing: 19 April 2000

Applicant: HemeBiotech A/S  
Roskildevej 12C  
DK-3400 Hillerød

This is to certify the correctness of the following information:

The attached photocopy is a true copy of the following document:

- The specification, claims, abstract, sequence listing and drawings as filed with the application on the filing date indicated above.

Patent- og  
Varemærkestyrelsen  
Erhvervsministeriet

TAASTRUP 24 August 2000

Lizzi Vester  
Head of Section

PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING  
PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC  
DISEASES

5

FIELD OF THE INVENTION

The present invention relates to novel methods of treating and preventing disease caused  
by absence or deficiency of the activity of enzymes belonging to the heme biosynthetic  
10 pathway. More specifically, the invention pertains to methods of alleviating the symptoms  
of certain porphyrias, notably acute intermittent porphyria including gene therapy, therapy  
with a combination of enzymatically active substances and therapy with recombinant  
produced enzymes such as PBGD. In addition the invention relates to an expression  
plasmid and a linear DNA fragment for use in the production of rhPBGD.

15

BACKGROUND OF THE INVENTION

Heme biosynthetic pathway

- 20 Heme is a vital molecule for life in all living higher animal species. Heme is involved in such  
important processes as oxygen transportation (haemoglobin), drug detoxification (cyto-  
chrome P450), and electron transfer for the generation of chemical energy (ATP) during  
oxidative phosphorylation in mitochondria.
- 25 Heme is synthesised in eight consecutive enzymatic steps starting with glycine and succinyl-  
CoA. Sassa S. 1996, Blood Review, 10, 53-58 shows a schematic drawing (Figure 1 in the  
article) of the heme biosynthetic pathway indicating that the first enzymatic step (delta-  
aminolevulinic-synthetase) and the last three steps (coproporphyrinogen oxidase,  
protoporphyrinogen oxidase and ferrochelatase) are located in the mitochondrion whereas,  
30 the remaining are cytosolic enzymes.

Important regulation of the heme biosynthetic pathway is delivered by the end product of  
the metabolic pathway, namely heme, which exerts a negative inhibition on the first rate-  
limiting enzymatic step (conducted by delta-aminolevulinic-synthetase) in the heme  
35 biosynthetic pathway (Strand et al. 1970, Proc. Natl. Acad. Sci. 67, 1315-1320).



Deficiencies in the heme biosynthetic enzymes have been reported leading to a group of diseases collectively called porphyrias.

- 5 A defect in the third enzymatic step leads to acute intermittent porphyria, AIP.

### Acute Intermittent Porphyria

---

Acute intermittent porphyria (AIP) is an autosomal dominant disorder in man caused by a  
 10 defect (50% reduction of activity) of the third enzyme in the heme biosynthetic pathway, porphobilinogen deaminase, (also known as porphobilinogen ammonia-lyase (polymerizing)), E.C. 4.3.1.8. (Waldenström 1937, J. Acta.Med. Scand. Suppl.82). In the following, this enzyme and the recombinant human form will be termed "PBGD" and "rhPBGD", respectively.

15

### Clinical manifestation of AIP

The reduction in enzymatic PBGD activity makes this enzyme the rate limiting step in the heme biosynthetic pathway, with a concomitant increase in urinary and serum levels of  
 20 delta-aminolevulinic acid (ALA) and porphobilinogen (PBG).

The clinical manifestation of AIP involves abdominal pain and a variety of neuropsychiatric and circulatory dysfunctions. As a result of the enzymatic block, heme precursors such as PBG and ALA are excreted in excess amounts in the urine and stool. In acute attacks, high  
 25 levels of PBG and ALA are also found in serum. These precursors are normally undetectable in serum in healthy individuals.

The neuropsychiatric disturbances observed in these patients are thought to be due to interference of the precursors with the nervous system or due to the lack of heme. For  
 30 instance, ALA bears a close resemblance to the inhibitory neurotransmitter 4-aminobutyric acid (GABA) and has been suggested to be a neurotoxin. (Jeans J. et al. 1996, American J. of Medical Genetics. 65, 269-273).

---

Abdominal pain is the most frequent symptom in AIP patients and occurs in more than 90%  
 35 during acute attacks, which will be followed rapidly by the development of peripheral

neuropathy with weakness in proximal muscles, loss of pinprick sensation, and paraesthesia. Tachycardia, obstipation or diarrhoea may also be present.

During acute attacks behavioral changes, confusion, seizures, respiratory paralysis, coma and hallucinations may be present.

5

Hypertension is also associated with AIP, with as high as 40% of patients showing sustained hypertension between attacks. An association between chronic renal failure (Yeung L. et al. 1983, Q J. Med 52, 92-98) and AIP as well as hepatocellular carcinoma. (Lithner F. et al. 1984, Acta.Med.Scand. 215, 271-274), has been reported.

10

The AIP is a lifelong disease, which usually becomes manifest in puberty.

#### Factors precipitating acute attacks.

15 Most precipitating factors exhibit an association with the first rate-limiting enzyme in the heme biosynthetic pathway through heme, the final product of the pathway. A lowering of the heme concentration will immediately increase the rate of ALA-synthetase. An overproduction of ALA then makes the partially deficient PBGD enzyme (50% activity) now rate-limiting with an accumulation of the heme precursors ALA and PBG. Drugs that  
20 induces cytochrome P450 such as barbiturates, estrogens, sulphonamides, progesterone, carbamazepine, and phenytoin can all precipitate acute attacks. (Wetterberg L. 1976, In Doss M. Nowrocki P. eds. Porphyrrias in Human Disease. Reports of the discussion. Matgurg an der Lahn, 191-202).

25 The clinical manifestation is more common in women, especially at time of menstruation. Endocrine factors such as synthetic estrogens and progesterone are known precipitating factors. A significant factor is also the lack of sufficient caloric intake. Hence, caloric supplementation during acute attacks reduces clinical symptoms. (Welland F.H. et al. 1964, Metabolism, 13, 232).

30

Finally, various forms of stress including illness, infections, surgery and alcoholic excess have been shown to lead to precipitation of acute attacks. There are also cases of acute attacks where no precipitating factor can be identified.

#### 35. Prevalence of AIP.

Prevalence of 0.21% has been reported (Tishler P.V. et al. 1985, Am.J.Psychiatry 142,1430-1436), with as high a prevalence as 1 per 1500 in geographic isolates in northern Sweden (Wetterberg L. 1967, Svenska bokförlaget Nordstedt, Stockholm). Prevalence up to 200 per 10,000 inhabitants has been reported from Arjepong in Northern Sweden (Andersson, Christer, Thesis, 1997, ISBN 91/7191/280/0, pp. 22-23).

---

#### Existing treatment of AIP

10 The treatment of AIP as well as of other types of porphyrias such as variegata, hereditary coproporphyria, harderoporphyria, and aminolevulinic acid dehydratase deficiency, are basically the same. Existing therapies for AIP, are all aimed at reducing circulating PBG and ALA by inhibiting the first rate-limiting enzymatic step ALA-synthetase. This inhibition of ALA-synthetase is achieved by increasing circulating heme, since heme is a negative  
15 feed back regulator of ALA-synthetase. Hematin treatment, high caloric intake or inhibition of heme breakdown by Sn-mesoporphyrin administration are the existing therapies today. These therapies have shown limited efficacy.

Treatment between acute attacks involves sufficient caloric intake and avoidance of drugs  
20 and immediate treatment of infections.

Patients that experience acute attacks are treated with intravenous carbohydrates usually dextrose (300 g/day) and intravenous hematin (3 - 8 mg/(kg day)).

25 Treatments with long acting agonistic analogues of LHRH, have been shown to reduce the incidence of pre-menstrual attacks by inhibiting ovulation in AIP patients. Finally, treatments involving heme analogues Sn-mesoporphyrin, which inhibit heme breakdown have also been attempted.

#### 30 Medical need in AIP

---

The lack of effective treatment for AIP is well recognized. In a US mortality study in AIP patients requiring hospitalization it was concluded that the mortality rate was 3.2-fold higher as compared to a matched general population.

Suicide was also a major cause of death, occurring at a rate of 370 times that expected in the general population (Jeans J. et al. 1996, Am. J. of Medical Genetics 65, 269-273).

Hematin therapy is usually initiated when high caloric intake is not sufficient to alleviate acute attacks. Studies with hematin have been performed but these studies generally used the patients as their own control after the patients did not respond to high carbohydrate treatment (Mustajoki et al. 1989, Sem. Hematol. 26, 1-9).

The one controlled study with hematin treatment reported, failed to reach statistical significance due to too small a patient number (Herrick A.L. et al 1989, Lancet 1, 1295-1297).

In conclusion, there is a definite need for the provision of novel therapeutic/prophylactic methods aimed at these diseases.

#### DISCLOSURE OF THE INVENTION

Levels of ALA and PBG found in urine in patients with symptomatic AIP, are in the range of 1-203 mg/day and 4-782 mg/day, respectively. Normal excretion of ALA and PBG is very low (0-4 mg/day). Important is the observation that these patients also have elevated levels of ALA and PBG in serum. It was shown in a study that AIP patients had significantly elevated levels of ALA (96  $\mu$ g %) and PBG (334  $\mu$ g %) in serum in connection with acute attacks and that the severity of the attacks were correlated to high levels of ALA and PBG. Hence, it is important to reduce the circulating levels of ALA and PBG in order to eliminate clinical symptoms and to normalize the heme pool.

The present inventors present a new therapeutic rational in the treatment of AIP, a rationale using PBGD, preferably recombinant human PBGD (rhPBGD), in order to reduce circulating high levels of PBG in serum by metabolizing (by enzymatic conversion) PBG to hydroxymethylbilane (HMB), which is the normal product of the reaction. This substitution therapy will lead to a normalization of PBG in serum as well as to a normalization of the heme pool. It will also lead to a normalization of ALA in serum, since these heme precursors are in equilibrium with each other. A lowering of serum ALA and PBG is expected to result in a concomitant relief of symptoms. The product of the reaction (HMB)

will diffuse back into the cells and enter the normal heme biosynthetic pathway and will become subsequently metabolized to heme.

Alternatively investigations in treating the porphyrias have also suggested gene therapy, thus aiming at introducing genetic material in relevant cells, which will then take over the *in vivo* production of the enzyme of interest.

Hence, PBGD administered by injections will carry out its normal catalytic function by converting PBG to HMB in serum (extracellularly, not inside the cells). The new therapeutic idea is based on the assumption that ALA, PBG and HMB permeate cellular membranes or is transported specifically across them. An alternative to this is to administer a form of PBGD, which will be able to act intracellularly, either as a consequence of formulation or as consequence of modification of PBGD so as to facilitate its entry into cells from the extracellular compartment.

15

The observation that AIP patients have large amounts of these heme precursors in the serum supports the idea that PBG does not accumulate intracellularly, but is released from the cells into serum when the intracellular concentration increases due to the PBGD enzymatic block.

20

The basic new therapeutic concept for AIP is valid for all porphyrias and therefore the invention is in general aimed at treating these diseases by substituting the reduced or missing enzymatic activity characterizing the porphyrias.

25 Hence, in its broadest aspect, the invention pertains to a method for treatment or prophylaxis of disease caused by deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway, the method comprising administering, to the subject, an effective amount of a catalyst which is said enzyme or an enzymatically equivalent part or analogue thereof.

30

Hence, by the term "catalyst" is herein meant either the relevant enzyme which is substituted as it is, or an enzymatically equivalent part or analogue thereof. One example of an enzymatically equivalent part of the enzyme could be a domain or subsequence of the enzyme which includes the necessary catalytic site to enable the domain or

subsequence to exert substantially the same enzymatic activity as the full-length enzyme or alternatively a gene coding for the catalyst.

An example of an enzymatically equivalent analogue of the enzyme could be a fusion

- 5 protein which includes the catalytic site of the enzyme in a functional form, but it can also be a homologous variant of the enzyme derived from another species. Also, completely synthetic molecules that mimic the specific enzymatic activity of the relevant enzyme would also constitute "enzymatic equivalent analogues".
- 

- 10 In essence, the inventive concept is based on the novel idea of substituting the reduced enzymatic activity in the subject simply by administering a catalyst which will "assist" the enzyme which is in deficit. The precise nature, however, of the catalyst is not all-important. What is important is merely that the catalyst can mimic the enzymatic *in vivo* activity of the enzyme.

15

The term "the heme biosynthetic pathway" refers to the well-known enzymatic steps (cf. e.g. Sassa S. 1996, Blood Review, 10, 53-58) which leads from glycine and succinyl-CoA to heme, and enzymes belonging to this synthetic pathway are delta-aminolevulinic acid synthetase, delta-aminolevulinic acid dehydratase, porphobilinogen deaminase,

- 20 uroporphyrinogen III cosynthetase, uroporphyrinogen decarboxylase, coproporphyrinogen oxidase, protoporphyrinogen oxidase and ferrochelatase. Hence, in line with the above, a catalyst used according to the invention is such an enzyme or an enzymatically equivalent part or analogue thereof. It should be noted that the genes encoding all of the above-mentioned enzymes have been sequenced, thus allowing recombinant or synthetic  
25 production thereof.

- The diseases related to reduced activity of these enzymes are acute intermittent porphyria (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary coproporphyrinogen oxidase deficiency (HCP), Acute erythropoietic protoporphyria (AEP), Variegata porphyria (VP), Congenital  
30 erythropoietic porphyria (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP).
- 

- By the term "effective amount" is herein meant a dosage of the catalyst which will supplement the lack or deficiency of enzymatic activity in a subject suffering from porphyria  
35 caused by reduced activity of one of the above-mentioned enzymes. The precise dosage

constituting an effective amount will depend on a number of factors such as serum half-life of the catalyst, specific activity of the catalyst etc. but the skilled person will be able to determine the correct dosage in a given case by means of standard methods (for instance starting out with experiments in a suitable animal model such as with transgenic animals so as to determine the correlation between blood concentration and enzymatic activity).

The disease which is the preferred target for the inventive method is AIP, and therefore the catalyst is PBGD or an enzymatically equivalent part or analogue thereof. It is most preferred that the catalyst is a recombinant form of the enzyme belonging to the heme biosynthetic pathway or of the enzymatically equivalent part or analogue thereof, since recombinant production will allow large-scale production which, with the present means available, does not seem feasible if the enzyme would have to be purified from a native source.

Preferred formulations and dosage forms of the catalyst are exemplified for, but not limited to, PBGD in the detailed description hereinafter, and these formulations also are apparent from the claims. It will be appreciated that these formulations and dosage forms are applicable for all catalysts used according to the invention.

One important embodiment of the method of the inventions is one wherein the catalyst, upon administration, exerts at least part of its enzymatic activity in the intracellular compartment. This can e.g. be achieved when the catalyst is an enzymatically equivalent part or analogue of the enzyme, since such variations of the enzyme can be tailored to render them permeate cell membranes. Hence, when the catalyst is a small artificial enzyme or an organic catalyst which can polymerize porphobilinogen to hydroxymethylbilane, it should be possible for the skilled man to introduce relevant side chains which facilitates entry into the intracellular compartment. Alternatively, the catalyst is the enzyme, but formulated in such a manner that it exerts at least part of its enzymatic activity intracellularly upon administration to the subject. This can be achieved by tagging the enzyme with specific carbohydrates or other liver cell specific structures for specific liver uptake, *i.e.* the enzyme (or analogue) is modified so as to facilitate active transport into e.g. liver cells.

Although the above embodiments are interesting, it is believed that the normal, practical embodiment of the invention will involve use of a catalyst which exerts substantially all its

enzymatic activity extracellularly in the bloodstream, since it is believed that the metabolic products of the enzymatic conversion of the relevant heme precursor will permeate freely into the intracellular compartment where the remaining conversions of the heme biosynthetic pathway can take place. Alternatively, the metabolic product may be excreted  
 5 from the subject via urine and/or faeces at least to some extent.

As mentioned above, it is preferred that the catalyst is produced recombinantly, *i.e.* by a method comprising

---

- 10 a) introducing, into a suitable vector, a nucleic acid fragment which includes a nucleic acid sequence encoding the catalyst;
- b) transforming a compatible host cell with the vector;
- c) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence; and
- 15 d) recovering the expression product from the culture  
 and optionally subjecting the expression product to post-translational processing, such as in vitro protein refolding, enzymatic removal of fusion partners, alkylation of amino acid residues, and deglycosylation, so as to obtain the catalyst.
- 20 For relatively small catalysts (e.g. those constituted mainly of the active site of the enzyme), the catalyst can alternatively be prepared by liquid-phase or solid-phase peptide synthesis.

A more detailed explanation of the recombinant production of the model enzyme PBGD is  
 25 given in the detailed section hereinafter, but as mentioned herein the same considerations apply for all other peptide catalysts of the invention. One of the main advantages of producing the catalyst by recombinant or synthetic means is, that if produced in a non-human cell, the catalyst is free from any other biological material of human origin, thus reducing problems with known or unknown pathogens such as viruses etc.

30

The dosage regimen will normally be comprised of at least one daily dose of the catalyst, (preferably by the intravenous route). Normally 2, 3, 4 or 5 daily dosages will be necessary,  
 but if sustained release compositions are employed, less than 1 daily dosage are  
 anticipated.

35



The daily dosage should be determined on a case by case basis by the skilled practitioner, but as a general rule, the daily dosage will be in the range between 0.01 – 1.0 mg/kg body weight per day of the catalyst. More often the dosage will be in the range of 0.05 – 0.5 mg/kg body weight per day, but it should never be forgotten that precise dosage depends  
5 on the dosage form and on the activity of the catalyst as well as on the degree of deficiency of the relevant enzyme or combinations of enzymes and an individualized treatment, where the dose is adjusted to normalize patient serum and urine precursor levels.

---

The most correct way of determining the correct dosage is based on the patient specific  
10 precursor levels. The precursor being the product of the enzymatic reaction.

For PBGD, the daily dosage is about 0.08-0.2 mg per kg body weight per day, and most often 0.1 mg per kg body weight per day will be the dosage of choice. It is believed that comparable dosages will be applicable for the other full-length enzymes or combinations of  
15 enzymes.

Finally, as will be appreciated from the above disclosure, the invention is based on the novel idea of providing substitution for the enzymes lacking in activity. To the best of the knowledge of the inventors, therapeutic use of catalysts having such effects have never  
20 been suggested before, and therefore the invention also pertains to a catalyst as defined herein for use as a pharmaceutical. Furthermore, use of such catalysts or combination of different catalysts for the preparation of pharmaceutical compositions for treatment of the above-discussed diseases is also part of the invention.

25 Legends to figures:

Figure 1: Circular map of plasmid pPBGD1.1

Figure 2: Flow chart for construction of plasmid pExp0

30

Figure 3: Circular map of plasmid pExp0

---

Figure 4: Flow chart for construction of plasmid pExp1

35 Figure 5: Circular map of plasmid pExp1

Figure 6: Flow chart for construction of pExp1-M2

Figure 7: Circular map of plasmid pExp1-M2

5

Figure 8: Flow chart for construction of rhPBGD expression plasmid pExp1-M2-BB

---

Figure 9: Circular map of rhPBGD expression plasmid pExp1-M2-BB

10 Figure 10: PCR strategy for construction of the *EcoR* I-*Hind* III linear DNA-fragment

Figure 11: Structure of the *EcoR* I-*Hind* III linear DNA-fragment used for transformation

Figure 12: Respiration and growth data from fermentation PD14 with strain PBGD-2

15

Figure 13: rhPBGD expression in fermentation PD14 with strain PBGD-2

Figure 14: Chromatography on DEAE-Sepharose FF (DEAE1)

20 Figure 15: Chromatography on DEAE-Sepharose FF (DEAE2)

Figure 16: Chromatography on Butyl-Sepharose 4 FF

Figure 17: Circular map of rhPBGD-His expression plasmid pExp2

25

Figure 18: PBGD reaction mechanism

Figure 19: DEAE chromatography elution profile

30 Figure 20: SDS-PAGE gel of DEAE eluates

---

Figure 21: Cobalt chromatography elution profile

Figure 22: SDS-PAGE gel results of cobalt eluates

35

Sequence list:

Seq. ID NO 1: Sequence of the expression plasmid pExp1-M2-BB

5

Seq. ID NO 2: Sequence of the EcoR I - Hind III linear fragment used for transformation in the hemC disruption strategy

Seq. ID NO 3: Sequence of the erythropoietic form (PBGD 1.1)

10

Seq. ID NO 4: Sequence of the non-erythropoietic form (PBGD 1.1.1)

Seq. ID NO 5: Sequence of PDGB from Spleen (PBGD 1.3)

15 Seq. ID NO 6: Sequence of PDGB from bone marrow (PBGD 2.1)

Seq. ID NO 7: Sequence of PDGB from bone marrow (PBGD 2.2)

Seq. ID NO 8: Sequence of PDGB from lymph node (PBGD 3.1)

20

Seq. ID NO 9: Sequence of PDGB from lymph node (PBGD 3.3)

Seq. ID NO 10: Sequence PDGB from total brain (PBGD 5.3)

25 Seq. ID NO 11: Sequence of PDGB from total brain (PBGD 6.1)

30

---

DETAILED DISCLOSURE OF THE INVENTION

In a first embodiment the invention relates to a method for treatment or prophylaxis of  
 35 disease caused by deficiency, in a subject, of one or more enzymes belonging to the heme

biosynthetic pathway, the method comprising administering, to the subject, an effective amount of a catalyst which is said enzyme or combination of enzymes or an enzymatically equivalent part or analogue thereof. The disease may be selected from the porphyria group and the catalyst may be an enzyme selected from the group consisting of

- 5 delta-aminolevulinic acid synthetase,  
delta-aminolevulinic acid dehydratase (ALAD),  
porphobilinogen deaminase (PBGD),

---

- uroporphyrinogen III cosynthetase,  
uroporphyrinogen decarboxylase,
- 10 coproporphyrinogen oxidase,  
protoporphyrinogen oxidase, and  
ferrochelatase,  
or an enzymatically equivalent part or analogue thereof.

- 15 The invention also relates to any combination of the enzymes mentioned above because one enzymatic deficiency may cause such alterations of the pathway that alternative enzymatic reactions are needed wherein an otherwise normal production of an enzyme for such alternative pathway is not sufficient. In alternative, the disease relating to the heme biosynthetic pathway may also be due to a deficiency of more than only one enzyme.
- 20 Accordingly, in the present context the term catalyst may also be interpreted as a combination of catalyst and the term enzyme may also include a mixture of different enzymes.

- In a preferred embodiment, the disease is AIP and the enzyme is PBGD or an
- 25 enzymatically equivalent part or analogue thereof optionally in combination with ALAD. In a further embodiment, the catalyst is a recombinant form of the enzyme belonging to the heme biosynthetic pathway or of the enzymatically equivalent part or analogue thereof.

- The catalyst may be administered by a route selected from the group consisting of the
  - 30 intravenous route, the intraarterial route, the intracutaneous route, the subcutaneous route, the oral route, the buccal route, the intramuscular route, the anal route, the transdermic route, the intradermal route, and the intratechal route.
- 

- The catalyst is preferable formulated in an isotonic solution, such as 0.9% NaCl and 10-50
- 35 mM sodium phosphate pH 7.0 +/- 0.5 up to pH 8.0 or sodium phosphate, glycine, mannitol

or the corresponding potassium salts. The catalyst may also be lyophilized, sterile filtered, and in a further embodiment formulated as lipid vesicles comprising phosphatidylcholine or phosphatidylethanolamine or combinations thereof. In a still other embodiment the catalyst is incorporated into erythrocyte ghosts.

5

Also a sustained release formulation may be performed involving biodegradable microspheres, such as microspheres comprising polylactic acid, polyglycolic acid or mixtures of these.

---

- 10 A further method according to the invention is wherein the catalyst is lyophilized in a two-compartment cartridge, where the catalyst will be in the front compartment and water for reconstitution in the rear compartment. The two compartment cartridge may be combined with an injection device to administer the catalyst either by a needle or by a needle-less (high pressure) device.

15

It may also be very convenient to administer the catalyst in a formulation of a physiological buffer containing an enhancer for nasal administration.

- Other formulations for the catalyst include an oral formulation containing lipid vesicles, 20 such as those comprising phosphatidylcholine, phosphatidylethanolamine, or sphingomyeline, or dextrane microspheres.

- The formulation is preferable one that is able to enhance the half-life of the catalyst in the subject's bloodstream. This may be use of a formulation wherein the catalyst has a 25 polyethylene glycol coating.

The catalyst may also be complexed with a heavy metal.

- In a further aspect the catalyst is an enzymatically equivalent part or analogue of the 30 enzyme and exerts at least part of its enzymatic activity intracellularly upon administration to the subject. This may be when the catalyst is a small artificial enzyme or an organic catalyst that can polymerise porphobilinogen to hydroxymethylbilane.
- 

- Furthermore, the catalyst may be said enzyme formulated in such a manner that it exerts at 35 least part of its enzymatic activity intracellularly upon administration to the subject.

In addition the catalyst may be tagged with specific carbohydrates or other liver cell specific structures for specific liver uptake.

- 5 In a further aspect the catalyst exerts substantially all its enzymatic activity extracellularly in the bloodstream.

---

In a still further aspect, the enzymatic activity of the catalyst on its relevant heme precursor results in a metabolic product which 1) either moves into the intracellular compartment and  
10 is converted further via the remaining steps of the heme biosynthetic pathway or 2) is excreted from the subject via urine and/or faeces.

A further embodiment of the invention relates to a method wherein the catalyst has been prepared by a method comprising

15

- a) introducing, into a suitable vector, a nucleic acid fragment which includes a nucleic acid sequence encoding the catalyst;
  - b) transforming a compatible host cell with the vector;
  - c) culturing the transformed host cell under conditions facilitating expression of the nucleic  
20 acid sequence; and
  - d) recovering the expression product from the culture
- and optionally subjecting the expression product to post-translational processing, such as in vitro protein refolding, enzymatic removal of fusion partners, alkylation of amino acid residues, and deglycosylation, so as to obtain the catalyst.

25

The catalyst may be prepared by liquid-phase or solid-phase peptide synthesis and it is preferable free from any other biological material of human origin.

As mentioned above the catalyst may be administered at least once a day, such as 2, 3, 4,  
30 and 5 times daily depending on the specific treatment regimen outlined for the patient in that precursor levels for each patient are measured before and/or during treatment for evaluation of the specific dosage.

---

Accordingly the daily dosage may be in the range of 0.01 – 1.0 mg/kg body weight per day, such as in the range of 0.05 – 0.5 mg/kg body weight per day. And the present invention also relates to the use of the catalyst for the preparation of a pharmaceutical composition.

- 5 It is estimated that a dosage will often be about 0.1 mg per kg body weight per day.

Accordingly, the invention also relates to a catalyst which is an enzyme of the heme

biosynthetic pathway or an enzymatically equivalent part or analogue thereof, for use as a medicament. Thus in a further embodiment, the invention relates to a catalyst which is an

- 10 enzyme of the heme biosynthetic pathway or an enzymatically equivalent part or analogue thereof for the preparation of a pharmaceutical composition for the treatment or prophylaxis of diseases caused by deficiency of said enzyme.

Naturally, the catalyst may be a recombinant form of the enzyme. An example is a

- 15 recombinant human PBGD based on any of Seq. ID NO 3 and Seq. ID NO 4.

In a preferred embodiment and as will be disclosed in detail below, the invention also relates to a method for treating a patient having a mutation in the PBGD gene causing an

- 20 enzyme defect, the method comprising use of a human PBGD cDNA sequence of either non-erythropoietic form or erythropoietic form according to the tissue in which PBGD should be expressed, and transfecting the patient with the relevant cDNA. Preferably the enzyme deficiency is selected from enzyme deficiencies resulting in a disease selected from Acute intermittent porphyria, (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary coproporphyria (HCP), Harderoporphyria (HDP), Variegata porphyria (VP), Congenital erythropoietic porphyria (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP).

In a preferred embodiment, the human PBGD cDNA sequence is selected from Seq. ID NO

- 30 3 and Seq. ID NO 4.

The transfection may be by use of a vector selected from adenovirus, retrovirus and associated adenovirus. The PBGD gene transfer vector into human cells

(erythropoietic and/or non-erythropoietic) preferable results in normal PBGD activity or

- 35 in an activity wherein the patient is free of symptoms of disease.

A further method of gene therapy treatment of patients with Acute Intermittent Porphyria (AIP) according to the invention is by a correction of one of the specific point mutations identified causing AIP by use of chimeraplasty gene repair. This  
5 involve specific designed oligonucleotides and a specific knowledge of both the mutation to be corrected and to the sequence on both sides on the mutation.

---

In a specific embodiment of chimeraplasty gene repair is by use of a delivery system for transfection by use of non-viral vectors formulated in a vehicle preparation  
10 comprising one or more components selected from cationic phospholipids, phospholipids, phospholipids mixed with neutral lipids, lictosylated PEI, liposomes liposomes comprising mixtures of natural phopholipids and neutral lipids.

The mutation may be selected from the mutations shown in Table A.  
15

The following description of preferred embodiments of the invention will focus on recombinant production of PBGD and formulations and uses thereof. It will be appreciated, however, that all disclosures relating to this polypeptide apply also for the other enzymes mentioned above. Hence, production and use of PBGD only exemplifies the invention, but  
20 all other enzymes of the heme biosynthetic pathway can substitute PBGD in the embodiments described hereinafter.

#### Production of recombinant human PBGD (rhPBGD)

25 As mentioned above, it is preferred to administer recombinant human versions of the various enzymes of the heme biosynthetic pathway. In the following will be described recombinant production of one of these enzymes, namely PBGD.

The gene for the erythropoietic PBGD, which is located in the human genome in the  
30 chromosomal region 11q 24, is composed of 15 exons spanning 10 kb of DNA and is shown in Grandchamp B. et al. 1996, J. of Gastroenerology and Hepatology 11, 1046-1052.

---



The gene coding the erythropoietic PBGD enzyme (344 amino acids) (Raich N. et al 1986, Nucleic. Acid. Res, 14, 5955-5968), will be cloned from a human erythropoietic tissue by use of a nested PCR (polymerase chain reaction) strategy.

- 5 The PBGD coding region will be inserted in a plasmid and transformed into a suitable host cell (a bacterium such as *E. coli* and *B. subtilis*, or a fungus such as *Saccharomyces*). The expression of the PBGD gene will be regulated by a promoter which is compatible with the selected host cell.
- 

- 10 For bacterial production: An endogenous ATG sequence is located at the NH<sub>2</sub>-terminal end of the PBGD structural gene for initiation of translation and cytoplasmic expression. Alternatively insert in front of the PBGD coding region a bacterial signal sequence for example an *E. coli* periplasmic enzyme signal peptide or a signal peptide from a secreted enterotoxin or endotoxin in *E. coli*, to obtain secretion in *E. coli*.

15

The plasmid used for production of rhPBGD in *E. coli* was constructed in the following way:

#### Construction of the plasmid harboring the coding region of human wild type PBGD

#### 20 (pBPBGD1.1)

##### Introduction:

- The erythropoietic expressed form of porphobilinogen deaminase (PBGD) (Raich N. et al. Nucleic Acids Research 1986 14(15): 5955-67) was cloned and sequence determined. Two forms of PBGD are known. The erythropoietic form is expressed specifically in erythroid progenitors and the constitutive form is expressed in all cells (Grandchamp B. et al. 1987, Eur J Biochem. 162(1):105-10). The two are expressed from the same gene and are identical except for the addition of 17 amino acids at the amino terminus of the constitutive form through alternative exon usage. It was decided to clone and express the erythropoietic form. There are three sequences for PBGD in the Genbank, the two isoforms mentioned above and the genomic sequence (Yoo HW. et al. 1993, Genomics. 15(1):21-9). These all have nucleotide differences translating to amino acid changes. Before choosing a specific sequence to be expressed for a human therapeutic it was therefore necessary to determine what is the wild type allele. To accomplish this, PBGD

cDNA clones were isolated and sequenced from a number of sources to define the most common amino acid usage. Oligonucleotide primers were designed to amplify the coding region from cDNAs by Polymerase Chain Reaction (PCR) (Saiki R.K. et al. 1985, Science 230(4732):1350-4). These were used to isolate cDNAs from 5 sources of mRNA which  
 5 were then cloned into a plasmid vector. Eight of these clones were sequenced and along with the published sequences define a wild type allele, which should be the most common amino acid sequence in the population. This wild type allele will be used for protein expression.

---

#### 10 Strategy:

A nested PCR strategy was devised to clone PBGD. The first primer set, (see Table 1) lco379 and lco382, are 20mers that bind to sequence outside of the coding region. lco379 is specific for the 5' untranslated region of the mRNA (cDNA) of the erythropoietic form of  
 15 PBGD. The binding site is in an exon region not expressed in the constitutive form of the enzyme. lco382 binds to the 3' untranslated region of both forms of PBGD. Internal to these are a second set of oligonucleotide primers to be used for the second round of PCR, lco375 and lco376, designed to distal ends of the PBGD coding region. lco375 has 22 bases of sequence homologous to the 5' end of the coding region of the erythropoietic form  
 20 of PBGD with the ATG start codon followed by an *EcoR* I endonuclease cleavage site for cloning of the PCR product and 4 bases of sequence to ensure efficient restriction. lco376 has 33 bases homologous to the 3' end of the PBGD coding region with 3 bases changed internally to introduce a *Mun* I/*Mfe* I endonuclease cleavage site through silent mutations and ending with the TAA stop codon. This restriction site will be used to easily introduce  
 25 sequence encoding a His-Tag to the DNA with oligonucleotide adapters or to enable other 3' modifications. Following the stop codon is a second stop codon to ensure good termination of translation and a *Hind* III endonuclease cleavage site for cloning the PCR product followed by 4 bases to ensure efficient restriction. The *EcoR* I and *Hind* III endonuclease cleavage sites introduced onto the ends of the PBGD PCR product ligate  
 30 into the respective unique restriction sites in the high copy number pBluescriptII SK- (Stratagene) vector for sequencing and will then be used to move the PBGD DNA into an *E. coli* expression vector for production of recombinant human porphobilinogen deaminase, rhPBGD.

---

#### 35 PCR:

Six cDNAs were used as a PCR source; spleen, bone marrow, lymph node, lung, whole brain and adipose tissue each from a different pool of human donors (produced by Donald Rao using BRL Superscript II with 500 ng Clontech poly-A RNA in 20 µl reaction volumes per manufacturers instructions except adipose which was made from 5 µg of Clontech total RNA from a single donor). List of equipment and supplies used (see lists below). One µl of each cDNA (approximately 25ng) was amplified with Advantage cDNA polymerase mix (Clontech) with 0.2mM dNTP (PE/ABI) and 0.3 µM each of Ico379 and Ico382 in 50 µl reaction volumes. Two cycle PCR was used, with an initial heat denaturation step at 94°C for 1' 40" then 28 cycles of 96°C for 16" and 68°C for 2'. A final extension of 6' at 74°C ensured that extension products were filled out. One fifth of the reaction was run out on a 1.2% agarose gel with 2 µl of 6X ficol loading dye in 0.5X TBE buffer (Maniatis T., E.F. Fritsch, J. Sambrook. Molecular Cloning (A laboratory Manual) Cold Spring Harbor Laboratory. 1982). The predicted band of 1.1 kb. was observed by ethidium bromide staining with all sources but lung tissue cDNA. These bands were excised and DNA was isolated with Microcon-30 with micropure inserts (Amicon/Millipore) per manufacturers instructions and buffer exchanged with dH<sub>2</sub>O. One tenth of the recovered DNA was amplified with Advantage cDNA polymerase mix (Clontech) with 0.2mM dNTP (PE/ABI) and 0.3µM each of the internal nested oligonucleotides (Ico375 and Ico376) at 0.3 µM in 50µl reactions. Two cycle PCR was used again with an initial heat denaturation step at 94°C for 1' 40" then 2 cycles of 96°C for 16" and 68°C for 2' then 13 cycles of 96°C for 16" and 72°C for 2' with a final extension of 6' at 74°C. Ten µl of the 50 µl reactions were run on a 1.2% agarose gel with 2 µl 6X loading dye. The resulting bands were of the expected size, 1.05 kb. The remainder of the PCR reactions were passed through Chromaspin-400 columns (Clontech) per manufacturers instructions to remove reaction components and to exchange buffer with TE (10mM Tris-HCl pH8.0/ 1mM EDTA). The DNA containing eluates were washed with dH<sub>2</sub>O and concentrated with Microcon-100 spin-filters (Amicon/Millipore) as described by the manufacturer's instructions.

### 30 Cloning:

The purified PBGD DNA was digested for 6 hours with 40 Units each of *EcoR* I and *Hind* III in *EcoR* I "U" buffer (New England Biolabs (NEB)) in 50 µl reactions at 37°C. Enzymes were heat killed for 20 minutes at 68°C and reactions were spun in Microcon 100 spin-filters to remove small DNA end pieces, washed with dH<sub>2</sub>O and concentrated. One fifth of

the resulting DNA was ligated with approximately 50 ng *EcoR* I and *Hind* III digested and twice gel purified pBluescriptII SK- (Stratagene) and 200 units T4 DNA ligase (NEB cohesive end units) for 15 hours at 16°C. The ligase was heat killed at 75°C for 10 minutes. The reactions were then buffer exchanged with dH<sub>2</sub>O and concentrated in Microcon-100 spin filters and volumes taken up to 5 µl with dH<sub>2</sub>O. One µl each was electroporated into 25 µl DH10B Electromax cells (Gibco/BRL) at 2.5Kv/200Ohms/25µF in 0.1cm cuvetts with a BioRad electroporator. One ml of SOC medium (Gibco/BRL) was added and the cells were outgrown at 37°C for one hour at 250 rpm. Cells were plated out on LB plates (Maniatis T., E.F. Fritsch, J. Sambrook. Molecular Cloning (A laboratory Manual) Cold Spring Harbor Laboratory. 1982) with 150 µg/ml ampicillin. The efficiency of all five were approximately twice background (vector ligated without insert). Colony PCR was used to analyze 18 transformants of each electroporation for the presence of PBGD. An internal PBGD specific primer (ICO381) was used with a pBluescript specific primer (ICO385) to both confirm identity and proper orientation in the vector. The 25 µl reactions were set up on ice to inactivate proteases with primer concentrations of 0.4 µM, 0.125U Taq polymerase (Fisher), and 0.2mM dNTP(PE/ABI.) Two cycle PCR was used, with an initial heat denaturation step at 94°C for 1' 40" a further denaturing step at 96°C for 20 seconds, then 30 cycles of 96°C for 16" and 68°C for 1' with a final extension of 4' at 74°C. Five µl of 6X loading dye was added and 12.5 µl each were run out on a 1.2% agarose gel. Results are as follows: 12/18 positive colonies for spleen; 10/18 for bone marrow; 8/18 for lymph node; 9/18 for brain and 10/18 for adipose tissue. Two positive colonies each for the first 3 and 1 each for the latter two were grown up in 25 ml. liquid LB culture with 150 µg/ml ampicillin over night at 37°C with 250 rpm. Plasmid DNA was purified from the cultures with Qiagen's Tip-100 DNA purification kit per manufacturer's instructions. UV absorbance at 260nm was used to determine the plasmid yields which varied from between 131 and 169 µg of highly purified DNA.

#### Sequencing:

Sequencing reactions of double stranded plasmid DNA with Big Dye terminator cycle sequencing were performed in a 9700 thermocycler (Perkin Elmer/Applied Biosystems). Two vector primers (ICO383 and ICO384) and two PBGD specific internal primers (ICO380 and ICO381) were used for all 8 plasmids. In addition a fifth vector primer (ICO385) was used for the brain and adipose derived clones. Reaction conditions were per manufacturers protocol as follows: 500 ng plasmid DNA and 4 pmol oligonucleotide primer with 8 µl ready

mix in 20 µl volumes with 30 cycles of 96°C for 12" and 60°C for 4'. Extension products were purified by isopropanol precipitation. To each reaction 20 µl of dH<sub>2</sub>O and 60 µl isopropanol were added. These were mixed by inversion and allowed to sit at room temperature for 15 minutes then spun for 40' at 3250 rpm in a Beckman GS-6KR centrifuge with the GH3 rotor and Microplate + carriers. Reactions were inverted then spun at 1680 rpm for 1' to remove liquid from the pelleted DNA. DNA sequence analysis was performed at the University of Washington Biochemistry Department sequencing Laboratory with an Applied Biosystems 377 sequencer.

#### 10 Analysis:

The inserts of all 8 clones were confirmed to be PBGD by complete double strand sequence analysis (see sequences 1 - 8). Each has some change(s) from the published sequences. Some changes are unique and some are shared with other clones (see Table 2 and Table 3). For differences found only in one clone, it is difficult to distinguish between PCR or cloning artifacts and actual allelic variations without additional sampling. However, when the same base difference is found in more than one sequence it is unlikely to be from cloning errors. From the alignment of all 11 PBGD sequences a set of common bases emerged, the consensus or wild type allele sequence. Five of the eight clones (1.1, 1.3, 2.1, 3.3, and 5.3.) have the wild type amino acid sequence. Within this set with wild type amino acid sequence, there is only one difference at the nucleic acid level. At position 555, 4 of the 5 sequences have a dGTP while 1 along with the published erythropoietic and genomic PBGD have a dTTP. These appear to be two common alleles, which result in no amino acid difference. There are 2 base changes between clone number 1.1 and the published erythropoietic PBGD. An adenine to guanine change at base 513 (Leu 171) is a silent mutation, which is also present in 9 out of the 11 sequences, compared. The second difference is a cytosine to adenine substitution at base 995 (Thr 332.) This is not a silent change, with a threonine to asparagine non-conservative mutation. It appears however that the difference is an error in the published erythropoietic PBGD sequence since all 10 other sequences have an adenine at this position. In addition to these natural variations, there are three additional silent mutations introduced during the cloning at positions 1017, 1018 and 1020 to create a *Mun* I site for future manipulations. The PBGD gene was ligated into pBluescript SK plasmid generating the pSK-PBGD 3988 bp plasmid, which was sequenced.

## Conclusion:

For any recombinant therapeutic protein it is important that the wild type allele be used to reduce the potential for immunogenicity. We feel confident through our survey of the  
5 literature and analysis of PBGD sequence from different individuals that clone number 1.1 represents the most prevalent "wild type" allele in the population with respect to amino acid sequence. Clone number 1.1 contains the consensus wild type amino acid sequence and differs from the published erythropoietic PBGD sequence by only one amino acid. Because  
10 this difference is found in all the other PBGD clones besides the erythropoietic PBGD sequence, it, rather than the published erythropoietic sequence, is deemed to be the prevalent wild type sequence. For this reason PBGD encoded by clone number 1.1 was chosen for production of recombinant human porphobilinogen deaminase (rhPBGD). In the following, the plasmid encoding the human wild type PBGD in clone number 1.1 will be termed "pPBGD1.1".

15

Equipment and supplies lists are shown in appendix 1 and 2, respectively.

Table 1 Oligonucleotide primers used for PCR amplification and sequencing of PBGD:

	Ico375-pbgds (32 mer)	coding region 5' end w/ EcoRI site sense
	5' CGT GGA ATT CAT GAG AGT GAT TCG CGT GGG TA 3'	
5	Ico376-pbgda (47 mer)	coding region 3'end w/ HindIII site antisense
	5' GGA GAA GCT TAT TAA TGG GCA TCG TTC AAT TGC CGT GCA ACA TCC AG 3'	
<hr/>		
	Ico379-esnonc (20 mer)	erythropoietic form non-coding sense
10	5' TCG CCT CCC TCT AGT CTC TG 3'	
	Ico380-sinter (21 mer)	internal coding sense
	5' CAG CAG GAG TTC AGT GCC ATC 3'	
15	Ico381-ainter (21 mer)	internal coding antisense
	5' GAT GGC ACT GAA CTC CTG CTG 3'	
	Ico382-anonc (20 mer)	non-coding antisense
	5' CAG CAA CCC AGG CAT CTG TG 3'	
20	Ico383-pSKT7 (22 mer)	pBluescript T7 promoter
	5' GTA ATA CGA CTC ACT ATA GGG C 3'	
	Ico384- pSKpjrev (22 mer)	pBluescript reverse1
25	5' CTA AAG GGA ACA AAA GCT GGA G 3'	
	Ico385- pSKrev (21 mer)	pBluescript reverse2
	5' CAG CTA TGA CCA TGA TTA CGC 3'	

---

Table 2 Variation of PBGD clones from published erythroid sequence:

PBGD clone	Differences from Erythroid mRNA			Genebank No.	Reference/Source
	silent	non-silent	total diffs		
Erythroid	0	0	0	X04217	Raich.N. et. al. 1986, Nucleic Acids Res. 14 (15), 5955-5968
Constitutive	1	2	3	X04808	Grandchamp.B. et. al. 1987, Eur. J. Biochem. 162 (1), 105-110
Genomic	1	2	3	M95623	Yoo,H.W. et. al. 1993, Genomics 15 (1), 21-29
1.1	1	1	2	-	Spleen (Clontech mRNA Lot No. 7120266)
1.3	2	1	3	-	Spleen (Clontech mRNA)
2.1	2	1	3	-	Bone Marrow (Clontech mRNA)
2.2	2	2	4	-	Bone Marrow (Clontech mRNA)
3.1	2	4	6	-	Lymph Node (Clontech mRNA)
3.3	3	1	4	-	Lymph Node (Clontech mRNA)
5.3	2	1	3	-	Total Brain (Clontech mRNA)
6.1	3	2	5	-	Adipose Tissue (Clontech mRNA)

Table 2:

- 5 Summary of the number of differences in amino acid sequence of our sequenced PBGD clones and clones from Genebank entries for the constitutive and genomic PBGD with published Erythropoietic PBGD sequence. Shown in different columns are the total number of silent mutations with a DNA base change not causing a corresponding amino acid change, the number of non-silent mutations with a DNA change causing an amino acid
- 10 difference and the sum of the two types of mutations. Not included in this table are the three silent mutations introduced into the clones to create an internal *Mun* I endonuclease cleavage site. Note that clone number 1.1 which will be used for production of recombinant human porphobilinogen deaminase (rhPBGD) has only one of each type of difference with the least number of total differences.



Table 3 Summary of mutations found in PBGD clones:

aa	aa No.	bp No.	mutation	aa change	cons.	gen.	1.1	1.3	2.1	2.2	3.1	3.3	5.3	6.1	No. /10
Asp	19	56	A→G	Asp→Gly							X				1
Phe	108	322	T deletion	frame shift						X					1
Lys	140	419	A→G	Lys→Arg							X				1
Leu	160	478	C→A	Leu→Met		X									1
Ala	168	503	C→T	Ala→Val							X				1
Leu	171	513	A→G	silent		X	X	X	X	X	X	X	X	X	9
Val	185	555	T→G	silent	X			X	X	X		X	X	X	7
Glu	193	577	G→A	Glu→Lys	X										1
Gly	243	729	C→T	silent								X			1
Ala	280	840	T→C	silent										X	1
Ala	286	856	G→A	Ala→Thr										X	1
Lys	328	984	A→G	silent							X				1
Thr	332	995	C→A	Thr→Asn	X	X	X	X	X	X	X	X	X	X	10
Gln	339	1017	G→A	silent			X	X	X	X	X	X	X	X	8
Gln	339	1018	C→T	silent			X	X	X	X	X	X	X	X	8
Leu	340	1020	T→G	silent			X	X	X	X	X	X		X	7
Leu	340	1020	T deletion	frame shift									X		1

Table 3: Summary of the genetic differences of our sequenced PBGD clones and Genbank entries for the constitutive and genomic PBGD with published erythropoietic PBGD sequence from the allele sequence alignment. Listed in different columns are the amino acid, base number from the ATG start codon, the actual genetic difference with corresponding amino acid change if any and a listing of the clones with differences shown with an X. In the final column the total number of clones with the different mutations are shown. The three mutations at position 1017, 1018 and 1020 are introduced with ICO376 during PCR amplification to create a *Mva* I endonuclease cleavage site. Note that clone number 1.1 which will be used for production of rhPBGD only has genetic differences which also are represented by a number of other clones.

## Expression plasmids

### Construction of the basic expression plasmid pExp0

The basic expression plasmid pExp0 was constructed by excising the PBGD coding  
 5 sequence (cDNA) from plasmid pPBGD1.1 (see Figure 1) with *EcoR* I and *Hind* III and  
 inserting it into the vector pKK223-3 (Pharmacia, Catalogue # 27-4935) cut with the same  
 enzymes, thus operatively linking it to the IPTG-inducible *tac* promoter (Amann E. et al.  
 1983, Gene 25(2-3):167-178). Figure 1 shows the construction details. Plasmid pExp0 was  
 constructed for a preliminary assessment of the expression levels and does not directly  
 10 lead to the construction of the final expression plasmid.

### Construction of the final expression plasmid

The final expression plasmid pExp1-M2-BB (Figure 9) was constructed in a multi-step  
 process. The individual steps used and all the intermediate plasmids are outlined below.

15

#### Construction of plasmid pExp1

Plasmid pExp1 was first constructed with modifications to the 5' untranslated region and  
 the initial part of the coding sequence both aimed at improving translation efficiencies (Gold  
 L. and Stormo G.D. 1990, Methods Enzymol 185:89-93). The changes are indicated below,  
 20 and include, insertion of a second ribosome binding site, an AT-rich sequence preceding  
 the ATG and three silent base substitutions shown in boldface.

AATTCTAACA TAAGTTAAGG AGGAAAAAAA A ATG AGA GTT ATT CGT GTC GGT AC  
 Met-Arg-Val-Ile-Arg-Val-Gly

25

A naturally occurring *Kpn* I site six amino acid residues into the coding sequence of the  
 human cDNA for PBGD (pPBGD1.1) was exploited for this purpose. Oligonucleotides  
 ICO386 and ICO387 were designed to provide upon annealing to each other a 5' *EcoR* I  
 adhesive end and a 3' *Kpn* I sticky end and the elements described above including the  
 30 codons for the first six amino acid residues as shown. Oligonucleotides ICO386 and  
 ICO387 were annealed and ligated with the *Kpn* I-*Hind* III, PBGD fragment from pPBGD1.1  
 into *EcoR* I -*Hind* III linearised pBluescript II SK- (Stratagene, Catalogue # 212206) to yield  
 plasmid pPBGD1.1Tra. In the second step, the *EcoR* I-*Hind* III fragment from  
 pPBGD1.1Tra was ligated into pKK223-3 cut with the same enzymes resulting in plasmid  
 35 pExp1 (Figures 4 and 5).

#### Construction of plasmid pExp1-M2

The tetracycline resistance gene was next restored using the following strategy. Plasmid pExp1 was cut with *Sal* I and *Bam*H I and the 5349 base-pair fragment containing part of the tetracycline coding sequence and the bulk of the plasmid was isolated. Into this was ligated the *Sal* I-*Hind* III fragment from pBR322 (New England BioLabs, Catalogue # 303-3S) containing rest of the coding sequence and an adapter formed by annealing oligonucleotides ICO424 and ICO425 to each other. The adapter contains part of the tetracycline promoter and provides *Hind* III and *Bam*H I overhangs for ligation but destroys the *Hind* III and *Bam*H I restriction sites. The resulting plasmid was called pExp1-M2 (Figures 6 and 7).


#### Construction of plasmid pExp1-M2-BB

In the final step the *rop* gene contained between *Bsa*A I and *Bsa*BI was deleted to increase copy number (Makrides S.C. 1996, Microbiol.Rev. 60(3):512-538). For this the plasmid pExp1-M2 was cycled through the *dam* minus strain, JM110 (F' [*tra*D36 *pro*A<sup>+</sup> *pro*B<sup>+</sup> *lac*I<sup>+</sup> Δ(*lac*Z)M15] *dam* *dcm* *sup*E44 *hsd*R17 *thi* *leu* *thr* *rps*L *lac*Y *gal*K *gal*T *ara* *ton*A *tsx* Δ(*lac-pro*AB) *lambda*<sup>-</sup>) as restriction with *Bsa*B I is blocked by overlapping *dam* methylation. It was then cut with *Bsa*A I and *Bsa*B I to excise the *rop* gene and the 5446 base-pairs long linear fragment was circularised by blunt-end ligation to yield the production plasmid pExp1-M2-BB (Figures 8 and 9).

#### Construction of the *hemC*-deletion host and the final expression strain

The parent strain JM105 (F' [*tra*D36 *pro*A<sup>+</sup> *pro*B<sup>+</sup> *lac*I<sup>+</sup> Δ(*lac*Z)M15] Δ(*pro-lac*) *hsd*R4 *sbc*B15 *rps*L *thi* *end*A1 *lambda*<sup>-</sup>), a derivative of *E. coli* K12 was obtained from Pharmacia, Catalogue # 27-1550-01. The *hemC* gene coding for the endogenous *E. coli* Porphobilinogen Deaminase was partially deleted. This was necessary to ensure that the purified product (rhPBGD) was free from contaminating *E. coli* PBGD as the *E. coli* and human enzymes are very similar in properties (Jordan P.M. 1994, Wiley, Chichester (Ciba Found Symp 180), p70-96) and may co-purify. The *hemC*-deletion host was derived from JM105 according to Scheme A. First a hemin-permeable variant was obtained by a three-step process. This was essential as a *hemC*-deletion mutant would require hemin for good growth and *E. coli* K12 strains are not freely permeable to hemin.

35 Scheme A. Scheme for obtaining *hemC*-deletion strain:



- 5 All mutant isolation was spontaneous. Approximately  $5 \times 10^{-8}$ - $5 \times 10^{-9}$  cells were plated on selective media. The media compositions are included as Appendix 1.

\* For details on the linear DNA-fragment see Figure 11.

- 10 In the first step, a heme-minus mutant was isolated carrying a defect in any of the biosynthetic steps leading to the formation of heme. Heme<sup>-</sup> strains fall into the general class of respiration deficient mutants that are defective in active transport and consequently resistant to low levels of antibiotics of the aminoglycoside family such as gentamicin (Lewis L.A. et al. 1991, Microbiol.Immunol. 35(4):289-301). Several

spontaneous mutants were isolated as dwarf colonies on LB+glucose +G-418 (gentamicin)-containing plates (Lewis L.A. et al. 1991, Microbiol.Immunol. 35(4):289-301). These were screened for their ability to respond weakly to hemin, indicating that they were heme<sup>-</sup> (as opposed to other respiration deficient mutants which would not respond to hemin at all). One such heme-strain (JM105-2-4, see Scheme A) which could also revert back spontaneously to robust growth on LB (as this is essential for the third step, see below) was selected. This strain was next plated on LB+hemin to obtain a better grower in the presence of hemin and was called JM105-H. It showed improved growth only in the presence of hemin, which meant that it still was heme<sup>-</sup> but had become hemin-permeable.

10 To restore the functionality of the heme biosynthetic pathway in JM105-H, spontaneous revertants were isolated on LB plates and only those retained which resembled the starting strain JM105 in growth, both untransformed and after transformation with the expression plasmid. One such strain used in this study was called JM105-H-R6 and should have retained the heme-permeable trait of its parent strain.

15

Strain JM105-H-R6 was transformed with the *EcoR* I-*Hind* III fragment (see Scheme A), to obtain the *hemC*-deletion host called JM105-H-R6-C by homologous gene replacement. This strain has the genotype, *F'*[*traD36 proA*<sup>+</sup> *proB*<sup>+</sup> *lac*<sup>F</sup>  $\Delta$ (*lacZ*)*M15*]  $\Delta$ (*pro-lac*) *hsdR4 sbcB15 rpsL thi endA1 lambda*<sup>-</sup> *hemC*:CAT hemin-permeable. It was transformed with the

20 expression plasmid pExp1-M2-BB to yield the final production strain PBGD-2 (PBGD-2 was deposited under the Budapest Treaty on 9 July 1999 with DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, Germany) under the accession No. DSM 12915).

25

In order to obtain the *EcoR* I-*Hind* III fragment, a multiple PCR strategy was used. Oligonucleotide pairs ICO437, ICO438 and ICO505, ICO440 were used to amplify separately, portions of *E. coli* JM105 genomic DNA segments flanking the *hemC* gene (see

30 Figure 10). These amplified gene products were digested with pairs of enzymes *EcoR* I, *Xho* I and *Xho* I, *Hind* III respectively, and in essence, assembled together between the *EcoR* I and *Hind* III sites of pUC19 to give plasmid phemCd. Next the fragment containing the chloramphenicol-resistance gene was PCR amplified from plasmid pBC SK<sup>+</sup> (Stratagene, Catalogue # 212215) using oligonucleotides ICO510 and ICO511. This

35 product was cut with *Xho* I and inserted into plasmid phemCd at the *Xho* I site. In essence,

the plasmid having the Cam gene in the orientation shown was called phemCdCm and formed the source of the *EcoR* I-*Hind* III linear DNA-fragment depicted in Figure 11.

In Figure 11 the structure of the linear DNA-fragment used for the transformation is shown.

- 5 The genetic organization of the *E. coli* polypeptides depicted by gray arrows (*cyaA*, *hemC*-5', *hemC*-3', *hemX* and *hemD*) is derived from the GenBank report Accession number AE000456. The black arrow represents the 767 base-pairs long PCR fragment carrying the cholamphenicol-resistance gene (*Cam*), encoding chloamphenicol acetyltransferase (*CAT*), replacing 806 base-pairs of the *hemC* coding sequence. *HemC*-5' and *hemC*-3' correspond
- 10 to 149 and 16 base-pairs respectively, of the coding sequence of the disrupted *hemC* gene. *EcoR* I, *Xho* I and *Hind* III are engineered restriction sites. The sequence of this 3225 base-pairs long fragment is shown in Seq. ID NO 2. The two *Xho* I sites are at positions 1072 and 1839 in the sequence, respectively.

- 15 Table 4 Oligonucleotide primers used in the construction of the production strain PBGD-2

ICO386 (54 mer) Construction of plasmid pExp1

5' AAT TCT AAC ATA AGT TAA GGA GGA AAA AAA AAT GAG AGT TAT TCG TGT CGG  
20 TAC 3'

ICO387 (46 mer) Construction of plasmid pExp1

5' CGA CAC GAA TAA CTC TCA TTT TTT TTT CCT CCT TAA CTT ATG TTA G 3'

25 ICO424 (32 mer) Construction of plasmid pExp1-M2

5' GAT CAC TCA TGT TTG ACA GCT TAT CAT CGA TT 3'

ICO425 (31 mer) Construction of plasmid pExp1-M2

5' AGC TAA TCG ATG ATA AGC GTC AAA CAT GAG T 3'

30

ICO437 (32 mer) Amplification of product P1

5' AGT CAG AAT TCA GAC GCA CGG CGG TAC GAT AA 3'

ICO438 (32 mer) Amplification of product P1

35 5' ATT CAC TCG AGG TCA CCA TCG GTA CCA GTT CA 3'

ICO440 (32 mer) Amplification of product P2  
 5' AGA TCA AGC TTC GGC CAG ACG CAG GTT ATC TA 3'

5 ICO505 (34 mer) Amplification of product P2  
 5' ATA CAC TCG AGA CCG GCA TGA GTA TCC TTG TCA C 3'

---

ICO510 (30 mer) Amplification of Cam gene  
 5' ACT GAC CTC GAG CGG CAC GTA AGA GGT TCC 3'

10

ICO511 (29 mer) Amplification of Cam gene  
 5' ACT GAA CTC GAG AAT TAC GCC CCG CCC TG 3'

15 Accordingly, the cDNA used for expressing rhPBGD was derived from plasmid pPBGD1.1. The starting host strain was derived from JM105 and is called JM105-H-R6-C. The genotype and the details on its construction are described above. A large part of the coding region of the *hemC* gene was replaced by the Cam gene, encoding chloramphenicol acetyltransferase. This gene replacement was confirmed by PCR amplification of the  
 20 segment of the *E. coli* genome followed by restriction analysis of the amplified product. As a result of the gene replacement, the strain is resistant to chloramphenicol and grows extremely poorly on LB medium. Growth improves when LB medium is supplemented with hemin.

## 25 Expression construct

The expression plasmid in the final production strain is pExp1-M2-BB. Its construction is described above. A detailed map of the plasmid showing the open reading frames and functionally relevant regions is shown in Figure 9. The complete DNA sequence is included in Seq. ID NO 1. All synthetic adapters and linkers used during the construction have been  
 30 sequenced along with all junctions created during ligation which directly impinge upon the expression of the cloned gene.

---

## Production strain

The final production strain is called PBGD-2. It was obtained by introducing the expression  
 35 plasmid pExp1-M2-BB into the host strain JM105-H-R6-C, essentially, by rendering the cells competent with 100mM CaCl<sub>2</sub> (Morrison D.A. 1979, Methods.Enzymol. 68:326-331)

and selecting for transformants on LB + ampicillin media at 30°C. The plasmid is a derivative of pBR322 without the *rop* gene and should be present extrachromosomally in moderate copy number at 30°C with a slightly higher copy number at elevated temperatures 37°C and greater (Makrides S.C. 1996, Microbiol.Rev. 60(3):512-538). It has both the ampicillin and tetracycline resistance genes as selectable markers. It also expresses rhPBGD which can complement the *hemC* defect of the host strain. As a result, the production strain should grow normally on LB/M9 media, be resistant to the antibiotics ampicillin and tetracycline and also be resistant to the antibiotic chloramphenicol (because of the presence of the Cam gene in the genome). It was confirmed to have all these characteristics.

### Expression

The expression of rhPBGD is driven by the *tac* promoter which is regulated by the copy of the *lac<sup>R</sup>* gene present in the host. Due to the modifications made to the system as described in the study plan, the uninduced level of expression is 1.8 units/mg (see Appendix 3 for assay details), which amounts to approximately 10% of the total soluble protein. The culture is grown throughout at 30°C and no induction step is used to increase expression.

### Evaluation and conclusions

The expression system developed for the production of rhPBGD in *E. coli* is a stable system, producing good amounts of rhPBGD in a constitutive manner when the cells are grown at 30°C. The host strain employed is partially deleted for the gene producing the endogenous *E. coli* porphobilinogen deaminase. After transformation with the expression plasmid, the resulting production strain PBGD-2 grows as well as the strain PBGD-1 (which is JM105 carrying the same expression plasmid) and makes the same amount of rhPBGD.

Alternative expression construct:

Expression plasmid pExp1-M2-Puc-BB and expression of rhPBGD in *E. coli*

30

The plasmid pExp1-M2 was digested with Pvu I and Afl III and the larger of the two fragments corresponding to a size of 4745 base-pairs was isolated. This was ligated to the 1257 base-pairs long Pvu I-AflIII fragment derived from pUC19 containing the origin of replication and part of the ampicillin resistance gene to obtain plasmid pExp1-M2-Puc. This was passaged through JM110 and cut with BsaA1 and BsaB1 to excise the *rom* gene



contained between the two sites and blunt-ended together to yield the final expression plasmid pExp1-M2-Puc-BB. The pExp1-M2-Puc-BB plasmid has been fully sequenced and differs from pExp1-M2-BB only in that C in position 2769 is T in pExp1-M2-Puc-BB.

5

#### Expression of rhPBGD in *E. coli*

The *E. coli* K12 host strain JM105 genotype endA thi rpsL sbcB15 hsdR4  $\Delta$ (lac-proAB)

---

[F'traD36 proAB lacI<sup>q</sup>  $\Delta$ (lacZ)M15 ] containing the expression plasmid pExp1-M2-Puc-BB

was grown in LB broth containing 100  $\mu$ g/ml ampicillin at to mid-log phase at 30°C from a 1

10 to 40 dilution of an overnight inoculum. The culture was then split into three and growth was continued for another 4 hours at 30°C, 37°C and 42°C respectively. Cells were spun down from 1 ml samples and frozen at -20°C. The thawed cell pellets were resuspended in 200-300  $\mu$ l of B-PER reagent PIERCE Cat. # 78243, incubated at room temperature for 10 minutes, spun at 16,000 for 10 minutes and PBGD activity was determined in the

15 supernatants. Total protein was estimated by the Bradford method using the BioRad reagent Cat # 500-0006 and bovine serum albumin as standard. The specific activities in the crude lysates obtained at the three growth temperatures are tabulated below. The results clearly show an increase of PBGD units/mg with increasing temperature in the range from 30°C to 40°C.

20

Temperature	PBGD Units/mg
30°C	363
37°C	573
42°C	1080

25

#### Other Production Systems For rhPBGD

For yeast production, the PBGD coding sequence can be inserted into a plasmid vector, for example YEP type, containing 2 u circular DNA (Ori) origin for high expression in yeast.

30 YEP plasmids contain TRP 1 and URA 3 as markers for selective maintenance in trp1-, ura3-yeast strains.

---

Alternatively, the PBGD gene can be inserted in bovine papilloma virus vectors BPV for high expression in a murine cell line C-127 (Stephens P.E. et. al. Biochem J. 248, 1-11, 1987) or vectors compatible with expression in CHO cells or COS cells.

5 An expression of PBGD can be made intracellularly.

---

A secretory signal in *Saccharomyces*, for example alpha-mating factor presequence, can be added in front of the rhPBGD structural gene for efficient secretion in yeast.

- 10 Similarly, a sequence encoding a mammalian signal peptide can be added for secretion of rhPBGD into the culture medium upon expression in for example CHO cells or COS cells.

A bacterial promoter for example the tryptophane (trp) promoter or the lac promoter or alternatively an alkaline phosphatase promoter, should be inserted before the PBGD

- 15 coding region for efficient transcription in prokaryotes for example *E. coli*.

A yeast promoter for example 3-phosphoglycerate kinase (PGK) or chelatin or alpha-mating factor should be inserted before the PBGD coding region for efficient transcription in yeast for example *Saccharomyces cerevesiae* or *Saccharomyces pombe*.

20

A mammalian promoter for example Metallothionin-1 (MT-1) or Aspartate transcarbamylase or Dihydrofolate reductase (DHFR) should be inserted before the PBGD coding region for efficient transcription in mammalian cell lines for example CHO cells or COS cells.

25

The yeast plasmid (Y-G&F-PBGD) containing a yeast promoter, signal and/or ATG codon (methionine) in front of the PBGD coding region and a yeast vector containing selectable markers such as URA 3 or TRP 1 will be transformed into the yeast host cell such as *Saccharomyces cerevesiae* or *Saccharomyces pombe* for production of rhPBGD.

30

---

The mammalian plasmid (M-G&F-PBGD) containing a mammalian promoter for example Metallothionine-1 or Dihydrofolate reductase and a mammalian signal sequence or an ATG codon in front of the PBGD coding region and vector pAT or pSV2 respectively. Plasmid (M-G&F PBGD) may be transfected into a mammalian cell line for example CHO cells, for

- 35 production of rhPBGD.

The E. coli cell containing plasmid (pExp1 or pExp1-M2 Puc-BB), may be fermented to stationary phase between 24-48 hours, in a medium containing casein hydrolysate, or yeast extract, glucose, vitamins and salts. pH oxygen may be monitored by electrodes  
5 during fermentation. Temperature will be kept at 37 +/- 2 C during the fermentation.

The yeast cell containing the plasmid (Y-G&F-PBGD), may be fermented to late log phase  
between 20-40 hours in a medium containing yeast extract, glucose, salts and vitamins. pH  
and temperature will be monitored by specific electrodes during fermentation. Temperature  
10 will be kept at 30 +/- 2 C during fermentation.

The mammalian cell line containing the plasmid (M-G&F-PBGD) may be fermented in a medium containing, foetal calf serum (or serum free), vitamins, glucose, antibiotics, growth factors. pH and temperature will be monitored continuously during fermentation by specific  
15 electrodes.

#### Fermentation and Purification

rhPBGD may be recovered from E. coli after fermentation by an extraction procedure involving for example ribipress, sonication, osmotic shock or total solubilization by  
20 detergent for example Tween 80, Triton X-100 or Brij. rhPBGD will be recovered from fermentation medium after production in yeast or from a total cellular extract using detergents such as Triton X-100, Tween 80 or Brij. rhPBGD will be recovered from mammalian culture medium or from a total cellular extract by ion-exchange chromatography or affinity chromatography.

25 rhPBGD may be purified from E. coli extract or from yeast medium or total cellular extract or from mammalian culture medium or total mammalian cellular extract by binding to an ion-exchange column for example DEAE-Sepharose or MonoQ-Sepharose and eluted with for example NaCl and Sodium phosphate buffer pH 7-8 or the corresponding potassium  
30 salts.

---

Alternatively, rhPBGD may be recovered from extracts by binding to an affinity chromatography column for example an anti-PBGD affinity column. rhPBGD will be eluted by lowering the pH to 4-2, or a thiol specific affinity column. rhPBGD has been "tagged"

with thiols residues when a thiol affinity column step is used. Thiols will be removed by a specific enzymatic cleavage step to generate authentic rhPBGD.

The ion-exchange or affinity purified rhPBGD will be further purified by hydrophobic

- 5 interaction chromatography on for example, TSK Phenyl 5 PW column or Octyl-Sepharose or Phenyl-Sepharose columns.

---

Binding of rhPBGD may be done at high ionic strength for example in 10-50 mM Tris-HCl pH 7-8, 1M NaCl or 10-15 mM Sodium phosphate pH 7-8, 0.5 M MgSO<sub>4</sub> and eluted by

- 10 lowering the ionic strength for example with 10-50 mM Tris-HCl pH 7-8 or 10-50 mM Sodium phosphate pH 7-8.

Three hydrophobic interaction steps will be applied consecutively.

- 15 rhPBGD is further purified with preparative RP-HPLC for example C12 or C18 matrixes. The rhPBGD is be eluted from the column by a gradient of 10-50 mM Sodium phosphate and 1-10% acetonitrile buffer.

Formulation of rhPBGD is done by passing the enzyme over a G-100 Sephadex column

- 20 and eluting it in an isotonic solution for example 0.9%NaCl and 10-50mM Sodium phosphate pH7.0 +/- 0.5 or Sodium phosphate, glycine, mannitol or the corresponding potassium salts.

For the preparation of a medicament, the formulation solution of rhPBGD may be sterile

- 25 filtered and filled aseptically in glass vials and lyophilised.

Alternatively, the sterile filtered rhPBGD solution is formulated in for example, lipid vesicles constituting phosphatidylcholine or phosphatidylethanolamine or combinations of these or incorporated into erythrocyte ghosts.

30

Reconstitution of lyophilised rhPBGD may be done in water for injection.

---

Alternatively, rhPBGD is formulated in a sustained release formulation involving a

- biodegradable microspheres, for example in polylactic acid, polyglycolic acid or mixtures of  
35 these.

Alternatively, rhPBGD is lyophilized in a two-compartment cartridge, where rhPBGD will be in the front compartment and water for reconstitution in the rear compartment. This two compartment cartridge may be combined with an injection device to administer either  
 5 rhPBGD by a needle or needle less (by high pressure) device.

Alternatively, rhPBGD may be formulated in a physiological buffer containing an enhancer for nasal administration.

---

10 Alternatively, rhPBGD is formulated in an oral formulation containing for example, lipid vesicles (phosphatidylcholine, phosphatidylethanolamine, sphingomyeline) or dextrane microspheres.

Although recombinant production of PBGD is preferred for the treatment of AIP, it can  
 15 alternatively be produced from human red blood cells.

A general production and manufacturing of recombinant PBGD may be done by the following steps.

20 Recombinant PBGD production process; an outline

A: Fermentation

1. Master cell bank
2. Working cell bank
- 25 3. Production of seed culture
4. Fermentation in large fermenter (250 L >)

B. Purification

1. Cell concentration by filtration/centrifugation
- 30 2. Cell disruption
3. Ultrafiltration

- 
4. Chromatography ion exchange, DEAE-Sepharose, MonoQ-Sepharose
  5. Hydrophobic interaction chromatography (Octyl/phenyl-Sepharose, TSK Phenyl, 5PW, Phenyl-Sepharose
  - 35 6. Chromatography ion exchange (MonoQ)

## 7. Formulation by Gel filtration Sephadex G-100

### C. Manufacturing

1. Sterile filtration
- 5 2. Aseptic filling
3. Lyophilization

## Treatment of other porphyrias

- 10 In analogy with the new treatment of AIP patients with (recombinant) PBGD, hepatic Porphyrias such as ALA deficiency Porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary Coproporphyria (HCP) and Variegata Porphyria (VP) can benefit from substitution therapy by rALA dehydratase, rUroporphyrinogen decarboxylase, rCoproporphyrinogen oxidase and rProtoporphyrinogen oxidase, respectively.

15

Patients having Erythropoietic Porphyrias such as Congenital erythropoietic Porphyria (CEP) or Erythropoietic protoporphyria (EPP) will benefit from substitution therapy with rUroporphyrinogen III syntetase and rFerrochelataase, respectively.

- 20 Hepatoerythropoietic Porphyrias e.g. Hepatoerythropoietic Porphyrias(HEP) can be treated with rUroporphyrinogen decarboxylase.

- All porphyrias can be treated by the administration of the enzymatic activity lacking or being reduced (normally 50%) in any of the eight steps in the heme biosynthetic  
25 pathway as described above.

The substitution of the enzymatic activity can be achieved by adding the corresponding recombinant enzyme or other molecules that will provide the missing enzymatic activity.

- 30 Gene therapy as an alternative treatment for patients wiht acute intermittent porphyria (AIP)

The human enzyme Porphobilinogen deaminase PBGD is coded for by a single gene located on chromosome 11q 24.

35

Mutations in this gene causes the disease Acute Intermittent Porphyria (AIP). The disease has been shown to be inherited in an autosomal dominant way.

Today over 100 mutations in the PBGD gene has been identified (Grandchamp B. J.

- 5 Gastroenterology and Hepatology, 11, 1046-1052, 1996, Table A) and the number is expected to increase when modern diagnostic systems based on screening programs will be applied more routinely in hospitals. A number of these mutations are shown in Table A.

Table A Reported mutations in the PBGD gene

	Position	Mutation	Consequences	Reference
Exon 1	3	ATG→ATA	Translation impairment	18
	33	GCG→GCT	DS	17
<i>Intron 1</i>	33 + 1	gtg→atg	DS	16
Exon 3	76	CGC→TGC	R26C	25
	77	CGC→CAC	R26H	26
Exon 4	91	GCT→CACT	A31T	24
	97	Del A	Frameshift	25
	100	CAG→AAG	Q34K	27
	100	CAG→TAG	Q34X	25
	125	TTG→TAG	L42X	19
Exon 5	163	GCT→TCT	A55S	24
	174	Del C	Frameshift	24
	182	Ins G	Frameshift	24
<i>Intron 5</i>	210 + 1	gta→ata	DS (Del exon 5)	24
Exon 6	218-219	Del AG	Frameshift	24
Exon 7	277	GTT→TTT	V93F	24
	293	AAG→AGG	K98R	25
	331	GGA→AGA	G111R	28
<i>Intron 7</i>	345-1	cag→caa	AS (Del exon 8)	29
Exon 8	346	CGG→TGG	R116W	20
	347	CGG→CAG	R116Q	30
Exon 9	445	CGA→TGA	R149X	25
	446	CGA→CAA	R149Q	31

41

446	CGA→CTA	R149L	24
463	CAG→TAG	Q155X	32
470	Ins A	Frameshift	29

---



Table A cont.

	Position	Mutation	Consequences	References
<i>Intron 9</i>	499-1	cag→caa	AS (Del exon 10)	21
Exon 10	499	CGG→TGG	R167W	33
	500	CGG→CAG	R167Q	27,34
	518	CGG→CAG	R173Q	34
	530	CTG→CGG	L177R	27
	593	TGG→TAG	W198X	19
	604	Del G	Frameshift	35
	610	CAG→TAG	Q204X	30
	612	CAG→CAT	DS (Del 9 bp exon 10)	31
Exon 11	625	GAG→AAG	E209K	28
<i>Intron 11</i>	652-3	cag→gag	AS (Del exon 12)	33
Exon 12	667	GAA→AAA	E223K	24
	673	CGA→GGA	R225G	25
	673	CGA→TGA	R225X	25
	713	CTG→CGG	L238R	25
	715-716	Del CA	Frameshift	19
	730-731	Del CT	Frameshift	36
	734	CTT→CGT	L245R	31
	739	TGC→CGC	C247R	36
	740	TGC→TTC	C247F	18
	742	Ins 8 bp	Frameshift	24
	748	GAA→AAA	E250K	24
	754	GCC→ACC	A252T	36
	755	GCC→GTC	A252V	36
	766	CAC→AAC	H256N	27
	771	CTG→CTA	DS (Del exon 12)	39
	771	CTG→CTC	DS (Del exon 12)	37
<i>Intron 12</i>	771 + 1	gta→ata	DS (Del exon 12)	19

Table A cont.

	Position	Mutation	Consequences	References
Exon 13	806	ACA→ATA	T269I	30
	820	GGG→AGG	G274R	30
Exon 14	838	GGA→AGA	G280R	25
	848	TGG→TAG	W283X	30
	886	CAG→TAG	Q296X	25
	900	Del T	Frameshift	31
Intron 14	912 + 1	gta→ata	DS (Del exon 14)	28
Exon 15	1062	Ins C	Frameshift	38
	1073	Del A	Frameshift	25

- 5 In one aspect, the present invention relates to a therapeutic method for AIP patients based on gene therapy.

The gene therapy treatment may involve the following steps.

- 10 1. Identification mutations in the PBGD gene causing AIP in humans  
 2. Selection of human PBGD cDNA sequence for gene therapy  
 3. Construction of PBGD gene therapy vectors.  
 4. Production of PBGD gene transfer vector  
 5. Delivery system of PBGD gene transfer vector

15

1. Identification of mutations in the PBGD gene causing AIP in humans

Patients having a point mutation in Exon 10 at position 593 TGG>TAG have a change in the amino acid sequence of the PBGD enzyme from W198X (stop codon). This mutation is  
 20 carried by approximately 50 % of all AIP patients in Sweden (Lee JS. et al. Proc. Natl. Acad. Sci. USA, 88, 10912-10915, and 1991). AIP patients with other mutations than W198X, which might also benefit from gene therapy, are given in Table A.

2. Selection of human PBGD cDNA sequence for gene therapy

25

There are two isoenzyme forms of human PBGD e.g. erythropoietic and the non-erythropoietic form, which are formed by an alternative splicing mechanism.

The non-erythropoietic form has a 17 amino acid extension on the N-terminal end of the erythropoietic PBGD form.

5

Non-erythropoietic PBGD form (nPBGD):

---

Met-Ser-Gly-Asn-Gly-Asn-Ala-Ala-Ala-Thr-Ala-Glu-Glu-Asn-Ser-Pro-Lys-Met-Arg-Val...

ATG-TCT-GGT-AAC-GGC-ATT-GCG-GCT-GCA-ACG-GCG-GAA-GAA-AAC-AGC-CCA-AAG-ATG-

10 AGA-GTG..

Erythropoietic PBGD form (ePBGD):

Met-Arg-Val-

15

ATG-AGA-GTG...

The nucleotide and amino acid sequence for human PBGD that will be used for gene therapy differs from that published by Raich N. et al. Nucl. Acid. Res. 14, 5955-5968, 1986 in that the amino acid residue in position 332 is an Asn residue rather than Thr. In order to make the "wild type enzyme" and avoiding formation of antibodies the PBGD sequence has to contain an Asn residue in position 332. The cDNA sequence that will be used for the erythropoietic PBGD form is shown above.

Patient with a defect erythropoietic PBGD enzyme will be transfected with the erythropoietic PBGD cDNA sequence and patients with a defect in the non-erythropoietic form will be transfected with the non-erythropoietic cDNA sequence.

### 3. Construction of PBGD gene therapy vectors

#### 30 Adenoviral vector system

The vector is based on adenovirus type 5 (Ad5), containing three essential genetic loci E.g. E1, E2, E4, encoding important regulatory proteins and one locus E3 which is non-essential for virus growth. Deletion of E1A and E1B region renders the virus replication deficient in vivo. Efficient complementation of the E1 function (recombinant viral stocks) can be obtained in an E1 expressing cell line such as human 293-cell line.

The human PBGD cDNA will be inserted in an adenovirus vector system.

The PBGD transgenes will be driven by the endogenous PBGD promoter or a cytomegalovirus promoter (CMV).

5

#### Retroviral vectors

Retroviral vectors are well suited for gene delivery for several reasons:

---

1. simplicity
- 10 2. capacity to integrate up to 8kbp DNA inserts
3. their safety, non pathogenic to humans
4. easy to improve and manipulate
5. defined integration sites of genes
6. long term regulated expression

15

One major disadvantage with the retroviral vectors though, is that they can only transduce dividing cells.

- Most common retroviridae considered for gene therapy, are the lentiviridae and the
- 20 mammalian C-type viridae. Other type retroviruses have also been considered. One such example, is a Moloney-murine leukemia retrovirus (Mo-MLV), which has been successfully used to transduce mouse and human fibroblasts with the uroporphyrinogen III synthetase (UROHIS). (Moreau-Gaudry et al. Human Gene Therapy 6, 13-20, 1995).

- 25 The expression of the UROHIS gene was driven by long terminal repeat (LTR). The UROHIS cDNA was also successfully transduced by the retrovirus vectors into human peripheral blood progenitor cells.

- The erythropoietic PBGD cDNA sequence can be inserted in a retrovirus vector LXS
- 30 (Miller et al BioTechniques 7, 980-990, 1989) and pMFG (Dranoff et al. Proc. Natl. Acad.Sci. USA. 90,3539-3543, 1993). This will lead to the following constructs e.g. LePSN and pMFG-ePBGD, respectively.
- 

LePSN:

35

> 1032 bp <  
 LTR-----/ cDNA ePBGD / SV40 / Neo /-----LTR

pMFG-ePBGD:

5

> 1032 bp <  
 LTR-----/ cDNA ePBGD/-----LTR

---

For transduction of non-erythropoietic tissues the non-erythropoietic cDNA (See sequence  
 10 12) will be inserted in the LSXN vector and the pMFG vector resulting in the LSnPN and  
 pMFG-nPBGD vectors, respectively.

LnPSN:

15 > 1083 bp <  
 LTR-----/ cDNA nPBGD / SV40 / Neo /-----LTR

pMFG-nPBGD:

20 > 1083 bp <  
 LTR-----/ cDNA nPBGD/-----LTR

The LePSN and LnPSN vectors can be converted to the corresponding virus by transfer  
 into an appropriate host cell line e.g.  $\Psi$  CRE as described by (Danos et al. Proc. Natl.  
 25 Acad. Sci. USA. 85, 6460-6464, 1988). Filtered supernatants from ectopic virus producing  
 cells were added to amphotropic cells  $\Psi$  CRIP, in the presence of Polybrene. Clones can  
 be isolated and tested for virus. Clones that show titers over 1.000.000 cfu/ml will be saved  
 (resistant to G418). The LnPSN vector will be cotransfected with the pMCI-Neo plasmid  
 (Pharmacia, Sweden) into the packaging cell line  $\Psi$  CRIP. Clones that shows integration of  
 30 provirus and high expression levels of message will be selected.

---

Filtrate from supernatants from virus producing cells (erythropoietic PBGD form) can be  
 mixed with Polybrene and incubated with peripheral blood progenitor cells (bone marrow  
 transplant) from an AIP patient for several hours. The transduced progenitor cells can then  
 35 be transplanted back into an AIP patient.

The success of the treatment will be measured as the increase in the PBGD activity in erythrocytes and reduced excretion of ALA and PBG in the urine. Clinically a success of the treatment can be evaluated as a reduction of frequency of spontaneous acute attacks or drug-induced attacks. This will be a more convenient way of administering the recombinant PBGD enzyme than regular injections. The efficacy of the therapy can be evaluated by measuring the PBGD activity in blood and reduced excretion of PBG and ALA in the urine. Clinically, a successful treatment should result in less number of acute attacks or preferably no more attacks.

10

#### Associated Adenovirus system (AAV)

AAV is a non-pathogenic human virus (Parvovirus) carried by more than 80% of all people. The advantage with AAV as compared to retroviral systems is that AAV can transduce both dividing and non-dividing cells. The virus genome, which is small, contains two Inverted Terminal Repeats (ITR) and a REP and CAP functions. The REP and CAP functions can be deleted and exogenous cDNA inserted. Construction of an AAV vector containing the erythropoietic PBGD cDNA can be made. This AAV/PBGD vector will be suitable to transduce AIP patient's bone muscle cells, as a "muscle factory" for PBGD enzyme production. The PBGD cDNA will be engineered in such a way that a signal sequence for secretion will be added on the 5'-end of the cDNA. This will allow the erythropoietic PBGD enzyme to become secreted from the muscle cells into the blood stream. By this system patients will receive a constant delivery of active PBGD enzyme into the bloodstream, which will metabolize PBG thereby avoiding acute attacks.

#### 25 - Non-erythropoietic

Alternatively, liver cells can be transduced with AAV containing the non-erythropoietic PBGD cDNA. The construct will be engineered in such a way that the translated PBGD enzyme will remain intracellular e.g. contain a Met residue at the N-terminal end of the PBGD enzyme without a signal sequence for secretion in mammalian cells. The PBGD transgene will be transcribed and translated into new PBGD enzymes that will remain intracellularly. Levels of new PBGD enzymes made in the liver will be normalized the PBGD activity to 100%. AIP patients have usually reduced PBGD activity (50-80%) in the liver depending on the mutation and individual variations.

This treatment would alleviate the clinical symptom e.g. acute attacks with abdominal pain and reduce excretion of PBG and ALA in the urine. The AAV containing the non-erythropoietic PBGD form can also be used to correct the genetic defect in other cell types such as neuronal tissue, pancreas spleen e.g. non-erythropoietic tissue, by a similar  
5 mechanism.

#### - Erythropoietic

The erythropoietic PBGD cDNA can be inserted in an AAV vector and used to transduce erythropoietic cells and stem cells in AIP patients, having a mutation affecting the  
10 erythropoietic form of PBGD.

#### 4. Production of PBGD gene transfer vector

Adenovirus have approximately 36 kbp double stranded DNA, containing three essential  
15 early gene loci (E1, E2, and E4) encoding important regulatory proteins. Loci E3 codes for a gene product that block immune response to virus infected cells *in vivo*. The PBGD gene transfer adenovirus vector can be produced by deleting the E1 and E3 loci. The PBGD gene cassette is inserted in that position instead. The virus will be replication defective when the E1 locus has been deleted. Efficient E1 complementation and thus high yield of  
20 recombinant virus vector (PBGD) can be obtained in an E1 expressing cell line, such as the human 293 cell line. (Graham, F. et al. 1977, Characteristics of a human cell line transformed by DNA from human adenovirus 5. J. Gen. Virol. 36, 59-72).

#### 5. Delivery systems of PBGD gene transfer vectors. 25

Delivery of viral vectors are based on injection into the patient of a virus particle that will transduce human cells *in vivo*.

#### Correction of point mutations causing AIP by Chimeraplasty Gene Repair

30 The basic technique involves the synthesis of chimeric (RNA-DNA) oligonucleotides. The oligonucleotide will repair point mutations on the chromosome by binding to the site of mutation and create a mismatch. The endogenous "mismatch repair system" which is present in all living cells, will correct the mutation.

35 The Chimeric oligonucleotides has the following general properties:

- a. 68 mer (65-70 is acceptable size)
- b. 25 base DNA stretches at the 5'-end homologous to the normal sequence of the gene
- c. the 25 base DNA is designed in such a way the 12 bp on each side of the mutation
- 5 is complementary to "wild-type DNA" where the mutation to be altered is located at position 13
- d. the 25 mere contains 4 T bases at the one end to loop back the oligo to the other  
DNA strand with a 25 base sequence homologous to the other strand of the chromosomal DNA.
- 10 e. the second strand is chimeric in that it contains 10 homologous bases of 2'O methyl RNA followed by 5 bases of DNA (containing a central mismatch e.g. correction of the human point mutation by mismatch repair) followed by another stretch of 10 bases of homologous 2'O methyl RNA. This stretch of DNA/RNA is followed with 5 bases of GC clamp and 4 T bases to form the second loop and finally a 5 base CG clamps
- 15 complementary to the other one.

#### EXAMPLE A

##### Correction of the PBGD mutation at position 593 TGG>TAG resulting in W198X

20

Normal Chromosomal Sequence:

5'-AG CGC ATG GGC TGG CAC AAC CGG GT-3'

Gln Arg Met Gly Trp His Asn Arg Val


25 AIP Chromosomal Sequence:

5'- AG CGC ATG GGC TAG CAC AAC CGG GT-3'

Stop



The sequence of the chimeric oligonucleotide ( Heme593W/X) is:



- 20 The same principle of chimeric oligonucleotide can be constructed to correct any of the mutations causing AIP depicted in Table A.

Chimeric oligonucleotides can be used to correct any other point mutation causing any of the 8 known Porphyrias in a similarly as described above.

25

#### Delivery of PBGD gene transfer of non viral vectors to humans

- The chimeric oligonucleotide can be formulated in a vehicles preparation containing
- 30 anionic or cationic phospholipids or phospholipids mixed with neutral lipids or lictosylated PEI.

Alternatively, the non-viral vectors can be formulated in liposomes containing mixtures of natural phospholipids and neutral lipids.

35

Specific protein sequences can be incorporated into liposomal membranes, that recognizes cellular receptors for specific targeting of non-viral vectors to a specific cell type such as liver, neuronal tissue or erythropoietic tissues, can be incorporated. Alternatively specific antibodies recognizing specific cellular surface antigens can be used for targeting. Thirdly,  
 5 carbohydrates on the liposomal membrane can be used for liver uptake of chimeric oligonucleotides.

---

The formulated chimeric oligonucleotide (HemeBiotech 595 W/X) will be administered by sc. or IV. injections to AIP patients.

10

The efficacy of the treatment can be evaluated as above.

Gene therapy as an alternative treatment of other porphyric diseases

15 The gene therapy strategies outlined herein can also be used for other Porphyric diseases. The general principle is to increase the cellular or systemic content of a particular defective enzyme causing the disease. The following Porphyric diseases can be encompassed by this strategy:

20 ALA deficiency porphyria (ADP)

Porphyria cutanea tarda (PCT)

Hereditary coproporphyria (HCP)

Harderoporphyria (HDP)

Variegata porphyria (VP)

25 Congenital erythropoietic porphyria (CEP)

Erythropoietic protoporphyria (EPP)

Hepatoerythropoietic porphyria (HEP)

30 In the following Examples, preferred embodiments of the invention is disclosed relating to rhPBGD

---

#### EXAMPLE 1

35 Fermentation of recombinant human Porphobilinogen Deaminase (rhPBGD)

Strain PBGD-1 is an *E. coli* K12 host strain JM105 genotype endA thi rpsL sbcB15 hsdR4  $\Delta(\text{lac-proAB})$  [F'traD36 proAB lacI<sup>q</sup>  $\Delta(\text{lacZ})$ M15 ] containing the expression plasmid pExp1-M2-BB. Strain PBGD-2 has the same expression plasmid pExp1-M2-BB but the host cell is  
 5 deleted for the hemC gene to facilitate rhPBGD purification. Since the strain PBGD-2 was not ready at the start of the study, the decision was made to start the study with strain PBGD-1. Both the strains are resistant against both tetracycline and ampicillin, but due to regulatory advantages it was decided to use oxytetracycline as selection pressure. To focus the first part of the study on the expression level of rhPBGD, and not the strain  
 10 stability, it was decided to start the development with selection pressure in the fermenter. When the expression level was satisfactory strain stability without selection pressure in the fermenter should be investigated. Preliminary tests performed showed that the expression level of rhPBGD was 1,5 times higher at 37°C compared to the expression at 30 °C. At 42°C it was as much as 3 times higher. Based on this knowledge one would suggest a  
 15 temperature induction to either 37°C or 42°C during the fermentation to boost the rhPBGD production. However, at higher fermentation temperatures the strain stability might be a problem. The time frame was too narrow to study the rhPBGD expression at all three temperatures, so the decision was to start the study without temperature induction and to keep the temperature at 30°C during the whole process.

20

#### Short description of the work

During the first two months the strain PBGD-1 was cultivated on agar plates and in shake flasks to obtain information about the strain characteristics. In parallel to this purchase of study dedicated chemicals, build up of the documentation system and technology transfer  
 25 of the analytical methods took place. When the PBGD-1 intermediary cell bank was prepared the actual fermentation work started. First two "simple" 1-L batch fermentations of strain PBGD-1 were used to test the newly designed substrate and to calculate the maximum growth rate for the strain. After that three 10 L fed batch fermentations of strain PBGD-1 was performed.

30

---

As soon as the strain PBGD-2 was available and an intermediary cell bank was prepared,

this strain was implemented in the fermentation procedure developed for strain PBGD-1. At present two 10-L fermentations of strain PBGD-2 have been performed.

The general outline of the fermentation is starting with inoculum preparation on M9-tc agar  
 35 plates and shake flasks. The cells are incubated at 30°C for 24 h on M9-tc agar plates and

are then transferred to M9-*tc* shake flasks. The shake flasks are incubated for 12-14 h at 30°C. The broth from 1-2 shake flasks are used to inoculate the 10 L fermenter containing a minimal medium supplemented with yeast extract, trace elements, thiamine and oxytetracycline as selection pressure. The fermentation starts with a 14-h batch phase where the cells grow at maximum growth rate. The glucose feed is started after 14 h and the feed rate profile is varied between 25-75 ml/h of a 600 g l<sup>-1</sup> glucose solution.

Broth taken from shake flasks and fermentations have been used to develop the down stream processing and to test and adjust the analytical methods provided. The general outline in the down stream processing is concentration of the fermentation broth on a 0,22 µm cross flow membrane followed by diafiltration (washing) with a buffer to exchange 90-95 % of the substrate with buffer. The diafiltered cell concentrate is homogenised in a homogeniser, where the pressure has been varied between 600 – 1000 bars. The cell debris is then removed from the homogenate either by filtration on the same membrane as mentioned above or by centrifugation. Finally the extract is sterile filtered into sterile containers.

## Results

### 20 Fermentation

The maximum growth rate for strain PBGD-1 was determined in shake flask experiments and in 1-L batch fermentations. The results are summarized in Table 5 below. The reason for the lower values in the shake flask with fermenter medium is probably acetic acid production and hence lower pH since the pH is not controlled. No experiments have been performed to calculate the maximum growth rate of strain PBGD-2, but from the fact that the batch phase has the same duration as for PBGD-1 we can draw the conclusion that the maximum growth rate is approximately the same.

Table 5 Maximum growth rates

Conditions	Maximum growth rate ( $\mu_{\max}$ ) [h <sup>-1</sup> ]
M9- <i>tc</i> Shake flask	0,3
Shake flask with fermenter substrate	0,3
1 L Fermenter with pH controlled at 7,0	0,4

The developed substrate for the fermentation is given in Table 6 on the next page. When implementing strain PBGD-2 it seems like this strain has different requirements on either the amount of yeast extract or the thiamine concentration in the substrate. When using the substrate developed for strain PBGD-1 the growth stops or lags during the fermentation 5 (PD14). When adding extra yeast extract and thiamine the growth starts again. This pattern is repeated at least two times during the fermentation.

Table 6 Fermenter substrate

Component	Mw [g/mol]	Concentration	Unit
$(\text{NH}_4)_2\text{SO}_4$	114,12	2,70	[g/l]
$\text{KH}_2\text{PO}_4$	136,08	3,25	[g/l]
$\text{K}_2\text{HPO}_4 \cdot 3\text{H}_2\text{O}$	228,23	2,80	[g/l]
$\text{C}_6\text{H}_5\text{Na}_3\text{O}_7 \cdot 2\text{H}_2\text{O}$	258,07	0,60	[g/l]
Yeast extract		5,00 - 20,0	[g/l]
$\text{C}_6\text{H}_{12}\text{O}_6 \cdot \text{H}_2\text{O}$	198,17	10,00	[g/l]
$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	246,50	1,07	[g/l]
Thiamine chloride $\text{C}_{12}\text{H}_{18}\text{Cl}_2\text{N}_4\text{OS} \cdot x\text{H}_2\text{O}$		1,00 - 10,0	[mg/l]
$\text{H}_3\text{BO}_3$	61,83	2,1	[mg/l]
$\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$	249,70	10,5	[mg/l]
$\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$	270,30	35,5	[mg/l]
$\text{MnSO}_4 \cdot \text{H}_2\text{O}$	169,02	6,6	[mg/l]
$\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$	287,50	5,3	[mg/l]
$\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$	237,93	9,3	[mg/l]
$\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$	147,02	14,0	[mg/l]
$\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$	241,95	9,3	[mg/l]
HCl	34,46	6,9	[ml/l]
Oxytetracycline $\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}_9 \cdot \text{HCl}$	496,90	6,0	[mg/l]

The strains seem to utilise different components in the yeast extract in a sequential order. The metabolism and respiration is different for different compounds. This gives rise to an irregular fermentation pattern with large changes in the respiration of the population during

the fermentation, e.g. the CO<sub>2</sub> and the O<sub>2</sub> outlet gas analysis and the dissolved oxygen tension (DOT) signal (see Figure 12).

As the fermentation proceeds, the fermentation broth is gradually coloured bright pink.

- 5 When centrifuging broth for dry weight analysis it is observed that it is the actual cells and not the supernatant that is pink. The colonies on the M9-tc agar plates used to inoculate the shake flasks are not coloured pink, they are rather yellow or white like "normal" *E.coli* cells.
- 10 The colonies on the agar plates used for the colony forming units (CFU) analysis from the fermentation are also pink. However, on the CFU plates from PD14, the first fermentation with the new strain PBGD-2, a small portion of yellow or white colonies was observed. This observation was made already from the plates spread with broth from the inoculum shake flask. The percentage of yellow-white cells was varying in the range 2-8 % during the
- 15 fermentation. Both the white and red colonies were resistant against the antibiotic oxytetracycline. When observing the white and red colonies in the microscope they both appeared as *E.coli* rod like cells. It was hard to see any clear difference, but possibly the white cells were a little bit shorter than the red ones. To investigate this further shake flask cultivation were started with one red and one yellow colony. The CFU analysis showed that
- 20 there were only red colonies from the shake flask inoculated with the red colony, but that the white colony gave rise to approximately 70% white and 30% red cells. The rhPBGD activity and protein concentration were measured in the broth from these shake flasks. The results are shown in Table 7 below. The difference in the protein concentration and the rhPBGD activity is in accordance with the difference in the OD<sub>620</sub> reached in the shake
- 25 flask, probably due to different size of the inoculum colony.

Table 7 rhPBGD activity and total protein from single colony shake flasks

Start colony	Protein [mg/ml broth]	PBGD activity [U/L broth]	Specific activity [U/mg protein]
White	0,01	9	0,8
Red	0,04	27	0,7

- 30 In the Table 8 below a summary of the final values of the fermentations are given. The lower OD<sub>620</sub> and Dw (dry weight) values in fermentation PD12 is a result of the lower

amount of glucose that totally was fed into the fermenter in this fermentation (600 ml compared to approximately 850 ml in PD11 and PD14). It is also interesting to notice the very high expression and specific activity of rhPBGD in fermentation PD14 compared to the earlier fermentations.

5

Table 8 Summary of final fermentation results

Batch	Strain	Time [h]	OD <sub>620</sub>	Dw [g/l]	PBGD activity [U/ml broth]	Specific PBGD activity [U/mg protein]
PD11	PBGD-1	27	82	29	7,7	2,6
PD12	PBGD-1	31	59	19	15,3	1,8
PD14	PBGD-2	30	87	32	39	3,1

Until now we have achieved the best fermentation results in fermentation PD14.

- 10 In the Figures 12 and 13 the fermentation results from this fermentation with the new strain PBGD-2 are shown. After a 14-h batch phase the glucose feed is started according to a schedule with three step changes in the feed rate. However after 16 h the glucose begins to accumulate in the fermenter due to that something else is limiting the growth more. The glucose feed is then stopped and restarted when the glucose concentration becomes
- 15 limiting again.

- The respiration pattern (i.e. CO<sub>2</sub>, O<sub>2</sub> and DOT signals) indicated that something in the substrate was depleted after 14,5 and 22,3 h and 26,3 h (see Figure 12). When extra yeast extract and thiamine was added to the fermenter growth respiration increased dramatically
- 20 for a while. There was a steady increase in the OD<sub>620</sub> and Dw during the whole fermentation and the final values are rather high. The increase in produced amount of rhPBGD correlates very well with the increase in biomass. This is something that has been observed also in the other fermentations. However, in fermentation PD14 there also seems to be a steady increase in the specific activity of the produced rhPBGD. Something
- 25 that has been much less pronounced in the other fermentations.

#### Down stream processing

- The different broths have been concentrated 1,9 – 6,9 times. The different values reflect problems with clogging of the membrane. This problem can probably be avoided by not
- 30 concentrating the broth too much. Instead a somewhat longer diafiltration has to be done.

The homogenisation has given a good yield of released enzyme compared to sonication. Removal of cell debris is in the laboratory scale rather easily done by centrifugation. For the production scale it would be preferred to use membrane filtration and because of that filtration has been tested. However, so far the transmission of enzyme through the  
 5 membrane has been low resulting in low yields. This yield may be improved by better controlled filtration parameters or extended diafiltration. Otherwise a separator could be used in the production.

In Table 9 some data from the down stream processing are shown.

10

Table 9 Summary of down stream results

Broth	Debris removal by	Sterile filtered extract			Yield from broth, %	
		protein mg/ml	activity U/ml	Spec. activity U/mg protein	protein	U
PD11	Filtration	2,7	5,1	1,9	30-60 1)	35-45 1)
PD12	Centrifugation	31	84	2,7	79	120 2)
PD14	Centrifugation	32	92	2,9	85	67
PD14	Filtration	3,8	11	2,8	15	18

1) Uncertainties in analysis, because the methods were not fully evaluated at this time.

15 2) Uncertainty in volume because of a tube leakage.

## Conclusions

20 Strain PBGD-2 has a maximum growth rate of approximately  $0,4 \text{ h}^{-1}$  in the fermenter substrate. This is similar to the maximum growth rate of strain PBGD-1, however the substrate requirement seems to be different for strain PBGD-2. An increase of the initial yeast extract and thiamine concentration in the substrate to  $20 \text{ g l}^{-1}$  and  $10 \text{ mg l}^{-1}$  respectively supports growth to a biomass similar to those achieved with the old strain

25 PBGD-1.

The general fermentation process outline is a 14 h batch phase followed by a 16 h feed phase were the glucose feed rate is increased in three steps.



The production of rhPBGD correlates very well with the biomass production and the specific activity of the rhPBGD also seems to increase during the fermentation.

The best result so far with strain PBGD-2 is a rhPBGD concentration of 39 U/ml and a specific activity of 3,1 U/mg protein after 30-hour fermentation. The final dry weight and OD<sub>620</sub> was 32 g/l<sup>1</sup> and 87 respectively. The plasmid stability is good during the fermentation when oxytetracycline is present as selection pressure.

---

## EXAMPLE 2

10

### Development of a purification process for recombinant human Porphobilinogen Deaminase (rhPBGD)

#### Introduction

15 For the capture step a weak anion exchange (DEAE-Sepharose FF) matrix has been tested primarily, because this has been the most common initial step for purification of PBGD. The disadvantage with anion exchange is that endotoxins and DNA adsorb on this type of gel. There is a risk that these impurities are coeluted with rhPBGD. To use a cation exchange in this project is not possible, because pI for rhPBGD is too low. For that reason  
20 a hydrophobic gel has also been tested as a capture step.

#### Material and methods

##### Cell extract

Cell extract (PD12, see Example 1) was supplied frozen (8x50 ml) from Biogaia. After the  
25 initial thawing a precipitation was found in the sample. The extract was centrifuged and the next day a new precipitation was found. This means that the extract has to be centrifuged in connection to a chromatography experiment. The protein content in the extract (BCA) was estimated to 29 mg/ml and the enzyme activity was found to be 63 U/ml. The pH and conductivity were estimated to 7.0 and 6 mS/cm, respectively.

##### Ion-Exchange

A DEAE- Sepharose FF hitrap (1 ml) column was used. The gel was equilibrated with Tris-HCl 25 mM, pH 8.5. The pH of the extract was adjusted to pH 8.5 with NaOH 5 M and the sample volume applied on the gel was 1.4 or 2.0 ml. After the sample has been applied, the gel was washed with 15 column volumes with equilibration buffer. For the desorption of

the gel the following KCl concentrations have been tested: 40, 120, 150 and 300 mM. Finally, after every experiment the gel was cleaned with NaOH 1 M.

#### Hydrophobic interaction chromatography

- 5 A Butyl-Sepharose 4 FF hitrap (1 ml) column was used. The gel was equilibrated with potassium phosphate 1.0-1.3 M pH 7.5. To the extract, potassium phosphate (2.5 M) was added to an end concentration of 1.0-1.3 M and the sample volume applied on the gel was 2.0 ml. After the sample has been applied, the gel was washed with 15 column volumes with equilibration buffer. For the desorption of the gel 500 mM, 20 mM potassium
- 10 phosphate and water were tested. Finally, after every experiment the gel was cleaned with NaOH 1 M.

#### Results

##### Ion-exchange

- 15 In Figures 14 and 15 chromatograms from two DEAE runs are shown. In Table 10 the results from these runs are shown. The difference between these experiments are that peak b in the first run was desorbed with 120 mM KCl and 150 mM in the second. Further, in the first run less sample was applied and the gel was also desorbed with 300 mM KCl. The recovery was in the best experiment found to be 75 % and the yield 47 %. To get this
- 20 recovery and yield 300 mM KCl has to be used. The purity of rhPBGD in peak b (DEAE2 ) was estimated to 31 % (RPC).

#### Hydrophobic interaction chromatography

- In Figure 16 a chromatogram from a Butyl run is shown. In Table 11 the result from the run
- 25 is shown. In this experiment 1.3 M potassium phosphate was used and the desorption was done with water. Conductivity in peak b was found to be 60 mS/cm. The recovery was calculated to 78 % and the yield 75 %. In an investigation it was found that a precipitation was formed in the extract at a potassium phosphate concentration of 1.5 M. The purity of rhPBGD in peak b was estimated to 40 % (RPC).

30

#### Comments and conclusions

- From the results of the experiments it can be seen that the mass balance in all experiments are not in balance. This seems to be valid for all analyses. The main reasons for this are probably insecurity of the analyses and that all proteins are not eluted from the gel. The
- 35 first reason is confirmed by the enzyme activity that seems to be too high in the extract

when high concentration of potassium phosphate is added. The second reason is confirmed by the elution peak with NaOH in ion-exchange experiments. This peak is not analyzed. For the hydrophobic matrix a cleaning with organic solution can be necessary. The conclusion of the results so far is that the Butyl-Sepharose 4 FF seems to be the best alternative for the capture step. The main reason for that is the higher yield of rhPBGD. Another advantage to use Butyl-Sepharose 4 FF is the small peak after cleaning with NaOH 1M compared with the large peak in DEAE-Sepharose FF runs. This probably means that few impurities stick on Butyl matrix. On the other hand there is a risk that a precipitation is formed when adding potassium phosphate. A desalting before the next chromatography step can be necessary, caused by the high ion strength in the product peak.

Table 10 Ion-exchange

15	Applied				Peak a			Peak b			Peak c		
	BCA A280 Act.				BCA A280 Act.			BCA A280 Act.			BCA A280 Act.		
	mg	mg	U		mg	mg	U	mg	mg	U	mg	mg	U
20 Exp.													
	DEAE1	37	166	76	10	122	21	5	6	29	9	11	7
25	DEAE2	42	229	129	17	143	56	10	14	25	-	-	-

Table 11 Hydrophobic interaction chromatography

35	Applied				Peak a			Peak b			Peak c		
	BCA A280 Act.				BCA A280 Act.			BCA A280 Act.			BCA A280 Act.		

mg mg U mg mg U mg mg U mg mg U

Exp.

5

Butyl 31 137 93 7 84 3 11 23 70 - - -

10

### 15 EXAMPLE 3

#### Development of a method for the purification of recombinant human Porphobilinogen deaminase with a "His-Tag" (rhPBGD-His)

#### 20 Nature and purpose of the study

Many groups have reported in the literature on the purification of porphobilinogen deaminase from various sources including *E. coli* and Human erythrocytes (Anderson P. M. and R. J. Desnick, 1979, The Journal of Biological Chemistry 255(5): 1993-99, Awan S.J. et al. 1997, Biochemistry 36(30): 9273-82, Grandchamp B. et al. 1987, Eur.J.Biochem. 162(1): 105-10, Jordan P.M. 1994, Wiley, Chichester (Ciba Found Symp 180), p70-96, Jordan P.M. et al. 1988, Biochem.J. 254:427-435, Lambert R. et al. Wiley, Chichester (Ciba Found Symp 180), p97-110, Louie G.V. et al. 1996, Proteins 25(1): 48-78, Maniatis T., E.F. Fritsch, J. Sambrook. Molecular Cloning (A laboratory Manual) Cold Spring Harbor Laboratory. 1982, Miyagi K. et al. 1979, Proc.Natl.Acad.Sci. 76(12):6172-76, Racich N. 30 1986, Nucleic Acids Research 14(15): 5955-67, Shoolingin-Jordan P.M. et al. 1997, Methods in Enzymology, 281:317-327). Most use a combination of ion exchange,

hydrophobic interaction and size exclusion chromatography to obtain fairly pure protein preparations. With the engineering of 5 additional Histidine residues on the C-terminus of 35 recombinant human porphobilinogen deaminase, rhPBGD we have a convenient "Tag" to

- help with purification. Histidine has an affinity to electropositive transition metals such as nickel, copper, zinc and cobalt. When a series of 6 or more electron-rich histidine residues are expressed on the end of a protein they can function as an anchor, firmly attaching the protein to a solid support coated with metal ions. Very thorough washing can be done
- 5 without dislodging the bound moiety. Elution can be accomplished in one of two ways, either by decreasing the pH to protonate the imidazole nitrogen (pKa of 5.97) of histidine, or by including imidazole, a molecule identical to the histidine side chain, in the elution buffer
- 
- which competitively dislodges the tagged protein off the support. The purpose of this study is to obtain pure rhPBGD-His for antibody production and for use as a standard in assays
- 10 and protein purification.

#### Study objectives

The objective of this study is to obtain 10 mg of highly pure active rhPBGD-His.

#### 15 Study Plan

##### Plan outline

Optimize induction time for the expression system and lysis

Purify 10 mg of rhPBGD-His for antibody production and standard

2 liter scale induction and lysis of strain

#### 20 DEAE ion exchange chromatography

Immobilized metal affinity chromatography

Characterization of rhPBGD-His

SDS-PAGE

Amino acid analysis

#### 25 Specific activity

HPLC

Mass spectrometry

Amino terminal sequencing

##### Plan body

- 30 Expression of rhPBGD-His is regulated by the bacterial Taq promoter, a derivative of the lac promoter which is inducible with IPTG (See Figure 17 for plasmid map). Different
- 
- proteins are produced at different rates in *E. coli* upon induction. This necessitates the optimization of the time required for optimum rhPBGD-His yield upon induction. To accomplish this a culture in mid-log phase will be induced with an excess of IPTG and
- 35 expression followed at timepoints with activity and protein concentration measurements.

After induction the cells must be lysed to release rhPBGD-His. Of the options available, sonication is the best for this scale of purification. It is compatible with any buffer system and should not be damaging to the protein. To follow efficiency of lysis, absorbance at 600nm will be measured after each cycle.

- 5 For use as a standard and for antibody production at least 10 mg of rhPBGD-His will be purified.

---

For protein purification a 2 liter flask culture of the strain producing rhPBGD-His is

sufficient. The culture will be inoculated with a fresh over-night culture of cells and grown to mid log phase then induced with IPTG.

- 10 Plans are to utilize a two step purification process. After lysis the debris will be removed by centrifugation and supernatant loaded onto a DEAE ion exchange column. This will remove the vast majority of contaminants from the lysate and leave a limited number of protein contaminants in the elution fractions containing rhPBGD-His. Protein will be loaded in a high pH and low ionic strength buffer to ensure binding of the weakly charged
- 15 rhPBGD-His. Extensive washing will be used to remove material that is not firmly bound to the column. A very shallow step gradient of KCl will be used to elute rhPBGD-His. This should separate the different forms of rhPBGD-His with differing charge properties from each other. Separation of different charged forms of PBGD, by ion exchange chromatography, has been reported by others (Anderson P. M. and R. J. Desnick, 1979,
- 20 The Journal of Biological Chemistry 255(5): 1993-99, Jordan P.M. et al. 1988, Biochem.J. 254:427-435, Miyagi K. et al. 1979, Proc.Natl.Acad.Sci.USA 76(12):6172-76).
- The second chromatographic step planned is a column containing Talon fast flow immobilized cobalt metal affinity resin (Clontech). This makes use of the 6-residue histidine tract at the amino terminus of the recombinant protein. Initially, a metal chelating resin
- 25 (Pharmacia) charged with nickel (Sigma) was tried for purification of rhPBGD-His but it was found to bind other proteins in the lysate as well which coeluted with rhPBGD-His. Although this cobalt resin has less binding affinity to His tagged proteins than nickel it retains the high binding capacity and is more discriminating which proteins to bind. This leads to elution from the metal with a lower concentration of imidazole or with higher pH and
- 30 achieves a higher level of purity. The cobalt is also bound more tightly to the matrix by a tetradentate metal chelator, effectively eliminating the leaching of metal ions from the solid

---

support during purification. The loss of reactive metal ions during elution is common problem with nickel based affinity columns (personal communications) which can lead to unwanted precipitation of purified proteins.

- 35 rhPBGD-His will be characterized by the following methods:

The first measure of protein purity will be by SDS-PAGE (polyacrylamide gel electrophoresis). This method will also give an indication of the molecular weight of the protein being produced.

- 5 To determine the specific activity of rhPBGD-His in the preparation it is first necessary to accurately determine protein concentration in solution. Amino acid analysis will be used as an accurate method. The method also provides the amino acid composition of the protein.

---

The concentration can be used to establish an extinction coefficient of rhPBGD-His.

- Activity of the enzyme is an important measure of correct structure of the enzyme. The
- 10 proper structure, equivalent to that produced in humans, is essential for rhPBGD-His to be used as a therapeutic. Any deviation from the natural structure can cause activation of the patient's immune system. Historically, activity of porphobilinogen deaminase has been measured in one of two ways, either by the metabolism of porphobilinogen substrate or by the formation of preuroporphyrinogen product. In the reaction catalyzed by PBGD,
  - 15 porphobilinogen monomers are covalently attached one at a time starting from the free alpha position of the dipyrromethane cofactor. After four molecules are added the linear tetramer of PBG, preuroporphyrinogen, is spontaneously released by hydrolysis from the cofactor, regenerating the active holoenzyme with covalently attached cofactor for further reactions (See Figure 18). After release the tetrapyrrole is circularized by the next enzyme
  - 20 of the heme pathway, uroporphyrinogen III synthase, forming uroporphyrinogen III, the central ring of heme and vitamin B12 in animals and chlorophyll in plants. The linear preuroporphyrinogen molecule can instead be oxidized to uroporphyrin with benzoquinone creating a molecule, which absorbs light at 405 nm. This is the basis for the activity assay used to measure PBGD activity
  - 25 The rhPBGD-His preparation will be further characterized by mass spectrometry, which will give an accurate measure of rhPBGD-His molecular weight and potentially identify molecular heterogeneity in the preparation. rhPBGD-His can exist with 1,2,3 and 4 substrate molecules bound to it. Each substrate molecule added to the holoenzyme will add roughly 209 daltons to the mass, which is detectable through mass spectrometry.
  - 30 Characterization by reversed phase HPLC will provide purity data.
- Amino terminal sequencing of rhPBGD-His will be used to ensure the correct amino terminus.
- 

## Materials and Methods

Induction and Lysis:

From a freshly streaked colony, a culture of pExp-2 in JM105 was grown for 13.5 hours in 100 ml LB (10g/l bacto-tryptone, 5g/l bacto-yeast extract, 10 g/l NaCl pH 7.0) + 100 µg/ml  
 5 ampicillin in a 500 ml baffled flask at 37°C at 350 rpm. The optical density measured at 600nm reached 1.6. This culture was used to inoculate 2 liters of terrific broth (12g/l bacto-tryptone, 24g/l bacto-yeast extract, 4ml/l glycerol, 2.31g/l KH<sub>2</sub>PO<sub>4</sub>, 12.54g/l K<sub>2</sub>HPO<sub>4</sub>  


---

 (Maniatis T., E.F. Fritsch, J. Sambrook. Molecular Cloning (A laboratory Manual) Cold Spring Harbor Laboratory. 1982) with 100 µg/ml ampicillin and split into four 2 liter baffled  
 10 flasks with 400 ml each and two 1 liter baffled flasks with 200 ml culture each. These were grown at 37°C with 350 rpm in a New Brunswick Scientific Innova 4000 incubator. When reaching an optical density of 0.7 at 600 nm the Taq promoter was induced with 4 mM IPTG, causing rhPBGD-His protein to be made. Growth was followed by hourly readings of absorbance at 600 nm. After 9 hours the cultures were stopped by chilling to 0°C after an  
 15 absorbance of 1.93 was reached. The culture was centrifuged, 4 X 250ml at a time, for 10 min at 4,000xg in a Beckman Avanti J25I centrifuge with a JLA-16.250 rotor. Supernatant was decanted and the remainder of the culture was added to the cell pellets and spun for an additional 10 min. The pellets were resuspended in 2 pools of 250 ml 50 mM Tris/HCl pH 8.5 (prechilled) each and stored for 8 hours on ice. Cells were centrifuged for 10 min at  
 20 4,000xg, liquid decanted and resulting pellets weighed in the bottles to determine the wet weights. Cells were then resuspended in 400 ml ice cold 50 mM Tris/HCl pH 8.5 and lysed by sonication with a Branson Sonifier 450 with 1/2 inch diameter stepped, tapped horn. Each round was for 30 seconds at maximal power with constant duty cycle in a Pyrex 150 ml glass beaker on ice. Lysate was mixed between cycles by either drawing into a 50ml  
 25 pipet a few times or by pouring between beakers on ice. Progress of lysis during sonication was ascertained by reading absorbance of the lysate at 600 nm. After six rounds of sonication for each of the 100 ml aliquots of cells, debris was removed by centrifuging at 16,000xg for 30 minutes at 4°C. Lysate was then pooled and vacuum filtered through a 0.22 µm Durapore membrane (Millipore) to remove any remaining particulate matter.

30

DEAE Sepharose Chromatography:

The first chromatographic step in purifying rhPBGD-His was by ion exchange  
 chromatography on a DEAE Sepharose fast flow column (Pharmacia). A 2.5 X 50 cm  
 35 Spectrum LC column with degassed resin was washed extensively with degassed 25 mM



Tris/HCl pH 8.5 buffer. Filtered lysate (380 ml) was applied to the column at 5 ml/min. The column was then washed with 720 ml 25 mM Tris/HCl pH 8.5. Elution of bound rhPBGD-His was with a shallow step gradient of KCl from 50 to 120 mM in 10 mM increments in 25 mM Tris/HCl pH 8.5 and degassed. Volumes for each step varied from between 105 and 5 470 ml depending on the elution profile (see Table 12).

Table 12

0 mM KCl	50	60	70	80	90	100	110	120
720 ml	470	120	175	270	105	130	180	300

- 10 Fractions were collected about every 50 ml. Absorbance at 280 nm was followed closely during elution. The next step was only applied after the absorbance had declined following a peak. BioRad's protein assay II in microtiter format was used per manufacturer's protocol to assay the amount of protein in each fraction. Coomassie stained 10% acrylamide Bis/Tris gels (Novex) were then prepared, with 5 µg protein in each lane, to characterize 15 the purity of each peak.

#### Cobalt Affinity Chromatography:

- The resin slurry was degassed prior to pouring into a 2.5 X 30 cm Spectrum LC column. It 20 was then washed extensively with degassed 25 mM Tris/HCl pH 8.5/ 150 mM NaCl at a flow rate of 5 ml/min. The sodium chloride was included to decrease protein to protein ionic interactions and to reduce ion exchange effects with the column matrix itself. A relatively high pH of 8.5 was used to keep rhPBGD-His well above the pI, and therefore negatively charged, to maintain high solubility during the purification. Two consecutive rhPBGD-His 25 affinity purifications were then run on the column. The first sample loaded was a sterile filtered pool of the entire first peak of eluate of activity from the DEAE sepharose column including fractions 9 through 12. The column was then washed with 2 liters of 25mM Tris pH8.5/150mM NaCl at 3 ml/min. To elute bound contaminants the column was then washed with 100 ml of 25mM Tris pH8.5/150mM NaCl/5mM imidazole at 5 ml/min followed 30 by 100 ml of 10mM imidazole buffer solution. Elution of his tagged protein was with 25mM Tris pH 8.5/150mM NaCl/50mM imidazole at 5 ml/min. A final elution with 100 mM imidazole was included to be certain all rhPBGD-His was eluted. To prepare the column for the second loading it was merely washed with ~100 ml of 25mM Tris pH8.5/150mM NaCl. It

was hoped that rhPBGD-His would displace the imidazole bound to the column (which turned out to be the case). The second loading of the column was with a sterile filtered pool with ~900 ml of all remaining peaks of activity from the DEAE Sepharose column at a flow rate of 5 ml/min. The column was then washed with 2 liters of 25mM Tris pH8.5/150mM NaCl at 5 ml/min, followed by imidazole containing buffers as with the first run above.

#### Polyacrylamide Gel Electrophoresis: (SDS-PAGE)

---

Gel electrophoresis was with the Novex system with Nupage 10% Bis/Tris gels run at 125V for 2 hours with or without reducing agent. Staining was with 50% methanol / 10% acetic acid / 0.25% Coomassie brilliant blue R-250 for 2 to 4 hours. Destaining was in 30% methanol / 10% acetic acid in a Bio-Rad gel destainer.

#### Amino Acid Analysis:

15

Amino acid analysis was performed by AAA Laboratory (6206 89<sup>th</sup> Avenue Southeast, Mercer Island, Washington 98040). rhPBGD-His was hydrolyzed for 20 hours with 6N-HCl / 0.05% mercaptoethanol / 0.02% phenol at 115°C. Serine was increased by 10% and Threonine increased by 5% to compensate for destruction of the individual acids during hydrolysis. A Beckman 7300 Amino Acid Analyzer was used coupled with System Gold software. Analysis was performed by post-column derivitization with ninhydrin using the ion-exchange chromatographic methods developed by Moore and Stein.

#### PBGD Activity Assay:

25

We performed assays in 96 well microtiter format with validation in cuvetts. Procedures were derived from published procedures (Awan S.J. et al. 1997, Biochemistry 36(30): 9273-82, Shoolingin-Jordan P.M. et al. 1997, Methods in Enzymology, 281:317-327). From 0.125 to 8 µg of purified rhPBGD-His protein per well have been used to determine enzymatic activity. Assay buffer is 50 mM Tris/HCl pH 8.2 with 1.0 mg/ml BSA (Sigma fraction 5) and 10 mM DTT. A Perkin Elmer 9700 PCR machine was used for thermal regulation, allowing for tight control of the temperature and reaction time. Assays have been started in two ways. One method was to start the reactions at 37°C with prewarmed substrate in a PCR block. Strategic placement of pauses in a thermocycle program was used with beeping at defined intervals for both addition of the substrate and for stopping

the reaction. An example cycle program is shown in Table 13 with reaction times varying from 10, 20, 40 and 60 minutes.

The reaction block is a 96 well block with tubes arranged in an 8x12 matrix.

- 5 It is kept throughout at 37°C. The reaction is initiated by adding PBG to eight tubes in the first row using an eight-channel pipettor. The addition is staggered so that each row receives PBG every 30 seconds. A ten second pause and beep interval is setup every 20 seconds to signal each addition at the end of the period. In this fashion all the 96 reactions are started
- 10 which takes a total of six minutes. At the end of a further four-minute incubation, the first three rows are stopped in a staggered manner giving a total of a ten-minute incubation period. This procedure is repeated for the next three rows after an additional ten minutes amounting to a total of twenty-minute reaction time. This scheme is illustrated in Table 13.
- 15 The p@37 represents the 10-second beep period which is configured in the thermocyclor as a pause plus beep interval.

Table 13

start	stop	stop	stop	stop									
add	10	20	40	60									
PBG	min	min	min	min									
<div><div> ---12X--- </div><div> ---3X--- </div><div> ---3X--- </div><div> ---3X--- </div><div> ---3X--- </div></div>													
37	p@37	37	37	p@37	37	37	p@37	37	37	p@37	37	37	p@37
20 sec	10 sec	4 min	20 sec	10 sec	10 min	20 sec	10 sec	20 min	20 sec	10 sec	20 min	20 sec	10 sec

20

- Reactions were stopped by acidification with HCl / p-benzoquinone solution. The final concentration of HCl used was 1 molar. Benzoquinone, which oxidizes the uroporphyrinogen to uroporphyrin, was used at a final concentration of 0.002% w/v (from
- 25 0.2% stock solution in methanol). At defined intervals the 150 µl samples were removed from the reaction tubes and added to 850 µl HCl / p-benzoquinone solution in wells of a 96 well X 2 ml plate on ice. The second method of initiating the assay was to set up the reactions complete with substrate on ice then to transfer to the PCR block for incubation at 37°C. Following the reaction the block was brought to 4°C to stop the reaction after which
  - 30 samples were removed and added to HCl / p-benzoquinone solution. For both methods the

incubation was allowed to proceed for 20 minutes on ice and in the dark after the last addition of reaction solutions. Then the plate was centrifuged for 10 min at 3750 rpm in a swing out rotor in a GS-6KR centrifuge to pellet precipitated protein (mostly BSA). 250  $\mu$ l was removed to a Corning 96 well assay plate. Absorbance was measured at 405 nm with a 605 nm reference wavelength in a BioTek FL-600 plate reader. Selected samples (normally the standard curve) were diluted 10X with 1M HCl and read in a quartz cuvet in a Beckman DU640B spectrophotometer at 405.5 nm. A 605 nm reference wavelength was used to subtract out background absorbance. These measurements in cuvetts produced a conversion factor from 1 cm pathlength reads to the plate data. Analysis was performed using the KC4 software included with the plate reader and with excel spreadsheets. An extinction coefficient of 548  $M^{-1}cm^{-1}$  was used to quantitate the oxidized reaction product (Shoolingin-Jordan P.M. et al. 1997, Methods in Enzymology, 281:317-327).

#### HPLC:

15

HPLC analysis was performed at the University of Washington Mass Spectrometry Analysis Facility for HPLC. Samples were prepared free of salts for mass spectrometry analysis by HPLC on a C4 column and eluted with an increasing gradient of acetonitrile. The instrument used was an Applied Biosystems (ABI) 140A Solvent Delivery System with an ABI 785A Programmable Absorbance Detector.

#### Mass Spectrometry:

Mass spectrometric analysis was performed at the University of Washington Mass Spectrometry Analysis Facility. One tenth of the HPLC run within the main elution peak was diverted prior to the absorbance detector to a Perkin Elmer SCIEX API3 Biomolecular Mass Analyzer for electro-spray mass spectrometry. Analysis was by HyperMass method on an average of 16 peaks (for Cobalt run #1 eluate).

#### 30 Amino Terminal Sequencing:

Amino terminal sequence analysis was performed at the University of Washington Mass Spectrometry Analysis Facility. An ABI 477A Protein Sequencer was used with an ABI 120A PTH Analyzer.

#### 35 Results

Purification:

## Induction and Lysis:

- 5 Growth of the 2-liter culture of bacteria slowed down after the first hour but growth still continued to 9 hrs (see Table 14).

Table 14

start	1 hr	2 hr	3 hr	4 hr	5 hr	6 hr	7 hr	8 hr	9 hr
0.699	1.300	1.521	1.607	1.660	1.732	1.797	1.841	1.890	1.927

10

After about 3 hrs of induction cells tended to clump together with most turbidity settling out of the broth by gravity in about an hour. Final density of cells stayed low for growth in a rich media such as terrific broth but final weight of pellets was adequate. The total wet weight was 35.3 g, corresponding to 17.7g/liter culture. Interestingly the cells were orange/pink

15 probably due to various intermediates in the heme biosynthetic pathway. It is clear from the low growth rate and final densities achieved that cultures were limited by the amount of oxygen available.

Lysis by sonication was essentially complete after 5 cycles as seen by following

- 20 absorbance readings (Table 15).

Table 15

# rounds	0	1	2	3	4	5	6	7
OD600	30.33	20.15	12.90	9.43	6.14	3.86	3.31	2.99
% down	-	34	36	27	35	37	14	9.7

- 25 It appears from the % decrease of optical density that for each of the first 5 rounds of sonication, about the same percentage of cells were lysed. After this the percentage of newly lysed cells dropped rapidly. For each of the first 4 rounds viscosity of the lysate was relatively high due to the presence of unfragmented genomic DNA but this decreased significantly after further rounds from shearing of the DNA into smaller fragments.

30

### DEAE Sepharose:

Elution of proteins from the DEAE ion exchange column occurred in 4 distinct peaks as seen in the elution profile in Figure 19 and by protein assay in Table 16. SDS-PAGE analysis of the eluted fractions shows that these peaks contain four separate peaks of rhPBGD-His eluted with the step gradient of KCl (Figure 20). The first and major peak was eluted in fractions 9 through 13 with 50 to 70 mM KCl. As seen by gel analysis (see Figure 20) purity was fairly good for a first step of the purification, especially in fractions 10 through 13. The second peak eluted in fractions 15 through 18 with 80 mM KCl. The major contaminant in this peak, in about equal molar proportions to desired product, was a protein running at about 5 kDa smaller than rhPBGD-His. The third peak in fractions 20 through 23 eluted with 90 to 100 mM KCl and had less visible contaminants than the second peak. The fourth and final peak eluted in fractions 26 through 29+ with 110 to 120 mM KCl. The fractions were split into 2 pools for further purification. The first pool, comprising the major peak of rhPBGD-His elution contained fractions 9 through 12. The second pool contained fractions 13 through 29 along with the next 50 ml of 120 mM KCl elution buffer. These two pools eluted by ion exchange contained 877 mg protein out of 3253 mg loaded, corresponding to a 3.7 fold decrease in total protein (See Table 16).

### 20 Cobalt Affinity:

From the first cobalt run the majority of rhPBGD-His eluted in a sharp peak with a volume of 30 ml upon addition of 50 mM imidazole (see Table 17 for protein assay and Figure 22 for SDS-PAGE results). A final elution with 100 mM imidazole released no detectable protein absorbing at 280nm. In the second cobalt run (Figure 21) surprisingly, the first imidazole wash of 5 mM eluted a small uncolored peak of absorbance with a volume of about 50 ml. The second wash with 10 mM imidazole then eluted a larger and broader orange/pink colored peak of about 150 ml. Further elution with 50 mM imidazole yielded a large sharp uncolored peak of 23 ml.

### 30 Characterization:

#### Amino Acid Analysis:

Amino acid analysis of 3 of the fractions (Cobalt run #1 50 mM imidazole eluate (in duplicate,) Cobalt run #2 10 and 50 mM imidazole eluates) yielded conclusive data that

rhPBGD-His was being purified. Results from the analysis allowed for a very accurate measure of protein concentration calculated from the concentration of individual amino acids (see Table 18).

## 5 Specific Activity:

Specific activity of the first 50 mM imidazole eluate of rhPBGD-His from the cobalt column turns out to be high at approximately 24 U/mg (Units are in  $\mu\text{mol}$  PBG consumed per mg protein in one hour). Activity of rhPBGD-His was found to be strongly dependent on pH with a sharp rise from 7.0 to 8.0 where it approached a plateau. The optimum was around pH 8.2. The optimum PBG substrate concentration was found to be around 1 mM. rhPBGD-His had activity with all concentrations of PBG, however with amounts less than 1 mM the reaction was limited by available substrate, decreasing both the  $V_{\text{max}}$  and the linearity over time as substrate was depleted. It was not found to be necessary to decolorize remaining benzoquinone with sodium metabisulfite as used in a published assay (Shoolingin-Jordan P.M. et al. 1997, Methods in Enzymology, 281:317-327). Strangely enough if acidification and oxidation were done in a smaller total volume (240  $\mu\text{l}$  vs 1 ml) as done by this research group then a highly colored product develops during the incubation on ice. This product must be decolorized with a saturated solution of sodium metabisulfite to obtain accurate reaction absorbances. There was no significant difference in enzymatic activity found as measured by these two variations of the method.

Generally assays have been set up with both time and enzyme concentration as variables. This allows for a more detailed analysis of the results with a built-in validation. If activity is fairly linear from different timepoints at any enzyme concentration then it can be inferred that substrate is not limiting and that reaction measurements are valid over that range. If a measurement is taken at only one timepoint then there is no indication of whether the enzyme is still functioning at  $V_{\text{max}}$ .

Reaction volumes in 96 well format have been limited by the size of PCR tubes to 150  $\mu\text{l}$ . Volumes from between 50 and 150  $\mu\text{l}$  have been tried with a noticeable increase in linearity over time and with increasing enzyme amounts seen with the larger volumes. Additional increases in volume would make even more substrate available and dilute the protein further, thereby increasing the linearity over time and enzyme concentrations. However the increase in cost of the assay from PBG substrate would be substantial.

For routine analysis of similar protein preparations at similar concentrations it should be possible to standardize the assay and use far fewer data points and still obtain an accurate measure of PBGD activity. Optimally a standard curve of rhPBGD-His of known activity

- 5 would be included to validate the results and to simplify analysis. Basically multiple variables including time would be internally controlled. With a four-parameter logistic curve of the standards one could use any time point and a wide range of sample concentrations to obtain accurate activity measurements. Single use aliquots of highly pure rhPBGD-His could be stored frozen for use as standards.

10

#### Mass Spectrometry:

Mass spectrometry of the 50 mM imidazole elution peaks from the two cobalt runs yielded molecular weights of:

- 15 1<sup>st</sup> cobalt run eluate: 38,816.8, standard deviation = 3.68  
 2<sup>nd</sup> cobalt run eluate: 38,814.6, standard deviation = 4.70  
 1<sup>st</sup> cobalt eluate dialyzed for antibodies: 38,817.1, STD deviation = 3.33

These weights correspond to the holoenzyme without any additional substrate molecules attached.

#### 20 Evaluation and conclusions

- We found that with a simple two step purification process involving ion exchange and cobalt affinity chromatography we could achieve a yield of 173 mg/l rhPBGD-His with a purity of greater than 98% starting from a bacterial crude lysate. Each one of the enzyme
- 25 intermediate complexes is stable and can be independently isolated (Anderson P. M. and R. J. Desnick, 1979, The Journal of Biological Chemistry 255(5): 1993-99, Jordan P.M. et al. 1988, Biochem.J. 254:427-435, Miyagi K. et al. 1979, Proc.Natl.Acad.Sci.USA 76(12):6172-76). This may be a major contributing factor to the differential binding of different enzyme fractions to the DEAE ion exchange matrix. Due to the negative charges
- 30 contributed by acetate and propionate side groups on the growing chain of porphobilinogen molecules it could be theorized that binding affinity to the ion exchange resin would be in the order; E<ES<ES2<ES3. That would imply that the first peak could be the holoenzyme followed by the others in the same order of the reaction progression. The cobalt column also eluted rhPBGD-His in different fractions during the second run. It is strange that the
- 35 elution profile from the second run was different from the first. It would be expected that all



closely related proteins with a his-tag would bind to cobalt with the same affinity. This implies that either the His-tag is partially digested away or partially obscured due to protein conformational changes or charge interactions. The difference in elution characteristics may also be due to differences between the various enzyme-substrate intermediate

5 complexes as hinted by the color difference in the 10 mM elution peak. From a report in the literature by Jordan P.M. 1994, Wiley, Chichester (Ciba Found Symp 180), p70-96, the ES2 intermediate complex has a pink colored chromophore. The 10 mM imidazole fraction

---

from the second cobalt column run has a pink color while the other fractions do not. This implies a separation of different enzyme substrate intermediates in different fractions. If the

10 colored protein peak is predominantly composed of the ES2 intermediate then it could be extrapolated that the peak at 5 mM would be ES3. Whatever would be decreasing the binding of ES2 to cobalt whether conformational or charge related as compared to ES would likely be enhanced with the ES3 intermediate. The peak released with 50 mM imidazole and with stronger binding to DEAE could then be the ES form. Holoenzyme by

15 itself may be the remaining form, purified during the first cobalt run, binding less tightly to DEAE due to a higher pI and elute from nickel with 50 mM imidazole. When the mass of the two 50 mM cobalt eluates were compared however there was no significant difference detected. Both corresponded to the weight expected for holoenzyme alone. Unfortunately no reliable mass measurement of the 10 mM eluate was obtained due possibly to

20 precipitation problems with a lower rhPBGD-His protein concentration. If a difference of elution characteristics between the different enzyme substrate intermediates is occurring then a likely explanation would be due to the large conformational changes that take place during the course of the reactions From E to ES4 (Jordan P.M. 1994, Wiley, Chichester (Ciba Found Symp 180), p70-96, Louie G.V. et al. 1996, Proteins 25(1): 48-78). The C-

25 terminal His-tag on the third domain of the protein could become partially hidden and rendered sterically less accessible when the reaction proceeds past the ES1 form. A direct interaction between the his-tag and the growing substrate chain would be less likely. At a pH of 8.5 histidines should be in an electron rich unprotonated state and the substrate complex should also be in an electron rich state even though acidic side chains are

30 neutralized by basic amino acids in the catalytic cleft (Jordan P.M. 1994, Wiley, Chichester (Ciba Found Symp 180), p70-96, Louie G.V. et al. 1996, Proteins 25(1): 48-78).

---

Conformational changes in rhPBGD-His occurring during the reaction could conceivably make accessible other charge groups for interaction with the his-tag either on the surface or perhaps the same ones meant for dampening charges from the growing substrate

35 polymer in the cleft.

Equipment and supplies lists are shown in appendix 4 and 5, respectively.

Table 16 Protein assay results on DEAE fractions (with BioRad's Protein assay II kit):

5

sample	vol(ml)	mM KCl	protein rhPBGD-His			gel #	well #	protein	
			mg/ml	mg/ml	mg prot			pool	mg pool
DEAE Load	380	0	8,56		3253	1	2		
DEAE FT	380	0	1,33		505	1	3		
DEAE #1	16	0	0,26	0,00	4	1	4		
2	60	0	0,23	0,00	14	1	5		
3	100	0	0,044	0,00	4	1	6		
4	215	0	0,002	0,00	0	1	7		
5	320	0	0,005	0,00	2	1	8		
6	75	50	0,11	0,00	8	1	9		
7	100	50	0,19	0,00	19	1	10		
8	100	50	0,14	0,00	14	1	11		
9	94	50	0,61	0,31	57	1	12	1	334
10	100	50	1,44	1,15	144	2	1	1	
11	38	60	1,05	0,84	40	2	2	1	
12	135	60-70	0,69	0,48	93	2	3	1	V
13	100	70	0,4	0,10	40	2	4	2	543
14	50	80	0,43	0,09	22	2	5	2	
15	50	80	0,96	0,34	48	2	6	2	
16	50	80	0,98	0,49	49	2	7	2	
17	50	80	0,57	0,29	29	2	8	2	
18	50	80-90	0,48	0,14	24	2	9	2	
19	50	90	0,42	0,13	21	2	10	2	
20	50	90	0,61	0,24	31	3	1	2	
21	50	90-100	0,93	0,70	47	3	2	2	
22	50	100	1,08	0,86	54	3	3	2	
23	50	100	0,57	0,34	29	3	4	2	
24	50	110	0,41	0,08	21	3	5	2	
25	50	110	0,61	0,09	31	3	6	2	
26	50	110	0,69	0,17	35	3	7	2	
27	50	110-120	0,73	0,44	37	3	8	2	
28	28	120	1,07	0,86	30	3	9	2	
29	50	120	1,08	0,76	54	3	10	2	V

Table 17 Second cobalt run fractions with other samples in Figure 20 gel

Sample description	Imidazole mM	volume ml	Conc. mg/ml	Total mg	Gel lane	Ico-pure mg
Co-1 load	0	367	0,78	286,3	2	
Co-1 FT	0	367	0,22	80,7	3	
Co-1 Eluate	50	30	6,46	193,8	4	193,8
MI #1 Nickel	500 ?		9,65		5	
PBGD-1 Lys	0		1,73		6	
Ab prep #1	0	3,3	4,00	13,2	7	
Cobalt-2 FT	0	900	0,23	207,0	8	
FT tail	0	30	0,02	0,6	-	
Cobalt-2 w1	5	100	0,01	1,0	-	
" w2	5	50	0,14	7,0	-	
" w3	5	52	0,02	1,0	-	
" w4	5	100	0,04	4,0	-	
" w5	10	50	0,07	3,5	-	
" w6	10	50	0,81	40,5	9	
" w7	10	50	0,81	40,5	10	101,5
" w8	10	50	0,41	20,5	11	
" w9	10	130	0,20	26,0	-	
" E1	50	22,5	2,29	51,5	12	51,5
" E2	50	30	0,11	3,3	-	

Total mg highly pure rhPBGD-His (by amino acid analysis) = 346,8

Table 18 rhPBGD-His amino acid analysis:

Cobalt eluates											
5.	aa	#aa	% whole	#1		#2		#3		#4	
				umol/ml							
				aa	[PBGD]	aa	[PBGD]	aa	[PBGD]	aa	[PBGD]
	Ala	29	8,31	4,8220	0,166	0,5920	0,020	1,6950	0,058	4,5406	0,157
	Arg	21	6,02	3,7279	0,178	0,4550	0,022	1,3050	0,062	3,5129	0,167
	Asn	10	2,87								
	Asp	19	5,44	4,7157	0,163	0,5755	0,020	1,6510	0,056	4,4442	0,153
	Cys	4	1,15								
	Gln	19	5,44								
	Glu	21	6,02	6,7648	0,169	0,8152	0,020	2,3592	0,059	6,3524	0,159
	Gly	27	7,74	4,3933	0,163	0,6120	0,023	1,5595	0,058	4,1137	0,152
	His	18	5,16	2,5664	<b>0,143</b>	0,2539	<b>0,014</b>	0,7947	<b>0,044</b>	2,4518	<b>0,136</b>
	Ile	20	5,73	3,0511	<b>0,153</b>	0,3661	0,018	1,0561	0,053	2,8381	0,142
	Leu	43	12,32	7,0235	0,163	0,8565	0,020	2,4506	0,057	6,6020	0,154
	Lys	18	5,16	2,9241	0,162	0,3538	0,020	1,0427	0,058	2,7135	0,151
	Met	6	1,72	0,8691	<b>0,145</b>	0,0996	<b>0,017</b>	0,3072	<b>0,051</b>	0,8252	<b>0,138</b>
	Phe	9	2,58	1,4713	0,163	0,1825	0,020	0,5216	0,058	1,4045	0,156
	Pro	16	4,58	2,7268	0,170	0,3708	0,023	1,1194	0,070	2,8441	0,178
	Ser	18	5,16	2,8356	0,158	0,3570	0,020	1,0121	0,056	2,8680	0,159
	Thr	20	5,73	3,4426	0,172	0,4272	0,021	1,2154	0,061	3,2746	0,164
	Trp	2	0,57								
	Tyr	3	0,86	0,5150	0,172	0,0626	0,021	0,1734	0,058	0,4823	0,161
	Val	26	7,45	4,0526	<b>0,156</b>	0,4920	0,019	1,4292	0,055	3,7740	0,145
Avg $\mu\text{mol/mol}$ rhPBGD-His:				0,167		0,021		0,059		0,159	
(w/o bold values)											
Avg mg/ml rhPBGD-His:				<b>6,46</b>		<b>0,81</b>		<b>2,29</b>		<b>6,17</b>	
(MW= 38759,4 )											
Volume (ml):				30		100		22,5		5	
amount in fraction (mg):				193,7		80,8		51,6		30,8	

sample	run #	imidazole	Notes
#1	1	50 mM	Major peak of cobalt eluate (from 50->60mM KCl elution from DEAE)
#2	2	10 mM	70->120mM KCl elution from DEAE; cobalt fractions W6,7
#3	2	50 mM	" fraction E-1
#4	1	-	#1 dialyzed -> PBS+ 5mM Tris/Cl pH 8.0 (used for 2nd round Antibodies)

Analysis done at: AAA Laboratory  
 By: Lowell Ericsson, Nancy Ericsson  
 Address: 6206 89th Ave SE, Mercer Island, Washington 98040-4599

## COMBINATION THERAPY

5

Combination therapy of rhALAD AND rhPBGD

The etiology behind AIP is not fully understood. However, the accumulation of the two heme- precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) are likely to be involved. ALA and PBG have been suggested to be toxic to the central and peripheral nervous system causing the well known symptoms such as abdominal pain, muscle weakness, loss of sensory functions as well as epileptic seizures, respiratory paralysis, hallucinations and psychosis, observed during acute attacks.

The rationale for the enzyme substitution therapy in AIP patients is based on the administration of rhPBGD by sc. injections to lower serum and intracellular PBG levels. PBG will be metabolized to preuroporphyrinogen. Preuroporphyrinogen will subsequently enter the normal heme biosynthetic pathway and be metabolized to heme. Hence, rhPBGD enzyme replacement therapy will have a dual action, i) reduce circulating levels of toxic PBG and ii) restore heme production.

20

In the etiology of the disease it has been suggested that ALA might have an even more toxic effect than PBG. Therefore, a reduction of both ALA and PBG may be desired. Treatment of AIP patients with rhPBGD will i) reduce circulating levels of PBG as well as ALA, since ALA and PBG are in equilibrium with each other through coupled enzyme reactions e.g. delta-aminolevulinic acid dehydratase (ALAD) and porphobilinogen deaminase PBGD and ii) restore heme production. A block in the PBGD enzyme will result in the accumulation of both PBG and ALA. Administration of rhPBGD will quickly metabolise PBG and lower ALA levels as well, through changes in the equilibrium of the ALAD enzyme reaction.

30

An accelerated reduction of ALA might be beneficial to AIP patients. Hence, a coadministration of both rhPBGD and rhALAD will rapidly reduce both heme precursors.

The mixing and administration of rhALAD and rhPBGD could be done in two ways, either: i) a product containing both enzymes at fixed proportions or ii) administration of rhPBGD and rhALAD by two separate subcutaneous injections. In the latter case the dose of the two

enzymes could be adjusted to obtain optimal individual therapy. Administration of separate enzymes provides also a possibility for optimal temporal order of administration to obtain the best individual therapeutic effect.

- 5 The above combination of PBGD and ALAD is also believed to be beneficial in connection with treatment of HCP and VP as these patients may also have elevated levels of the enzymes PBG and ALA.

Combination therapy of rhPBGD and rhUroporphyrinogen III cosynthetase

- 10 Coadministration of rhPBGD and rhUroporphyrinogen III cosynthetase to some AIP patients are likely to be beneficial, by improving conversion of preuroporphyrinogen to its uroporphyrinogen III isomer rather than the I isomer. The I isomer forms spontaneously from preuroporphyrinogen and can not be further metabolised into heme. Hence, a coadministration of rhPBGD and Uroporphyrinogen III cosynthetase will ensure a better  
15 restoration of normal heme synthesis in that less amount of the uroporphyrinogen I isomer will be formed.

Combination therapy of rhALAD, rhPBGD and rhUroporphyrinogen III cosynthetase

- rhPBGD cosynthetase can be coadministered with both rhPBGD and rhALAD to specific  
20 patients to obtain beneficial heme synthesis restoration.

It is within the scope of the present invention to extend a combination therapy to other enzymes mentioned herein and to treatment of the other porphyrias.

25

TREATMENT OF OTHER PORPHYRIAS

- In analogy with the new treatment of AIP patients with (recombinant) PBGD, hepatic Porphyrias such as ALA deficiency Porphyria (ADP), Porphyria cutanea tarda (PCT),  
30 Hereditary Coproporphyria (HCP) and Variegata Porphyria (VP) can benefit from substitution therapy by rhALA dehydratase, rhUroporphyrinogen decarboxylase, rhCoproporphyrinogen oxidase and rhProtoporphyrinogen oxidase, respectively.


Patients having Erythropoietic Porphyrrias such as Congenital erythropoietic Porphyrria (CEP) or Erythropoietic protoporphyria (EPP) will benefit from substitution therapy with rhUroporphyrinogen III synthetase and rhFerrochelatase, respectively.

- 5 Hepatoerythropoietic Porphyrrias e.g. Hepatoerythropoietic Porphyrrias (HEP) can be treated with rhUroporphyrinogen decarboxylase.

---

All porphyrias can be treated by the administration of the enzymatic activity lacking or being reduced (normally 50%) in any of the eight steps in the heme biosynthetic pathway  
10 as described above.

The substitution of the enzymatic activity can be achieved by adding the corresponding recombinant enzyme or other molecules that will provide the missing enzymatic activity. In situations where a combination of enzymes are beneficial, such therapy may be applied in  
15 a manner similar as disclosed above.



## Examble B

## EXPRESSION OF HOUSEKEEPING PORPHOBILINOGEN DEAMINASE FROM MOUSE IN HELA CELLS AND NIH 3T3 CELLS

## Experimental Procedures

## 5 Construction of the Recombinant Plasmid pNGVL3-GTC1-PBGD

A liver from a healthy mouse was homogenized and the total RNA was extracted. Complementary DNA was synthesized from total RNA using reverse transcriptase from murine leukemia virus and random priming (First-Strand cDNA Synthesis Kit, 10 Amersham Pharmacia Biotech). The PBGD cDNA housekeeping form was amplified by using nested primers in the polymerase chain reaction (PCR). In the first primer pair the forward primer was 5'-GGAGTCATGTCCGGTAACG-3' and the backward 5'-CAGACCAGTTAGCGCACATC-3'. In the second primer pair the forward primer was 5'-CGCGGGGTCGACGCCACCATGTCCGGTAACGGCGGC-3' that contained the 15 restriction site *Sa*I and a Kozak site necessary for optimal translation and the backward primer was 5'-CCCGGGGGTACCTTAGCGCACATCATTAAAG-3' that contained a *Kpn*I restriction site. The amplified PBGD was digested by *Sa*I and *Kpn*I and ligated into the plasmid pNGVL3-GTC1 that was digested with the same restriction enzymes. The vector pNGVL3-GTC1 contains a cytomegalovirus (CMV) 20 promoter and a kanamycin resistance gene obtained from National Gene Vector Laboratory (University of Michigan). *Escherichia coli* was transformed by the recombinant vector and the transformed bacteria was selected by the antibiotic kanamycin. The recombinant plasmid, pNGVL3-GTC1-PBGD, was isolated from selected clones and the PBGD cDNA insert was confirmed by restriction enzyme 25 analysis and sequencing.

## Cell Cultures

HeLa cells and NIH 3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and gentamycin to a final 30 concentration of 50 ng/mL.



## Transfection

Before transfection, the cells were seeded on a 3 cm 6-well plate at 100 000 cells/well and grown 24 hours in an incubator at +37°C containing 5% CO<sub>2</sub> to a 60-70 % confluency. The cells in each well were transfected with the following polyethylenimine (PEI) based transfection protocol (final volume 20  $\mu$ L):

- 
- 5  $\mu$ L of 1  $\mu$ g/ $\mu$ L plasmid (pNGVL3-GTC1-PBGD, housekeeping form, or pNGVL3-GTC1)
  - 7.6  $\mu$ L H<sub>2</sub>O
  - 10 • 5  $\mu$ L of 20% glucose
  - 2.4  $\mu$ L of a 0.1 mol/L 25 kD PEI solution

All reagents were added to a testtube in the order described above, mixed thoroughly and left at room temperature for ten minutes. A volume of 200  $\mu$ L DMEM from the well was removed and mixed with the 20  $\mu$ L of the transfection mixture and transferred back to the well. 24 hours after the transfection the cells were washed once with phosphate buffered saline (PBS) and lysed with 500  $\mu$ L of passive lysis buffer (PLB)/well (PLB is obtained from Promega) and the plate was placed on an orbital shaker for 15 minutes. The cell lysates were kept in the freezer -20 °C.

## PBGD Activity Assay

20

The PBGD activity assay is according to Magnussen et al Blood, 44 , 857-868, 1974 with some modifications. Three hundred  $\mu$ L of the cell lysate was mixed with 1.15 mL Tris-HCl buffer (50 mmol/L, pH 8.2). The reaction was initiated by adding 50  $\mu$ L of 3 mmol/L porphobilinogen (PBG). The mixture was incubated at +37°C for 60 minutes in the dark in a waterbath with shaking and the reaction was terminated by adding 1.50 mL of 25 % trichloroacetic acid (TCA). The samples were centrifuged for ten minutes in a Heraeus Megafuge at 3509 *g* to remove particles and precipitated proteins and the supernatant was transferred to a clean testtube. The samples were kept dark for 2.5 hours and the fluorescence of the product uroporphyrin I in the supernatant was measured at the excitation wavelength 405  $\mu$ m and the emission wavelength 596  $\mu$ m.

30

---

A tissue blank was included in the assay, which was cell lysate from HeLa cells. A volume of 300  $\mu$ L cell lysate was mixed with 1.15 mL Tris-HCl buffer (50 mmol/L, pH

8.2), and by adding 1.5 mL of 25 % TCA to the sample prior to incubation the PBGD were precipitated and no formation of product could occur.

Uroporphyrin I was used as standard with a concentration range between 0 to 33.3ng/mL.

As positive control bloodsamples from two different acute intermittent (AIP) patients was  
5 used, one with very high level of PBGD activity (erythroid form) in the erythrocytes and one with low level, and a third control was the PBGD activity in erythrocytes from a normal healthy individual.

---

#### Protein Assay

10

The protein concentration in the cell lysate was determined by the dye-binding reaction, Bio-Rad *DC* Protein Assay. Bovine serum albumin was used as standard and Seronorm™ Protein as control.

#### Results

15 The basal activity in the two different cell lines were measured (four times in HeLa and five times in NIH 3T3). Three samples from each cell line were transfected with pNGVL3-GTC1-PBGD and one sample from each was transfected with the plasmid pNGVL3-GTC1 without PBGD insert. The table on the next page illustrates the results obtained from the PBGD activity analysis and the protein assay.

20 *Table 1: Results from the PBGD activity assay and the protein assay in HeLa cells and NIH 3T3 cells, non-transfected and transfected with pNGVL3-GTC1-PBGD and pNGVL3-GTC1.*

25

30

35

---

40

1.1.1.1.1 Sample	Protein concentration g/L	PBGD Activity (nkat/L)	PBGD Activity/Protein conc (pkat/g prot)
HeLa	2,11	0,0353	16,73
HeLa	1,88	0,0273	14,52
HeLa	1,94	0,0246	12,68
HeLa	1,54	0,0227	14,74
HeLa + pNGVL3-GTC1-PBGD	1,73	12,07	6977
HeLa + pNGVL3-GTC1-PBGD	1,94	7,858	4051
HeLa + pNGVL3-GTC1-PBGD	1,91	12,65	6623
HeLa + pNGVL3-GTC1	2,03	0,0175	8,62
NIH 3T3	1,94	0,0451	23,25
NIH 3T3	2,06	0,0494	23,98
NIH 3T3	1,76	0,0496	28,18
NIH 3T3	1,95	0,0453	23,23
NIH 3T3	1,63	0,0429	26,32
NIH 3T3 + pNGVL3-GTC1-PBGD	1,76	0,486	276,1
NIH 3T3 + pNGVL3-GTC1-PBGD	1,81	0,462	255,2
NIH 3T3 + pNGVL3-GTC1-PBGD	1,86	0,381	204,8
NIH 3T3 + pNGVL3-GTC1	1,93	0,0261	13,52

(1 nkat/L corresponds to 0.060 units/L)

Figure sheet 23 and 24 illustrate these numbers in diagrams. The expression of PBGD in HeLa cells was increased up to 475 times from the basal activity and in NIH 3T3 cells up to 11 times. According to the method described herein, the expression of PBGD can be increased at least 100 times from the basal activity, such as at least 200 times, preferably at least 300 times, more preferably 400 times, such as about 500 times and even a higher increase may be obtained.

In NIH 3T3 cells an increase of at least 3 times, such as at least 6 times, preferably at least 10 times such as 11 times can be obtained according to the present method and it is believed that it may be increased further.

## 5 References:

Anderson P. M. and R. J. Desnick. 1979, Purification and Properties of Uroporphyrinogen I Synthase from Human Erythrocytes: Identification of Stable Enzyme-Substrate Intermediates *The Journal of Biological Chemistry* 255(5):1993-99

---

10 Andersson, Christer, Thesis, 1997, ISBN 91/7191/280/0, pp. 22-23

Amann, E., Brosius, J., and Ptashne, M. 1983, Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in *Escherichia coli*. *Gene* 25(2-3):167-178

15

Awan S.J. et al. 1997, Reconstitution of the Holoenzyme Form of *E. coli* Porphobilinogen Deaminase from Apoenzyme with Porphobilinogen and Preuroporphyrinogen: A Study Using Circular Dichroism Spectroscopy *Biochemistry* 36 (30):9273-82

20

Gold, L. and Stormo, G.D. 1990, High-level translation initiation. *Methods Enzymol.* 185:89-93:89-93

Grandchamp B. et al. 1987, Tissue-specific expression of porphobilinogen deaminase.

25 Two isoenzymes from a single gene. *Eur J Biochem.* Jan;162(1):105-10

Grandschamp B. et al. 1996, *J. of Gastroenterology and Hepatology* 11, 1046-1052

Herrick A.L. et al. 1989, *Lancet* 1, 1295-1297

30

Jeans J. et al. 1996, *American J. of Medical Genetics*, 65, 269-273

---

Jordan P.M., S.D.-Thomas and M.J. Warren. 1988, Purification, crystallization and properties of porphobilinogen deaminase from a recombinant strain of *Escherichia coli*

35 K12. *Biochem. J.* 254: 427-435

Jordan, P.M. The biosynthesis of uroporphyrinogen III: mechanism of action of porphobilinogen deaminase. In: The biosynthesis of the tetrapyrrole pigments 1994 Wiley, Chister (Ciba Found Symp 180), p70-96

5

Lambert R. et al. 1994, Structural studies on porphobilinogen deaminase. In: The biosynthesis of the tetrapyrrole pigments. Wiley, Chichester (Ciba Found Symp 180), p97-110

---

- 10 Lewis, L.A., Li, K.B., Gousse, A., Pereira, F., Pacheco, N., Pierre, S., Kodaman, P., and Lawson, S. 1991, Genetic and molecular analysis of spontaneous respiratory deficient (res-) mutants of *Escherichia coli* K-12. *Microbiol.Immunol.* 35(4):289-301

Lithner F. et al. 1984, *Acta.Med.Scand.* 215, 271-274

15

Louie, G.V. et al. 1996, The three-dimensional structure of *Escherichia coli* porphobilinogen deaminase at 1.76-A resolution *Proteins* 25(1):48-78

Makrides, S.C. 1996, Strategies for achieving high-level expression of genes in

- 20 *Escherichia coli*. *Microbiol.Rev.* 60(3):512-538

Maniatis T., E.F. Fritsch, J. Sambrook. *Molecular Cloning (A laboratory Manual)* Cold Spring Harbor Laboratory. 1982

- 25 Miller et al. 1989, *BioTechniques* 7, 980-990

Miyagi K. et al. 1979, Uroporphyrinogen I synthase from human erythrocytes: Separation, purification, and properties of isoenzymes. *Proc. Natl. Acad. Sci.* 76:12 6172-76

30

---

Morrison D.A. 1979, Transformation and preservation of competent bacterial cells by freezing. *Methods Enzymol.* 68, 326-331.

Mustajoki et al. 1989, *Sem. Hematol.* 26, 1-9

Raich N. et al. 1986, Molecular cloning and complete primary sequence of erythrocyte porphobilinogen deaminase. *Nucleic Acids Research* 14(15): 5955-67

5 Raich N. et al. 1986, *Nucleic. Acid. Res*, 14, 5955-5968

Saiki R.K. et al. 1985, Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. *Science*, 20;230(4732):1350-4.

10

Sassa S. 1996, *Blood Review*, 10, 53-58

Shoolingin-Jordan P.M., M.J. Warren and S.J. Awan, 1997, Dipyrrromethane Cofactor Assembly of Porphobilinogen Deaminase: Formation of Apoenzyme and Preparation of  
15 Holoenzyme. *Methods in Enzymology* 281: 317-327

Stephens P.E. et. al. *Biochem J.* 248, 1-11, 1987

Strand et al. 1970, *Proc. Natl. Acad. Sci.* 67, 1315-1320

20

Tishler P.V. et al. 1985, *Am.J.Psychiatry* 142,1430-1436

Waldenström J. 1937, *Acta.Med. Scand. Suppl.*82

25 Welland F.H. et al. 1964, *Metabolism*, 13, 232

Wetterberg L. 1967, Svenska bokförlaget Nordstedt, Stockholm

Wetterberg L. 1976, In Doss M. Nowrocki P. eds. *Porphyrias in Human Disease*.  
30 Reports of the discussion. *Matgurg an der Lahn*, 191-202

Yeung L. et al. 1983, *Q J. Med* 52, 92-98

Yoo H.W. et al. 1993, Hydroxymethylbilane synthase: complete genomic sequence and amplifiable polymorphisms in the human gene. *Genomics* Jan; 15(1):21-9

---

---

# Appendices

## Appendix 1 Equipment list

Item	Manufacturer	Serial Number
Pipetman P-1000	Gilson	N55287E
Pipetman P-200	Gilson	N52324E
Pipetman P-20	Gilson	N53465M
Pipetman P-10	Gilson	P626586
5415C centrifuge	Eppendorf	5415B68381
GS-6KR centrifuge	Beckman	NGD97J18
Avanti J-25 I centrifuge	Beckman	JJY97J14
DU 640B Spectrophotometer	Beckman	4323015
Genie II vortex	VWR	2-241186
GeneAmp PCR system 2400	Perkin Elmer (PE) / Applied Biosystems (ABI)	803N6021903
GeneAmp PCR system 2400	PE / ABI	803S7100104
GeneAmp PCR system 9700	PE / ABI	805S7121566
1545 incubator	VWR	0902597
heat block 1	VWR	0795
heat block 1	VWR	0511
Gene Pulser II Apparatus	BioRad	340BR2745
Pulse Controller Plus	BioRad	339BR1377
Power Pac 1000	BioRad	286BR00770
Sub Cell	BioRad	16S/8860
Wide-Mini Sub Cell	BioRad	02S/7951
Foto/Prep transilluminator	Fotodyne	PTG1-0997-2831
Elutrap Electro-separator	Schleicher + Schuell	Order No. 57880
Innova 4000 incubator	New Brunswick Scientific	890165366
Power Mac G3 computer	Macintosh	XA8061A3BBW
Trinitron Multiscan 200GS monitor	Sony	8057052
DNA analysis Software: Geneworks	Intelligenetics	Version 2.5.1



## Appendix 2 Supplies List

Item	Supplier	Cat No.	Lot No.
Human Spleen Poly A + RNA	Clontech	6542-1	7120266
Human Bone Marrow Poly A + RNA	Clontech	6573-1	56714
Human Lung Poly A + RNA	Clontech	6524-1	7050104
Human Lymph Node Poly A + RNA	Clontech	6594-1	6120292
Human Brain Poly A + RNA	Clontech	6516-1	63101
Human Adipose Total RNA	Clontech	D6005-01	7907005
Superscript II reverse transcriptase	Gibco/BRL	18064-014	JM6418
100 mM dNTP set	Pharmacia	27-2035-01	6072035011
pBluescriptII SK- phagemid	Stratagene	212206	0270702
Advantage cDNA polymerase mix	Clontech	8417-1	8060354
GeneAmp dNTP	PE/ABI	N-808-0007	H0172.4,H0553
Xba-I endonuclease	New England Biolabs (NEB)	145S	30
Pvu-II endonuclease	NEB	151L	14
EcoR-I endonuclease	NEB	101L	25
Hind-III endonuclease	NEB	104S	49
Tris six-Pack "C"	Sigma	T-PAC-C	77H9049
0.5 M EDTA pH 8.0	Sigma	E-7889	16H8924
Chromaspin TE 400	Clontech	K1323-1	7090795
Chromaspin 400 DepC dH <sub>2</sub> O	Clontech	K1333-1	7040086
Quiaquick gel extraction kit	Qiagen	28704	BY97017/0397/119
Microcon-30	Amicon	42410	L8JM4330B
Microcon-100	Amicon	42413	L8DM3296A

Micropure 0.22 $\mu$ m	Amicon	42544	CCB017
Seakem GTG agarose	FMC	50074	709397
100 bp DNA Ladder	NEB	323-1	3
123 bp DNA Ladder	Gibco/BRL	15613-029	JK9706
T4 DNA Ligase	NEB	202S	64
Ampicillin	Sigma	A-9518	76H0434
LB media	Gibco/BRL	12795-084	12E1072B
Bacto Agar	Difco	0140-07-4	106728JA
DH10B electromax	Gibco/BRL	18290-015	KHN430
SOC media	Gibco/BRL	15544-042	1010351
Taq polymerase	Fisher	FB-6000-15	H0436
TaqStart antibody	Clontech	5400-1	6070479
Qiafilter Midi DNA isolation kit	Qiagen	12243	PO No. 514
Isopropanol	Sigma	I-9516	47H3724
Big Dye terminator cycle sequencing kit	PE/ABI	4303152	9803008

## Appendix 3

Media, Strains and Transformation:

5 LB media (Bacto LB broth, Miller et al. 1989, BioTechniques 7, 980-990, from Difco, Catalogue # 0446007-5) was used as the basic growth media throughout the course of this study. The antibiotics ampicillin (Sigma, Catalogue # A9518), tetracycline (Sigma, Catalogue # T-3383), chloramphenicol (Sigma, Catalogue # C-1919) and G-418 (Gibco/BRL, Catalogue # 11811-015) were used at concentrations of 150  $\mu$ g/ml, 10 12  $\mu$ g/ml, 25  $\mu$ g/ml and 12  $\mu$ g/ml, respectively. Wherever indicated, glucose (Sigma, Catalogue # G-5400) was added at 0.2% and hemin (Sigma, Catalogue # H-2258) at 50  $\mu$ g/ml. The stock solution for hemin was 50 mg/ml in 0.1M NaOH. The composition of M9 medium was from Maniatis T., E.F. Fritsch, J. Sambrook. Molecular Cloning (A laboratory Manual) Cold Spring Harbor Laboratory. 1982. It was 15 supplemented with 1 mM  $\text{MgSO}_4$  and 1 g/ml thiamine hydrochloride. For all solid media, Bacto Agar (Difco, Catalogue # 0140-07-4) was used at a concentration of 1.5%.

The ligation mixes for constructing plasmids pExp0, pPBGD1.1 and pExp1 were 20 transformed in to DH12S (Gibco/BRL, Catalogue # 18312-017). For the plasmids pExp1-M2 and pExp1-M2-BB strain JM105 was used. For all steps leading to the construction of the plasmid phemCdCm (used as the source of the *EcoR* I-*Hind* III linear fragment for *hemC* disruption) strain DH10B cells (Gibco/BRL, Catalogue # 18290-015) were used. Transformation into DH12S or DH10B was by 25 electroporation using a BioRad electroporator at 2.0Kv/2000ohms/25mF in 0.1 cm cuvetts. Transformations into JM105 and all it derivatives and JM110 was done using  $\text{CaCl}_2$  (Morrison D.A. 1979, *Methods Enzymol.* 68, 326-331).

Enzyme Assays:

30 All enzyme assays were performed as described in example 3 under the subtitle "PBGD Activity Assay". The cultures were grown in LB + ampicillin under the conditions of temperature and induction as described in the report. The final densities of harvest ranged between 0.8 and 1.3 OD units at  $A_{600}$ . For activity determinations, cells were spun down from 1 ml samples and frozen at  $-20^\circ\text{C}$ . The thawed cell

pellets were resuspended in about 100  $\mu$ l of B-PER reagent (PIERCE, Catalogue # 78243), incubated at room temperature for 10 minutes, spun at 16,000 for 10 minutes and PBGD activity was determined in the supernatants. Total protein was estimated by the Bradford method using the BioRad reagent (Catalogue # 500-0006) and bovine serum albumin as standard.

#### Molecular Biology Supplies:

---

All restriction endonucleases and T4 DNA ligase were purchased from New England Biolabs, the kit for PCR reactions from Clontech (Catalogue # 8417-1) and the kit for DNA sequencing for the Big Dye terminator cycle sequencing from PE/ABI (Catalogue # 4303152). Plasmid DNAs were made using either the RPM AFS Kit (BIO 101, Catalogue # 2072-200), the RPM SPIN Midi Kit (BIO 101, Catalogue # 2005-200) or the RMP-1G Kit (BIO 101, Catalogue # 2077-000). DNA was extracted from agarose gel slices with GENECLEAN III (BIO 101, Catalogue # 1001-600), GENECLEAN Spin Kit (BIO 101, Catalogue # 1101-000) or Quiaquick gel extraction kit (Qiagen, Catalogue # 28704).

---

## Appendix 4 Equipment list:

Item	Manufacturer	Serial Number
Pipetman P-1000	Gilson	N55287E
Pipetman P-200	Gilson	N52324E
Pipetman P-20	Gilson	N53465M
Pipetman P-10	Gilson	P626586
5415C centrifuge	Eppendorf	5415B68381
GS-6KR centrifuge	Beckman	NGD97J18
Avanti J-25 I centrifuge	Beckman	JJY97J14
DU 640B Spectrophotometer	Beckman	4323015
Genie II vortex	VWR	2-241186
GeneAmp PCR system 2400	Perkin Elmer (PE) / Applied Biosystems (ABI)	803N6021903
GeneAmp PCR system 2400	PE / ABI	803S7100104
GeneAmp PCR system 9700	PE / ABI	805S7121566
1545 incubator	VWR	0902597
BioTek FL-600 plate reader	BioTek	
ProTeam LC System 210	ISCO	
Nupage Electrophoresis System	NOVEX	
Gel Destainer	BioRad	
Power Pac 200	BioRad	
Power Pac 1000	BioRad	
Innova 4000 incubator	New Brunswick Scientific	890165366
Innova 4000 incubator	New Brunswick Scientific	
Power Mac G3 computer	Macintosh	XA8061A3BBW
Trinitron Multiscan 200GS monitor	Sony	8057052
DNA analysis Software: Geneworks	Intelligenetics	Version 2.5.1
Sonifier 450	Branson	
1/2" diameter stepped disruptor horn	Branson	
2.5 X 50 cm LC column	Spectrum	
1.5 X 30 cm LC column	Spectrum	

## Appendix 5 Supplies List

Item	Supplier	Cat #	Lot #
Ampicillin	Sigma	A-9518	76H0434
Bacto Agar	Difco	0140-07-4	106728JA
Tris six-pack "C"	Sigma	T-PAC-C	77H9049
Trizma Base	Sigma	T-8524	28H5436
HCl	Sigma	H-1758	37H3495
PBG (5mg)	Sigma	P-1134	77H0930
PBG (1mg)	Sigma	P-1134	36H1297
BSA (fraction 5)	Sigma	A-6003	87H7603
DTT	Sigma	D-9779	105H7711
Methanol	Fisher	A452SK-4	982215
P-Benzoquinone	Acros	10563-0050	A011202801
DEAE Sepharose Fast Flow	Pharmacia	17-0709-01	256288
Chelating Sepharose Fast Flow	Pharmacia	17-0575-01	253865
Nickel Sulfate	Sigma	N73-100	985482
Talon Superflow Metal Affinity Resin	Clontech	8908-2	8110601
Centricon Plus-80 (Biomax 8)	Millipore	UFC5 BFC 02	Not available
Nupage 10% Bis/Tris gels	Novex	NP0302	Various
Protein Assay Kit II	BioRad	500-0002	59163A,62171A
Centricon-10	Millipore	4321	L8PM2042
KCl	Sigma	P-9333	68H01001
NaCl	Sigma	S-3014	97H1151
Imidazole	Fisher	03196-500	985421
Corning microtiter plate	Fisher	07-200-89	Not available
Costar 96 well X 2ml plate	Fisher	097-61-117	Not available
MicroAmp Reaction Tubes	Perkin Elmer	N801-0838	S18N8-41

MicroAmp Full Plate Cover	Perkin Elmer	N801-0550	090397
Spectra/Por 2.1 Biotech DispoDialyzers MWCO: 15k	Spectrum	135030	11987
Bacto LB broth, Miller	Difco	0446007-5	133116JC
Bacto Yeast Extract	Difco	0127-17-9	132389JC
Bacto Tryptone	Difco	0123-17	135850XA
Nalgene 0.22 $\mu$ m filter 500 ml	Fisher	169-0020	Not available
Nalgene 0.22 $\mu$ m filter 250 ml	Fisher	168-0020	Not available
Millipore Durapore Filter	Fisher	SCGF-U05RE	Not available

## CLAIMS

1. A method for treatment or prophylaxis of disease caused by deficiency, in a subject, of one or more enzymes belonging to the heme biosynthetic pathway, the  
5 method comprising administering, to the subject, an effective amount of one or more catalysts which is/are said enzyme(s), or an enzymatically equivalent part or analogue thereof.

---

2. A method according to claim 1, wherein the disease is selected from the group  
10 consisting of  
acute intermittent porphyria (AIP),  
ALA deficiency porphyria (ADP),  
Porphyria cutanea tarda (PCT),  
Hereditary coproporphyria (HCP),  
15 Harderoporphyria (HDP),  
Variegata porphyria (VP),  
Congenital erythropoietic porphyria (CEP),  
Erythropoietic protoporphyria (EPP), and  
Hepatoerythropoietic porphyria (HEP).

20  
3. A method according to claim 1, wherein the catalyst is one or more enzymes selected from the group consisting of  
delta-aminolevulinic acid synthetase,  
delta-aminolevulinic acid dehydratase (ALAD),  
25 porphobilinogen deaminase (PBGD),  
uroporphyrinogen III cosynthetase,  
uroporphyrinogen decarboxylase,  
coproporphyrinogen oxidase,  
protoporphyrinogen oxidase, and  
30 ferrochelatase,  
~~or an enzymatically equivalent part or analogue thereof.~~

---

4. A method according to claim 1, wherein the disease is AIP and the enzyme is PBGD or an enzymatically equivalent part or analogue thereof.



5. A method according to claim 1, wherein the catalyst is a recombinant form of the enzyme belonging to the heme biosynthetic pathway or of the enzymatically equivalent part or analogue thereof.

5 6. A method according to claims 1, wherein the catalyst is administered by a route selected from the group consisting of the intravenous route, the intraarterial route, the intracutaneous route, the subcutaneous route, the oral route, the buccal route, the intramuscular route, the anal route, the transdermic route, the intradermal route, and the intratechal route.

---

10

7. A method according to any of claim 1, wherein the catalyst is formulated in an isotonic solution, such as 0.9% NaCl and 10-50 mM Sodium phosphate pH 6.50 to 8 or Sodium phosphate, glycine, mannitol or the corresponding potassium salts.

15 8. A method according to any of claim 7, wherein the catalyst is lyophilised.

9. A method according to any of claim 8, wherein the catalyst is sterile filtered.

10. A method according to any of claim 1, wherein the catalyst is formulated as lipid  
20 vesicles comprising phosphatidylcholine or phosphatidylethanolamine or combinations thereof.

11. A method according to any of claim 1, wherein the catalyst is incorporated into erythrocyte ghosts.

25

12. A method according to any of claim 1, wherein the catalyst is formulated as a sustained release formulation involving biodegradable microspheres, such as microspheres comprising polylactic acid, polyglycolic acid or mixtures of these.

30 13. A method according to any of claim 1, wherein the catalyst is lyophilized in a two-compartment cartridge, where the catalyst will be in the front compartment and water for reconstitution in the rear compartment.

---

14. A method according to claim 13, wherein the two compartment cartridge is combined with an injection device to administer the catalyst either by a needle or by a needle-less (high pressure) device.
- 5 15. A method according to any of claim 1, wherein the catalyst is formulated in a physiological buffer containing an enhancer for nasal administration.
- 
16. A method according to claim 1, wherein the catalyst is formulated as an oral formulation containing lipid vesicles, such as those comprising phosphatidylcholine,  
10 phosphatidylethanolamine, or sphingomyeline, or dextrane microspheres.
17. A method according to claim 1, wherein the catalyst is formulated so as to enhance the half-life thereof in the subject's bloodstream.
- 15 18. A method according to claim 17, wherein the catalyst has a polyethylene glycol coating.
19. A method according to claim 17, wherein the catalyst is complexed with a heavy metal.  
20
20. A method according to claim 1, wherein the catalyst is an enzymatically equivalent part or analogue of the enzyme and exerts at least part of its enzymatic activity intracellularly upon administration to the subject.
- 25 21. A method according to claim 20, wherein the catalyst is a small artificial enzyme or an organic catalyst which can polymerize porphobilinogen to hydroxymethylbilane
22. A method according to claim 1, wherein the catalyst is said enzyme formulated in such a manner that it exerts at least part of its enzymatic activity intracellularly  
30 upon administration to the subject.
- 
23. A method according to claim 22, wherein the catalyst is tagged with specific carbohydrates or other liver cell specific structures for specific liver uptake.

24. A method according to claim 1, wherein the catalyst exerts substantially all its enzymatic activity extracellularly in the bloodstream.

25. A method according to claim 24, wherein the enzymatic activity of the catalyst  
5 on its relevant heme precursor results in a metabolic product which 1) either moves into the intracellular compartment and is converted further via the remaining steps of the heme biosynthetic pathway or 2) is excreted from the subject via urine and/or faeces.

---

10 26. A method according to claim 1, wherein the catalyst has been prepared by a method comprising

a) introducing, into a suitable vector, a nucleic acid fragment which includes a nucleic acid sequence encoding the catalyst;

15 b) transforming a compatible host cell with the vector;

c) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence; and

d) recovering the expression product from the culture

and optionally subjecting the expression product to post-translational processing,

20 such as in vitro protein refolding, enzymatic removal of fusion partners, alkylation of amino acid residues, and deglycosylation, so as to obtain the catalyst.

27. A method according to claim 1, wherein the catalyst has been prepared by liquid-phase or solid-phase peptide synthesis.

25

28. A method according to claim 26 of the preceding claims, wherein the catalyst is free from any other biological material of human origin.

29. A method according to any claim 1, wherein the catalyst is administered at least  
30 once a day, such as 2, 3, 4, or 5 times daily.

---

30. A method according to claim 29 wherein the daily dosage is in the range of 0.01 – 1.0 mg/kg body weight per day, such as in the range of 0.05 – 0.5 mg/kg body weight per day.

31. A method according to claim 29, wherein the daily dosage is about 0.1 mg per kg body weight per day.
- 5 32. A method according to claims 1 wherein the catalyst is a recombinant form of the enzyme.
- 
33. A method according to claim 32 wherein the catalyst is recombinant human PBGD based on any of Seq. ID NO 3 (clone PBGD 1.1) and Seq. ID NO 4 (non-  
10 erythro PBGD 1.1.1).
34. A method for treating a patient having a mutation in the PBGD gene causing an enzyme defect, comprising the use of a human PBGD cDNA sequence of either non-erythropoietic form or erythropoietic form according to whether the tissue in which  
15 PBGD should be expressed is in cells of erythroid origin or in other cells, and transfection of the patient with the relevant cDNA.
35. The method according to claim 34, wherein the enzyme deficiency is selected from enzyme deficiencies resulting in a disease selected from Acute Intermittent Porphyria, (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary  
20 coproporphyria (HCP), Harderoporphyria (HDP), Variegata porphyria (VP), Congenital erythropoietic porphyria (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP).
- 25 36. The method according to claim 35 wherein the disease is Acute Intermittent Porphyria, (AIP).
37. The method according to claim 34, wherein the human PBGD cDNA sequence is selected from Seq. ID NO 3 (clone PBGD 1.1) and Seq. ID NO 4 (non-erythro PBGD  
30 1.1.1).
- 
38. The method according to any of claims 34 wherein the transfection is by use of a vector selected from adenovirus, retrovirus and associated adenovirus.

39. The method according to claim 34 wherein the PBGD transfection of the patient (erythropoietic and/or non-erythropoietic cells) results in substantially normal PBGD activity measured as a normalisation in urinary and/or serum levels of delta-aminolevulinic acid (ALA) and porphobilanogen (PBG) compared to the levels before  
5 treatment or to a reduction in the frequency of attack of symptoms.

40. A method of gene therapy treatment of patients with Acute Intermittent Porphyrria (AIP) by a correction of one of the specific point mutations identified causing AIP by use of chimeraplasty gene repair.

---

10

41. The method according to claim 40 comprising a delivery system for transfection which is by use of non-viral vectors formulated in a vehicle preparation comprising one or more components selected from cationic phospholipids, phospholipids, phospholipids mixed with neutral lipids, lictosylated PEI, liposomes liposomes  
15 comprising mixtures of natural phopholipids and neutral lipids.

42. A method according to claim 40 wherein the mutation is selected from Table A.

43. A catalyst which is an enzyme of the heme biosynthetic pathway or an  
20 enzymatically equivalent part or analogue thereof, for use as a medicament.

44. A catalyst according to claim 43, which is recombinant human PBGD based on any of Seq. ID NO 3 (clone PBGD 1.1) and Seq. ID NO 4 (non-erythro PBGD 1.1.1).

25 45. An expression plasmid pExp1-M2-BB as shown in Seq. ID NO 1 for use in the expression of rhPBGD in *E. coli*.

46. A DNA fragmet, EcoR I - Hind III linear fragment as shown in Seq. ID NO 2, capable of obtaining *hemC*-deletion in a host.

30

---

47. A production strain of rhPBGD obtained by use of the DNA fragmet, EcoR I - Hind III linear fragment as shown in Seq. ID NO 2 to obtain *hemC*-deletion in the host JM105-H-R6-C by homologous gene replacement and transforming the resulting strain with the expression plasmid pExp1-M2-BB to yield the final production strain

PBGD which is free from production of PBGD of non human origin (Accession No 12915).

48. A method for the preparation of rhPBGD by a method comprising

- 5 a) introducing, into a suitable vector, a nucleic acid fragment which includes a nucleic acid sequence encoding PBGD;
  - b) transforming a compatible host cell with the vector;
  - c) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence;
  - 10 d) recovering the expression product from the culture.
- 

49. A method according to claim 48 further comprising a fermentation step.

50. A method according to claim 48 further comprising a purification step.

15

51. A method according to claim 50 wherein the purification is performed with a His-Tag (rhPBGD-His).

20

---

## Abstract

A method for treatment or prophylaxis of disease caused by deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway, the method comprising

5 administering, to the subject, an effective amount of a catalyst which is said enzyme or an enzymatically equivalent part or analogue thereof. The disease is selected from the group consisting of acute intermittent porphyria (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary coproporphyria (HCP), Harderoporphyria (HDP), Variegata porphyria (VP), Congenital erythropoietic porphyria

10 (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP). The catalyst is one or more enzymes selected from the group consisting of delta-aminolevulinic acid synthetase, delta-aminolevulinic acid dehydratase (ALAD), porphobilinogen deaminase (PBGD), uroporphyrinogen III cosynthetase, uroporphyrinogen decarboxylase, coproporphyrinogen oxidase, protoporphyrinogen

15 oxidase, and ferrochelatase, or an enzymatically equivalent part or analogue thereof. In addition the invention relates to the use of PBGD, to human recombinant PBGD and to a method of gene therapy. The invention also relates to an expression plasmid pExp1-M2-BB (Seq. ID No.1) and to use of a DNA fragment, the EcoR I - Hind III linear fragment (seq. ID No. 2), used for transformation in the hemC disruption

20 strategy for production of rhPBGD expressed in *E. coli*.

# SEQUENCE LISTING

<110> HEMEBIOTECH A/S

<120> Acute Intermittent Porphyria (AIP)

<160> 13

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 5446

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence of the expression plasmid pExp1-M2-BB

<400> 1

ctggcctgca	gtttgaaatc	attgctatgt	ccaccacagg	ggacaagatt	cttgatactg	180
cactctctaa	gattggagag	aaaagcctgt	ttaccaagga	gcttgaacat	gccctggaga	240
agaatgaagt	ggacctgggt	gttcaactcct	tgaaggacct	gccactgtg	cttctcctg	300
gcttcacat	cggagccatc	tgcaagcggg	aaaaccctca	tgatgctgtt	gtctttcacc	360
caaaatttgt	tgggaagacc	ctagaaaccc	tgccagagaa	gagtgtggtg	ggaaccagct	420
ccctgcgaag	agcagcccag	ctgcagagaa	agttcccgc	tctggagttc	aggagtattc	480
ggggaaacct	caacaccctg	cttcggaagc	tggacgagca	gcaggagttc	agtgccatca	540
tcctggcaac	agctggcctg	cagcgcatgg	gctggcaca	ccgggttggg	cagatcctgc	600
accctgagga	atgcatgtat	gctgtgggct	agggggcctt	gggctgtgaa	gtgcgagcca	660
aggaccagga	catcttggat	ctggtgggtg	tgctgcacga	tcccagagact	ctgcttcgct	720
gcatcgctga	aagggccttc	ctgaggcacc	tggaaggagg	ctgcagtgtg	ccagtagccg	780
tgcatacagc	tatgaaggat	gggcaactgt	acctgactgg	aggagtctgg	agtctagacg	840
gctcagatag	catacaagag	accatgcagg	ctaccatcca	tgccctgcc	cagcatgaag	900
atggccctga	ggatgaccca	cagttggtag	gcatcactgc	tcgtaacatt	ccacgagggc	960
cccagttggc	tgcccagaac	ttgggcatca	gcctggccaa	cttgttgctg	agcaaaggag	1020
ccaaaaacat	cctggatggt	gcacggcaat	tgaacgatgc	ccattaataa	gcttggctgt	1080
tttggcggat	gagagaagat	tttcagcctg	atacagatta	aatcagaacg	cagaagcggt	1140
ctgataaaac	agaatttgcc	tggcggcagt	agcgcggtgg	tcccacctga	ccccatgccg	1200
aactcagaag	tgaacgcgcg	tagcgccgat	ggtagtgtgg	ggtctcccca	tgcgagagta	1260
gggaactgcc	aggcatcaaa	taaaacgaaa	ggctcagtcg	aaagactggg	cctttcgttt	1320
tatctgttgt	ttgtcgggtg	acgctctcct	gagtaggaca	aatccgcccg	gagcggattt	1380
gaacgttgcg	aagcaacggc	ccggaggggtg	gcgggcagga	cgcccgccat	aaactgccag	1440
gcatcaaatt	aagcagaagg	ccatcctgac	ggatggcctt	tttgcgtttc	tacaaactct	1500
tttgtttatt	tttctaaata	cattcaaata	tgtatccgct	catgagacaa	taaccctgat	1560
aatgcttca	ataatattga	aaaaggaaga	gtatgagtat	tcaacatttc	cgtgtcgccc	1620
ttattccctt	ttttgcggca	ttttgccttc	ctgtttttgc	tcaccagaa	acgctggtga	1680
aagtaaaaga	tgtgaagat	cagttgggtg	cacgagtggg	ttacatcgaa	ctggatctca	1740
acagcggtaa	gatccttgag	agttttcgcc	ccgaagaacg	ttttccaatg	atgagcactt	1800
ttaaagtctt	gctatgtggc	gcggtattat	cccgtgttga	cgccgggcaa	gagcaactcg	1860
gtcgccgcat	acactattct	cagaatgact	tgtttgagta	ctcaccagtc	acagaaaagc	1920
atcttacgga	tggcatgaca	gtaagagaat	tatgcagtgc	tgccataacc	atgagtgata	1980
acactgcggc	caacttactt	ctgacaacga	tccgaggacc	gaaggagcta	accgcttttt	2040
tgcaacaacat	gggggatcat	gtaactcgcc	ttgatcgttg	ggaaccggag	ctgaatgaag	2100
ccataccaaa	cgacgagcgt	gacaccacga	tgcctgtagc	aatggcaaca	acgttgcgca	2160
aactattaac	tggcgaacta	cttactctag	cttcccggca	acaattaata	gactggatgg	2220
aggcggtata	agttgcagga	ccacttctgc	gctcgccctt	tccggctggc	tggtttatgt	2280
ctgataaata	tggagccggt	gagcgtgggt	ctcgcggtat	cattgcagca	ctggggccag	2340
atggtaagcc	ctcccgtatc	gtagttatct	acacgacggg	gagtcaggca	actatggatg	2400



aacgaaatag	acagatcgct	gagataggtg	cctcactgat	taagcattgg	taactgtcag	2460
accaagttta	ctcatatata	ctttagattg	atttaaaact	tcatttttaa	tttaaaagga	2520
tctaggtgaa	gatccttttt	gataatctca	tgaccaaact	cccttaacgt	gagttttcgt	2580
tccactgagc	gtcagacccc	gtagaaaaga	tcaaaggatc	ttcttgagat	cctttttttc	2640
tgcgcgtaat	ctgctgcttg	caaacaaaaa	aaccaccgct	accagcgggtg	gtttgtttgc	2700
cggatcaaga	gctaccaact	ctttttccga	aggtaactgg	cttcagcaga	gcgcagatac	2760
caaatactgt	ccttctagtg	tagccgtagt	taggccacca	cttcaagaac	tctgtagcac	2820
cgctacata	cctcgctctg	ctaactctgt	taccagtggc	tgctgccagt	ggcgataagt	2880
cgtgtcttac	cgggttggac	tcaagacgat	agttaccgga	taaggcgag	cggtcgggct	2940
gaacgggggg	ttcgtgcaca	cagcccagct	tggagcgaac	gacctacacc	gaactgagat	3000
acctacagcg	tgagctatga	gaaagcgcca	cgcttcccga	agggagaaaag	gcggacaggt	3060
atccggtaag	cggcagggtc	ggaacaggag	agcgcacgag	ggagcttcca	gggggaaaacg	3120
cctggatatct	ttatagtcct	gtcgggtttc	gccacctctg	acttgagcgt	cgatttttgt	3180
gatgctcgtc	agggggggcg	agcctatgga	aaaacgccag	caacgcggcc	tttttacggt	3240
tcctggcctt	ttgctggcct	tttgctcaca	tggtctttcc	tgcttatcc	cctgattctg	3300
tgataaacg	tattaccgcc	tttgagttag	ctgataccgc	tcgccgcagc	cgaacgaccg	3360
agcgcagcga	gtcagtgagc	gaggaagcgg	aagagcgct	gatgcggtat	tttctcctta	3420
cgcactctgtg	cggtatttca	caccgcatac	ggtgcactct	cagtacaatc	tgctctgatg	3480
ccgcatagtt	aagccagtat	acactccgct	atcgctacag	atccggaaca	taatggtgca	3540
gggcgctgac	ttccgcgttt	ccagacttta	cgaaacacgg	aaaccgaaga	ccattcatgt	3600
tggtgctcag	gtcgcagacg	ttttgcagca	gcagtcgctt	cacgttcgct	cgcgatcgg	3660
tgattcattc	tgctaaccag	taaggcaacc	ccgccagcct	agccgggtcc	tcaacgacag	3720
gagcacgac	atgcgcaccc	gtggccagga	cccaacgctg	cccagatgc	gccgcgtgcg	3780
gctgctggag	atggcggacg	cgatggatat	gttctgcca	gggttggttt	gcgcattcac	3840
agttctccgc	aagaattgat	tggtcccaat	tcttgagtg	gtgaatccgt	tagcgaggtg	3900
ccgcggcctt	ccattcaggt	cgaggtggcc	cggtccatg	caccgcgacg	caacgcgggg	3960
aggcagacaa	ggtatagggc	ggcgccctaca	atccatgcca	accggttcca	tgtgctcgcc	4020
gaggcggcat	aaatcgccgt	gacgatcagc	ggtccagtga	tcgaagttag	gctggtaaga	4080
gccgcgagcg	atccttgaag	ctgtccctga	tggtcgctcat	ctacctgcct	ggacagcatg	4140
gcctgcaacg	cgggcatccc	gatgccgcgg	gaagcgagaa	gaatcataat	ggggaaggcc	4200
atccagcctc	gcgtcgcgaa	cgccagcaag	acgtagccca	gcgcgtcggc	cgccatgcgg	4260
gcgataatgg	cctgcttctc	gccgaaacgt	ttggtggcgg	gaccagtgc	gaaggcttga	4320
gcgagggcgt	gcaagattcc	gaataccgca	agcgacaggc	cgatcatcgt	cgcgctccag	4380
cgaaagcggg	cctcgccgaa	aatgaccag	agcgctgcgg	gcacctgtcc	tacgagttgc	4440
atgataaaga	agacagtcac	aagtgcggcg	acgatatgca	tgccccgcgc	ccaccggaag	4500
gagctgactg	ggttgaaggc	tctcaagggc	atcggtcgac	gctctccctt	atgcgactcc	4560
tgcattagga	agcagccag	tagtaggttg	aggccgttga	gcaccgccc	cgcaagggaat	4620
ggtgcatgca	aggagatggc	gccccaacagt	cccccgcca	cggggcctgc	caccataccc	4680
acgccgaaac	aagcgtcat	gagcccgaag	tggcgagccc	gatcttcccc	atcggtgatg	4740
tcggcgatat	aggcgccagc	aaccgcacct	gtggcgccgg	tgatgcgggc	cacgatgcgt	4800
ccggcgtaga	ggatccacag	gacgggtgtg	gtcgccatga	tcgcgtagtc	gatagtggct	4860
ccaagttagc	aagcgacgag	gactgggcgg	cggccaaagc	ggtcggacag	tgctccgaga	4920
acgggtgcgc	atagaaattg	catcaacgca	tatagcgcta	gcagcacgcc	atagtactg	4980
gcgatgctgt	cggaaatggac	gatatcccgc	aagaggcccg	gcagtaccgg	cataaccaag	5040
cctatgccta	cagcatccag	ggtgacgggtg	ccgaggatga	cgatgagcgc	attgttagat	5100
ttcatacacg	gtgcctgact	gcgttagcaa	tttaactgtg	ataaactacc	gcattaaagc	5160
taatcgatga	taagctgtca	aacatgagtg	atccgggctt	atcgactgca	cggtgcacca	5220
atgcttctgg	cgtcaggcag	ccatcggaag	ctgtggtatg	gctgtgcagg	tcgtaaataca	5280
ctgcataatt	cgtgtcgctc	aaggcgcact	cccgttctgg	ataatgtttt	ttgcgccgac	5340
atcataacgg	ttctggcaaa	tattctgaaa	tgagctgttg	acaattaatc	atcggtcgt	5400
ataatgtgtg	gaattgtgag	cggataacaa	tttcacacag	gaaaca		5446

&lt;210&gt; 2

&lt;211&gt; 3225

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Sequence of the EcoR I - Hind III linear fragment  
used for transformation in the hemC disruption  
strategy

&lt;400&gt; 2.

aattcgtcaa	gcagcagtat	atgctgggtg	gagccacaat	cttcgcccc	caggctgccg	60
ctttcattat	gacggaagcg	gttttcatca	atcaggaaga	agctgacttc	cacacccagc	120
gagcgggccc	agttttccag	caggctacat	ttacgttgta	gcaattggcg	ctcttcgcta	180
tcgagccagg	attgatgaca	gaccagata	tccaggtcag	aggaacaact	ttgccctacg	240
gacgaggtgc	tgcccatggt	gtatacacca	gtaattggaa	gtcaccttt	cggcggtacc	300
tgtactgaca	ttccacgata	cagttcaagc	tcgttcaggt	agtggcggtg	agtttcatca	360
ggcgtgtaaa	ggcaaatgcc	tttgggaacg	ttaccatcaa	ggtagcccg	cattagcgga	420
tggtgatagt	gcaacaatgt	cggcagtaga	ctgtagacct	gttggaatgc	aggccccata	480
gcagcaagcg	gcgcatccac	acgcaattga	tttatggcat	ccagtctctg	tttcagagtc	540
tcaatataga	ggtacaagac	gtatcgccgt	atttgcctacc	cgctcatgact	gtgattccgc	600
caacatcaac	ggtaaacacg	ggcattcggt	atatttcgta	tgtcaaagg	aaccgttacc	660
acttttcg	cctgggtttt	ttagtttcac	gacgaaaaa	tggtctaaaa	cgtgatcaat	720
ttaacacctt	gctgattgac	cgtaaagaaa	gatgcgctac	atacaagtgt	agcaccgttt	780
attctctgta	aattccttat	tacaacggcg	tgaacgcct	gtcaggatcc	actgccagac	840
ctcattttac	ggtttgccga	ggcgtctacg	tttcaccaca	acactgacat	cactctggca	900
aggatggttag	gatggaccac	ggatgataat	gacggtaaca	agcatggttag	acaatgtttt	960
aagaattgcc	acacgccaaa	gcccacttgc	actctggcag	gcacactatg	tcaaagacaa	1020
gttgatggcg	agccatccgg	gcttggctgt	tgaactggta	ccgatggtga	cctcgagcgg	1080
cacgtaagag	gttccaactt	tcaccataat	gaaataagat	cactaccggg	cgtatttttt	1140
gagttgtcga	gattttcagg	agctaaggaa	gctaaaatgg	agaaaaaat	cactggatat	1200
accaccgttg	atatatccca	atggcatcgt	aaagaacatt	ttgaggcatt	tcagtcagtt	1260
gctcaatgta	cctataacca	gaccgttcag	ctggatatta	cggccttttt	aaagaccgta	1320
aagaaaaata	agcacaagtt	ttatccggcc	tttattcaca	ttcttgcccg	cctgatgaat	1380
gctcatccgg	aattacgtat	ggcaatgaaa	gacggtgagc	tggtgatatg	ggatagtggt	1440
cacccttggt	acaccgtttt	ccatgagcaa	actgaaacgt	tttcatcgct	ctggagtgaa	1500
taccacgacg	atttccggca	gtttctacac	atatattcgc	aagatgtggc	gtgttacggt	1560
gaaaacctgg	cctattttcc	taaagggttt	attgagaata	tgtttttcgt	ctcagccaat	1620
ccctgggtga	gtttcaccag	ttttgattta	aacgtggcca	atatggacaa	cttcttcgcc	1680
ccggttttca	ccatgggcaa	atattatacg	caaggcgaca	aggtgctgat	gccgctggcg	1740
attcaggttc	atcatgccgt	ttgtgatggc	ttccatgtcg	gcagaatgct	taatgaatta	1800
caacagtaact	gcgatgagtg	gcagggcg	gcgtaattct	cgagaccggc	atgagtatcc	1860
ttgtcaccgc	cccgctctcc	gctggagaag	agttagttag	ccgtctgcgc	acactggggc	1920
aggtggcctg	gcattttccg	ctgattgagt	tttctccggg	tcaacaatta	ccgcaacttg	1980
ctgatcaact	ggcagcgctg	ggggagagcg	atctgttggt	tgccctctcg	caacacgcgg	2040
ttgcttttga	ccaatcacag	ctgcacacg	aagatcgtaa	atggccccga	ctacctgatt	2100
atttcgccat	tgacgcgacc	accgcactgc	cactacatac	cgtaagtgga	cagaagattc	2160
tctaccgcga	ggatcgggaa	atcagcgaag	tcttgctaca	attacctgaa	ttacaaaata	2220
ttgcgggcaa	acgtgcgctg	atattacgtg	gcaatgggtg	tcgtgagcta	attggggata	2280
ccctgacggc	gcgcggtgct	gaggtcaact	tttgtgaatg	ttatcaacga	tgcgcaatcc	2340
attacgatgg	tgcagaagaa	gcgatgcgct	ggcaagcccg	cgaggtgacg	atggctcggtg	2400
ttaccagcgg	tgaaatggtg	cagcaactct	ggtcgctgat	cccacaatgg	tatcgtgagc	2460
actggttact	acactgtcga	ctattggtcg	tcagtgagcg	tttggcgaaa	ctcgcccg	2520
aactgggctg	gcaagacatt	aaggctcgccg	ataacgctga	caacgatgcg	cttttacggg	2580
cattacaata	actctcataa	caggaagcca	taatgacgga	acaagaaaaa	acctccgccc	2640
tggttgaaga	gaccagggag	gccgtggaca	ccacgtcaca	acctgtcgca	acagaaaaaa	2700
agagtaagaa	caataccgca	ttgattctca	gcgcggtggc	tatcgctatt	gctctggcgg	2760
cgggcatcgg	tttgtatggc	tggggtaaac	aacaggccgt	caatcagacc	gccaccagcg	2820
atgccctggc	taaccaactg	acggcattgc	aaaaagccca	ggagagccaa	aaagccgagc	2880
tggaaggcat	tattaagcaa	caagctgcac	aacttaagca	ggcgaatcgt	cagcaagaaa	2940
cgctggcaaa	acagttggat	gaagtccaac	aaaaggctgc	caccatttcc	ggcagcgatg	3000
ctaaaacctg	gctgctggct	caggccgatt	ttctggtgaa	aetgseegga	eggaagctgt	3060
ggagcgatca	ggacgtcacg	accgctgcag	cgttgctgaa	aagtgcagac	gccagcctgg	3120
cggatatgaa	tgaccgaggt	ctgattaccg	ttcgtcgggc	aattaccgat	gatatcgcca	3180
gcctttctgc	agtatcgag	gtggattatg	acggcatcat	cetta		3225

&lt;210&gt; 3

&lt;211&gt; 1035

&lt;212&gt; DNA

&lt;213&gt; Human tissue

&lt;400&gt; 3

atgagagtga	ttcgcgtggg	tacccgcaag	agccagcttg	ctcgcataca	gacggacagt	60
gtggtggcaa	cattgaaagc	ctcgtaccct	ggcctgcagt	ttgaaatcat	tgctatgtcc	120
accacagggg	acaagattct	tgatactgca	ctctctaaga	ttggagagaa	aagcctgttt	180
accaaggagc	ttgaacatgc	cctggagaag	aatgaagtgg	acctggttgt	tcactccttg	240
aaggacctgc	ccactgtgct	tcctcctggc	ttcaccatcg	gagccatctg	caagcgggaa	300
aaccctcatg	atgctgttgt	ctttcaccca	aaatttggtg	ggaagaccct	agaaaccctg	360
ccagagaaga	gtgtggtggg	aaccagctcc	ctgcgaagag	cagcccagct	gcagagaaag	420
ttcccgcata	tggagttcag	gagtattcgg	ggaaacctca	acaccgggct	tcggaagctg	480
gacgagcagc	aggagttcag	tgccatcata	ctggcaacag	ctggcctgca	gcgcatgggc	540
tggcacaacc	gggttgggca	gacccctgcac	cctgaggaat	gcattgtatgc	tgtgggccaq	600
ggggccttgg	gcgtggaagt	gcgagccaag	gaccaggaca	tcttggatct	ggtgggtgtg	660
ctgcacgata	ccgagactct	gcttcgctgc	atcgctgaaa	gggccttcct	gaggcacctg	720
gaaggaggct	gcagtgtgcc	agtagccgtg	catacagcta	tgaaggatgg	gcaactgtac	780
ctgactggag	gagtctggag	tctagacggc	tcagatagca	tacaagagac	catgcaggct	840
accatccatg	tccttgccca	gcataagat	ggccctgagg	atgaccacac	gttggtaggc	900
atcactgctc	gtaacattcc	acgagggccc	cagttggctg	cccagaactt	gggcatcagc	960
ctggccaact	tgttgctgag	caaaggagcc	aaaaacatcc	tggatgttgc	acggcaattg	1020
aacgatgccc	attaa					1035

&lt;210&gt; 4

&lt;211&gt; 1113

&lt;212&gt; DNA

&lt;213&gt; Human tissue

&lt;400&gt; 4

cacacagcct	actttccaag	cggagccatg	tctggtaacg	gcaatgcggc	tgcaacggcg	60
gaagaaaaca	gccc aaagat	gagagtgtt	cgctgggta	cccgaagag	ccagcttgct	120
cgcatacaga	cggacagtgt	ggtggcaaca	ttgaaagcct	cgtaacctgg	cctgcagttt	180
gaaatcattg	ctatgtccac	cacaggggac	aagattcctg	atactgcaat	ctctaagatt	240
ggagagaaaa	gcttgtttac	caaggagctt	gaacatgccc	tggaagaaga	tgaagtggac	300
ctgggttgtt	actccttgaa	ggacctgccc	actgtgcttc	ctcctggctt	caccatcgga	360
gccatctgca	agcgggaaaa	ccctcatgat	gctgttgtct	ttcacccaaa	atttgttggg	420
aagaccctag	aaaccctgcc	agagaagagt	gtggtgggaa	ccagctccct	gcgaagagca	480
gcccagctgc	agagaaagtt	cccgcactct	gagttcagga	gtattcgggg	aaacctcaac	540
acccggcttc	ggaagctgga	cgagcagcag	gagttcagtg	ccatcatcct	ggcaacagct	600
ggcctgcagc	gcattgggctg	gcacaaccgg	gttgggcaga	tcctgcaccc	tgaggaatgc	660
atgtatgctg	tgggccaggg	ggccttgggc	gtggaagtgc	gagccaagga	ccaggacatc	720
ttggattctg	tgggtgtgct	gcacgatccc	gagactctgc	ttcgtgcat	cgctgaaagg	780
gccttctctg	ggcaccttga	aggaggtctg	agtgtgccag	tagccgtgca	tacagctatg	840
aaggatgggc	aactgtacct	gactggagga	gtctggagtc	tagacggctc	agatagcata	900
caagagacca	tgcaggctac	catccatgtc	cctgcccagc	atgaagatgg	ccctgaggat	960
gacccacagt	tggtaggcat	cactgctcgt	aacattccac	gagggcccca	gttggctgcc	1020
cagaacttgg	gcatacgcct	ggccaacttg	ttgctgagca	aaggagccaa	aaacatcctg	1080
gatgttgca	ggcaattgaa	cgatgcccat	ttaa			1113

&lt;210&gt; 5

&lt;211&gt; 1035

&lt;212&gt; DNA

&lt;213&gt; Human tissue

&lt;400&gt; 5

atgagagtga	ttcgcgtggg	tacccgcaag	agccagcttg	ctcgcataca	gacggacagt	60
gtggtggcaa	cattgaaagc	ctcgtaccct	ggcctgcagt	ttgaaatcat	tgctatgtcc	120
accacagggg	acaagattct	tgatactgca	ctctctaaga	ttggagagaa	aagcctgttt	180
accaaggagc	ttgaacatgc	cctggagaag	aatgaagtgg	acctggttgt	tcactccttg	240
aaggacctgc	ccactgtgct	tcctcctggc	ttcaccatcg	gagccatctg	caagcgggaa	300
aaccctcatg	atgctgttgt	ctttcaccca	aaatttggtg	ggaagaccct	agaaaccctg	360
ccagagaaga	gtgtggtggg	aaccagctcc	ctgcgaagag	cagcccagct	gcagagaaag	420

ttccccgcatc	tggagttcag	gagtatctcg	ggaaacctca	acacccggct	tcggaagctg	480
gacgagcagc	aggagttcag	tgccatcatc	ctggcaacag	ctggcctgca	gcgcatgggc	540
tggcacaacc	gggtggggca	gatcctgcac	cctgaggaat	gcatgtatgc	tgtgggccag	600
ggggccttgg	gcgtggaagt	gcgagccaag	gaccaggaca	tcttggatct	ggtgggtgtg	660
ctgcacgata	ccgagactct	gcttcgctgc	atcgctgaaa	gggccttcct	gaggcacctg	720
gaaggaggct	gcagtgtgcc	agtagccgtg	catacagcta	tgaaggatgg	gcaactgtac	780
ctgactggag	gagtctggag	tctagacggc	tcagatagca	tacaagagac	catgcaggct	840
accatccatg	tccctgcccc	gcatgaagat	ggccctgagg	atgaccacaca	gttggtaggc	900
atcactgctc	gtaacattcc	acgagggccc	cagttggctg	cccagaactt	gggcatcagc	960
ctggccaact	tgttgctgag	caaaggagcc	aaaaacatcc	tggatgttgc	acggcaattg	1020
aacgatgccc	attaa					1035

&lt;210&gt; 6

&lt;211&gt; 1035

&lt;212&gt; DNA

&lt;213&gt; Human tissue

&lt;400&gt; 6

atgagagtga	ttcgctggg	tacccgcaag	agccagcttg	ctcgcataca	gacggacagt	60
gtggtggcaa	cattgaaagc	ctcgaccct	ggcctgcagt	ttgaaatcat	tgctatgtcc	120
accacagggg	acaagattct	tgatactgca	ctctctaaga	ttggagagaa	aagcctgttt	180
accaaggagc	ttgaacatgc	cctggagaag	aatgaagtgg	acctggttgt	tcactccttg	240
aaggacctgc	ccactgtgct	tcctcctggc	ttcaccatcg	gagccatctg	caagcgggaa	300
aaccctcatg	atgctgttgt	ctttcaccca	aaatttgttg	ggaagaccct	agaaaccctg	360
ccagagaaga	gtgtggtggg	aaccagctcc	ctgcgaagag	cagcccagct	gcagagaaag	420
ttccccgcatc	tggagttcag	gagtatctcg	ggaaacctca	acacccggct	tcggaagctg	480
gacgagcagc	aggagttcag	tgccatcatc	ctggcaacag	ctggcctgca	gcgcatgggc	540
tggcacaacc	gggtggggca	gatcctgcac	cctgaggaat	gcatgtatgc	tgtgggccag	600
ggggccttgg	gcgtggaagt	gcgagccaag	gaccaggaca	tcttggatct	ggtgggtgtg	660
ctgcacgata	ccgagactct	gcttcgctgc	atcgctgaaa	gggccttcct	gaggcacctg	720
gaaggaggct	gcagtgtgcc	agtagccgtg	catacagcta	tgaaggatgg	gcaactgtac	780
ctgactggag	gagtctggag	tctagacggc	tcagatagca	tacaagagac	catgcaggct	840
accatccatg	tccctgcccc	gcatgaagat	ggccctgagg	atgaccacaca	gttggtaggc	900
atcactgctc	gtaacattcc	acgagggccc	cagttggctg	cccagaactt	gggcatcagc	960
ctggccaact	tgttgctgag	caaaggagcc	aaaaacatcc	tggatgttgc	acggcaattg	1020
aacgatgccc	attaa					1035

&lt;210&gt; 7

&lt;211&gt; 1034

&lt;212&gt; DNA

&lt;213&gt; Human tissue

&lt;400&gt; 7

atgagagtga	ttcgctggg	tacccgcaag	agccagcttg	ctcgcataca	gacggacagt	60
gtggtggcaa	cattgaaagc	ctcgaccct	ggcctgcagt	ttgaaatcat	tgctatgtcc	120
accacagggg	acaagattct	tgatactgca	ctctctaaga	ttggagagaa	aagcctgttt	180
accaaggagc	ttgaacatgc	cctggagaag	aatgaagtgg	acctggttgt	tcactccttg	240
aaggacctgc	ccactgtgct	tcctcctggc	ttcaccatcg	gagccatctg	caagcgggaa	300
aaccctcatg	atgctgttgt	ctttcaccca	aaatttgttg	gaagacccta	gaaaccctgc	360
cagagaagag	tgtggtggga	accagctccc	tgcgaagagc	agcccagctg	cagagaaagt	420
ttccccgcatc	ggagttcagg	agtattcggg	gaaacctcaa	cacccggctt	cggaagctgg	480
acgagcagca	ggagttcagt	gccatcatcc	tggcaacagc	tggcctgcag	cgcatgggct	540
ggcacaaccg	ggtggggcag	atcctgcacc	ctgaggaatg	catgtatgct	gtgggccagg	600
gggccttggg	cgtggaagtg	cgagccaagg	accaggacat	cttggatctg	gtgggtgtgc	660
tgacagatcc	cgagactctg	cttcgctgca	tcgctgaaag	ggccttcctg	aggcacctgg	720
aaggaggctg	cagtgtgcc	gtagccgtgc	atacagctat	gaaggatggg	caactgtacc	780
tgactggagg	agtctggagt	ctagacggct	cagatagcat	acaagagacc	atgcaggcta	840
ccatccatgt	ccctgcccag	catgaagatg	ggcctgagga	tgaccacacag	ttggtaggca	900
tcactgctcg	taacattcca	cgagggcccc	agttggctgc	ccagaacttg	ggcatcagcc	960
tggccaactt	gttgctgagc	aaaggagcca	aaaacatcct	ggatgttgca	cggcaattga	1020
acgatgcccc	ttaa					1034

&lt;210&gt; 8

&lt;211&gt; 1035

&lt;212&gt; DNA

&lt;213&gt; Human tissue

&lt;400&gt; 8

atgagagtga	ttcgcgtggg	tacccgcaag	agccagcttg	ctcgcataca	gacgggcagt	60
gtggtggcaa	cattgaaagc	ctcgtaccct	ggcctgcagt	ttgaaatcat	tgctatgtcc	120
accacagggg	acaagattct	tgatactgca	ctctctaaga	ttggagagaa	aagcctgttt	180
accaaggagc	ttgaacatgc	cctggagaag	aatgaagtgg	acctggttgt	tcactccttg	240
aaggacctgc	ccactgtgct	tcctcctggc	ttcaccatcg	gagccatctg	caagcgggaa	300
aaccctcatg	atgctgttgt	ctttcaccca	aaatttggtg	ggaagaccct	agaaaccctg	360
ccagagaaga	gtgtggtggg	aaccagctcc	ctgcgaagag	cagcccagct	gcagagaagg	420
ttcccgcata	tggagttcag	gagtattcgg	ggaaacctca	acacccggct	tcggaagctg	480
gacgagcagc	aggagttcag	tgcatcatc	ctggcaacag	ctggcctgca	gcgcattggc	540
tggcacaacc	gggttgggca	gacccctgcac	cctgaggaat	gcatgtatgc	tgtgggcccag	600
ggggccttgg	gcgtgggaagt	gcgagccaag	gaccaggaca	tcttggatct	ggtgggtgtg	660
ctgcacgata	ccgagactct	gcttcgctgc	atcgctgaaa	gggccttcct	gaggcacctg	720
gaaggaggct	gcagtgtgcc	agtagccgtg	catacagcta	tgaaggatgg	gcaactgtac	780
ctgactggag	gagtctggag	tctagacggc	tcagatagca	tacaagagac	catgcaggct	840
accatccatg	tccttgccca	gcatgaagat	ggccctgagg	atgaccacaca	gttggttaggc	900
atcactgctc	gtaacattcc	acgagggccc	cagttggctg	cccagaactt	gggcatcagc	960
ctggccaact	tggtgctgag	caagggagcc	aaaaacatcc	tggatgttgc	acggcaattg	1020
aacgatgccc	attaa					1035

&lt;210&gt; 9

&lt;211&gt; 1035

&lt;212&gt; DNA

&lt;213&gt; Human tissue

&lt;400&gt; 9

atgagagtga	ttcgcgtggg	tacccgcaag	agccagcttg	ctcgcataca	gacggacagt	60
gtggtggcaa	cattgaaagc	ctcgtaccct	ggcctgcagt	ttgaaatcat	tgctatgtcc	120
accacagggg	acaagattct	tgatactgca	ctctctaaga	ttggagagaa	aagcctgttt	180
accaaggagc	ttgaacatgc	cctggagaag	aatgaagtgg	acctggttgt	tcactccttg	240
aaggacctgc	ccactgtgct	tcctcctggc	ttcaccatcg	gagccatctg	caagcgggaa	300
aaccctcatg	atgctgttgt	ctttcaccca	aaatttggtg	ggaagaccct	agaaaccctg	360
ccagagaaga	gtgtggtggg	aaccagctcc	ctgcgaagag	cagcccagct	gcagagaaag	420
ttcccgcata	tggagttcag	gagtattcgg	ggaaacctca	acacccggct	tcggaagctg	480
gacgagcagc	aggagttcag	tgccatcatc	ctggcaacag	ctggcctgca	gcgcattggc	540
tggcacaacc	gggttgggca	gacccctgcac	cctgaggaat	gcatgtatgc	tgtgggcccag	600
ggggccttgg	gcgtgggaagt	gcgagccaag	gaccaggaca	tcttggatct	ggtgggtgtg	660
ctgcacgata	ccgagactct	gcttcgctgc	atcgctgaaa	gggccttcct	gaggcacctg	720
gaaggagggt	gcagtgtgcc	agtagccgtg	catacagcta	tgaaggatgg	gcaactgtac	780
ctgactggag	gagtctggag	tctagacggc	tcagatagca	tacaagagac	catgcaggct	840
accatccatg	tccttgccca	gcatgaagat	ggccctgagg	atgaccacaca	gttggttaggc	900
atcactgctc	gtaacattcc	acgagggccc	cagttggctg	cccagaactt	gggcatcagc	960
ctggccaact	tggtgctgag	caaaggagcc	aaaaacatcc	tggatgttgc	acggcaattg	1020
aacgatgccc	attaa					1035

&lt;210&gt; 10

&lt;211&gt; 1034

&lt;212&gt; DNA

&lt;213&gt; Human tissue

&lt;400&gt; 10

atgagagtga	ttcgcgtggg	tacccgcaag	agccagcttg	ctcgcataca	gacggacagt	60
gtggtggcaa	cattgaaagc	ctcgtaccct	ggcctgcagt	ttgaaatcat	tgctatgtcc	120
accacagggg	acaagattct	tgatactgca	ctctctaaga	ttggagagaa	aagcctgttt	180
accaaggagc	ttgaacatgc	cctggagaag	aatgaagtgg	acctggttgt	tcactccttg	240

aaggacctgc	ccactgtgct	tctctctggc	ttcaccatcg	gagccatctg	caagcgggaa	300
aaccctcatg	atgctgttgt	ctttcaccca	aaatttggtg	ggaagaccct	agaaaccctg	360
ccagagaaga	gtgtggtggg	aaccagctcc	ctgcgaagag	cagcccagct	gcagagaaag	420
ttcccgcatc	tggagtccag	gagtattcgg	ggaaacctca	acaccgggct	tcggaagctg	480
gacgagcagc	aggagtccag	tgccatcatc	ctggcaacag	ctggcctgca	gcgcatgggc	540
tggcacaacc	gggtggggca	gatcctgcac	cctgaggaat	gcatgtatgc	tgtgggccag	600
ggggccttgg	gcgtggaagt	gcgagccaag	gaccaggaca	tcttggatct	ggtgggtgtg	660
ctgcacgata	ccgagactct	gcttcgctgc	atcgctgaaa	gggccttcc	gaggcacctg	720
gaaggaggct	gcagtgtgcc	agtagccgtg	catacagcta	tgaaggatgg	gcaactgtac	780
ctgactggag	gagtcctggag	tctagacggc	tcagatagca	tacaagagac	catgcaggct	840
accatccatg	tccctgccca	gcataagat	ggcctgagg	atgaccaca	gttggtaggc	900
atcactgctc	gtaacattcc	acgagggccc	cagttggctg	cccagaactt	gggcatcagc	960
ctggccaact	tgttgctgag	caaaggagcc	aaaaacatcc	tggatgttgc	acggcaatta	1020
acgatgccca	ttaa					1034

&lt;210&gt; 11

&lt;211&gt; 1035

&lt;212&gt; DNA

&lt;213&gt; Human tissue

&lt;400&gt; 11

atgagagtga	ttcgcgtggg	taccgcgaag	agccagcttg	ctcgcataca	gacggacagt	60
gtggtggcaa	cattgaaagc	ctcgtaacct	ggcctgcagt	ttgaaatcat	tgctatgtcc	120
accacagggg	acaagattct	tgatactgca	ctctctaaga	ttggagagaa	aagcctgttt	180
accaaggagc	ttgaacatgc	cctggagaag	aatgaagtgg	acctggttgt	tcactccttg	240
aaggacctgc	ccactgtgct	tctctctggc	ttcaccatcg	gagccatctg	caagcgggaa	300
aaccctcatg	atgctgttgt	ctttcaccca	aaatttggtg	ggaagaccct	agaaaccctg	360
ccagagaaga	gtgtggtggg	aaccagctcc	ctgcgaagag	cagcccagct	gcagagaaag	420
ttcccgcatc	tggagtccag	gagtattcgg	ggaaacctca	acaccgggct	tcggaagctg	480
gacgagcagc	aggagtccag	tgccatcatc	ctggcaacag	ctggcctgca	gcgcatgggc	540
tggcacaacc	gggtggggca	gatcctgcac	cctgaggaat	gcatgtatgc	tgtgggccag	600
ggggccttgg	gcgtggaagt	gcgagccaag	gaccaggaca	tcttggatct	ggtgggtgtg	660
ctgcacgata	ccgagactct	gcttcgctgc	atcgctgaaa	gggccttcc	gaggcacctg	720
gaaggaggct	gcagtgtgcc	agtagccgtg	catacagcta	tgaaggatgg	gcaactgtac	780
ctgactggag	gagtcctggag	tctagacggc	tcagatagca	tacaagagac	catgcaggcc	840
accatccatg	tccctacca	gcataagat	ggcctgagg	atgaccaca	gttggtaggc	900
atcactgctc	gtaacattcc	acgagggccc	cagttggctg	cccagaactt	gggcatcagc	960
ctggccaact	tgttgctgag	caaaggagcc	aaaaacatcc	tggatgttgc	acggcaattg	1020
aacgatgcc	attaa					1035

&lt;210&gt; 12

&lt;211&gt; 3988

&lt;212&gt; DNA

&lt;213&gt; Human tissue

&lt;400&gt; 12

cacctgacgc	gccctgtagc	ggcgcattaa	ggcggcgggg	tgtggtggtt	acgcgcagcg	60
tgaccgctac	acttgccagc	gccctagcgc	cgctcctttt	cgctttcttc	ccttcctttc	120
tcgccacgtt	cgccggcttt	ccccgtcaag	ctctaaatcg	ggggctccct	ttagggttcc	180
gatttagtgc	tttacggcac	ctcgacccca	aaaaacttga	ttagggtgat	ggttcacgta	240
gtggggccatc	gccctgatag	acggtttttc	gccctttgac	ggtggagtcc	acgttcttta	300
atagtggact	cttggttcaa	actggaacaa	cactcaaccc	tatctcggtc	tattcttttg	360
atttataagg	gattttgccc	atttcggcct	attggttaaa	aaatgagctg	atttaacaaa	420
aatttaaage	gaatttttaa	aaaatattaa	cgcttacaat	ttccatttgc	cattcagget	480
gcgcaactgt	tgggaagggc	gatcggtgcy	ggcctcttcg	ctattacgcc	agctggcgaa	540
agggggatgt	gctgcaaggc	gattaagtgg	ggtaacgcca	gggttttccc	agtcacgacg	600
ttgtaaaacg	acggccagtg	aattgtaata	cgactcacta	tagggcgaa	tgggtaccgg	660
gccccccctc	gaggctgacg	gtatcgataa	gcttattaat	gggcatcggt	caattgccgt	720
gcaacatcca	ggatgttttt	ggctcctttg	ctcagcaaca	agttggccag	gctgatgcc	780
aagttctggg	cagccaactg	gggcctctcg	ggaatgttac	gagcagtgat	gcctaccaac	840
tgtgggtcat	cctcagggcc	atcttcatgc	tgggcaggga	catggatggt	agcctgcatg	900

gtctcttcta	tgctatctga	gccgtctaga	ctccagactc	ctccagtcag	gtacagttgc	960
ccatccttca	tagctgtatg	cacggctact	ggcacactgc	agcctccttc	caggtgcctc	1020
aggaaggccc	tttcagcgat	gcagcgaagc	agagtctcgg	gatcgtgcag	cacacccacc	1080
agatccaaga	tgtcctggtc	cttggctcgc	acttccacgc	ccaaggcccc	ctggcccaca	1140
gcatacatgc	attcctcagg	gtgcaggatc	tgcccaaccc	ggttgtgcca	gcccattgcg	1200
tgcaggccag	ctgttgccag	gatgatggca	ctgaactcct	gctgctcgtc	cagcttccga	1260
agccgggtgt	tgaggtttcc	ccgaatactc	ctgaactcca	gatgcgggaa	ctttctctgc	1320
agctgggctg	ctcttcgcag	ggagctgggt	cccaccacac	tcttctctgg	cagggtttct	1380
agggtcttcc	caacaaatth	tgggtgaaag	acaacagcat	catgagggtt	ttcccgttg	1440
cagatggctc	cgatggtgaa	gccaggagga	agcacagtgg	gcaggtcctt	caaggagtga	1500
acaaccaggt	ccacttcatt	cttctccagg	gcattgtcaa	gtccttgggt	aaacaggctt	1560
ttctctccaa	tcttagagag	tgcagtatca	agaatcttgt	cccctgtggg	ggacatagca	1620
atgatttcaa	actgcaggcc	agggtacgag	gctttcaatg	ttgccaccac	actgtccgtc	1680
tgatgagcag	caagctggct	cttgggggta	cccacgcgaa	tcactctcat	gaattcctgc	1740
agccccgggg	atccactagt	tctagagcgg	ccgccaccgc	ggtaggagtc	cagcttttgt	1800
tccctttagt	gaggggtaat	tctagagctt	gcgtaatcat	ggcatagct	gtttcctgtg	1860
tgaattgtt	atccgctcac	aattccacac	aacatacgag	ccggaagcat	aaagtgtaaa	1920
gcctgggggt	cctaattgag	gagctaactc	acattaattg	cgttgcgctc	actgcccgtc	1980
ttccagtcgg	gaaacctgtc	gtgccagctg	cattaatgaa	tcggccaacg	cgcggggaga	2040
ggcggtttgc	gtattgggag	ctcttccgct	tctcgtctca	ctgactcgct	gcgctcggtc	2100
gttcggctgc	ggcgagcggg	atcagctcac	tcaaaggcgg	taatacgggt	atccacagaa	2160
tcaggggata	acgcaggaaa	gaacatgtga	gcaaaaaggc	agcaaaaagg	caggaaccgt	2220
aaaaaaggcc	cgttgctggc	gtttttccat	aggctccgcc	cccctgacga	gcatacaaaa	2280
aatcgacgct	caagtcagag	gtggcgaaac	ccgacaggac	tataaagata	ccaggcggtt	2340
ccccctggaa	gctccctcgt	gcgctctcct	gttccgaccc	tgccgcttac	cggataccctg	2400
tccgccttcc	tcccttcggg	aagcgtggcg	ctttctcata	gctcacgctg	taggtatctc	2460
agttcggtgt	aggctcgttc	ctccaagctg	ggctgtgtgc	acgaaccccc	cgttcagccc	2520
gaccgctgcg	ccttatccgg	taactatcgt	cttgagtcca	acccggttaag	acacgactta	2580
tcgccactgg	cagcagccac	tggttaacagg	attagcagag	cgaggatagt	aggcggtgct	2640
acagagttct	tgaagtggtg	gcctaactac	ggctacacta	gaaggacagt	atttggtatc	2700
tgcgctctgc	tgaagccagt	taccttcgga	aaaagagttg	gtagctcttg	atccggcaaa	2760
caaaccaccg	ctggtagcgg	tgggtttttt	gtttgcaagc	agcagattac	gcgcagaaaa	2820
aaaggatctc	aagaagatcc	tttgatcttt	tctacggggg	ctgacgctca	gtggaacgaa	2880
aactcacgtt	aagggtatth	ggtcatgaga	ttatcaaaaa	ggatcttcac	ctagatcctt	2940
ttaaattaaa	aatgaagttt	taaatcaatc	taaagtatat	atgagtaaac	ttggtctgac	3000
agttaccaat	gcttaatcag	tgaggcacct	atctcagcga	tctgtctatt	tcgttcatcc	3060
atagttgcct	gactccccgt	cgtgtagata	actacgatac	gggaggggct	accatctggc	3120
cccagtgctg	caatgatacc	gcgagaccca	cgctcacccg	ctccagattt	atcagcaata	3180
aaccagccag	ccggaagggc	cgagcgcaga	agtggctcgt	caactttatc	cgctccatc	3240
cagtcattta	attggtggcg	ggaagctaga	gtaagtagtt	cgccagttaa	tagtttgccg	3300
aacgttggtg	ccattgctac	aggcatcggt	gtgtcacgct	cgctgtttgg	tatggcttca	3360
ttcagctccg	gttcccaacg	atcaaggcga	gttacatgat	cccccatggt	gtgcaaaaaa	3420
gcgggttagct	ccttcgggtc	tccgateggt	gtcagaagta	agttggccgc	agtgttatca	3480
ctcatgggtta	tggcagcact	gcataattct	cttactgtca	tgccatccgt	aagatgcttt	3540
tctgtgactg	gtgagtactc	aaccaagtca	ttctgagaat	agtgtatgcg	gcgaccgagt	3600
tgctcttgcc	cggcgtcaat	acgggataat	accgcgccac	atagcagaac	tttaaaagtg	3660
ctcatcattg	gaaaacgttc	ttcggggcga	aaactctcaa	ggatcttacc	gctgttgaga	3720
tccagttcga	tgtaacccac	tctgtcaccc	aactgatctt	cagcatcttt	tactttcacc	3780
agcgtttctg	ggtagcga	aacaggaagg	caaaatgcgg	caaaaaaggg	aataaggcg	3840
acacggaaat	ggtgaatact	catactcttc	ctttttcaat	attattgaag	catttatcag	3900
ggttattgtc	tcatgagcgg	atacatatth	gaatgtatth	agaaaaataa	acaaataggg	3960
gttccgcgca	catttccccg	aaaagtgc				3988

&lt;210&gt; 13

&lt;211&gt; 1260

&lt;212&gt; DNA

&lt;213&gt; Human tissue

&lt;400&gt; 13

cacaggaaac	agctatgacc	atgattacgc	caagctcgaa	attaaccctc	actaaaggga	60
acaaaagctg	gagctccacc	gcgggtggcg	ccgctctaga	actagtggat	ccccggggt	120

gcaggaattc	atgagagtga	ttcgcgtggg	tacccgcaag	agccagcttg	ctcgcataca	180
gacggacagt	gtggtggcaa	cattgaaagc	ctcgtaccct	ggcctgcagt	ttgaaatcat	240
tgctatgtcc	accacagggg	acaagattct	tgatactgca	ctctetaaga	ttggagagaa	300
aagcctgttt	accaaggagc	ttgaacatgc	cctggagaag	aatgaagtgg	acctggttgt	360
tcactccttg	aaggacctgc	ccactgtgct	tcctcctggc	ttcaccatcg	gagccatctg	420
caagcgggaa	aaccctcatg	atgctgttgt	ctttcaccca	aaatttggtg	ggaagacctt	480
agaaaccctg	ccagagaaga	gtgtggtggg	aaccagctcc	ctgcgaagag	cagcccagct	540
gcagagaaag	ttcccgcata	tggagtccag	gagtattcgg	ggaaacctca	acaccgggt	600
tcggaagctg	gacgagcagc	aggagtccag	tgccatcata	ctggcaacag	ctggcctgca	660
gcgcatgggc	tggcacaacc	gggttgggca	gatcctgcac	cctgaggaat	gcatgtatgc	720
tgtgggccag	ggggccttgg	gcgtggaagt	gcgagccaag	gaccaggaca	tcttggtatc	780
ggtgggtgtg	ctgcacgata	ccgagactct	gcttcgctgc	atcgctgaaa	gggccttcct	840
gaggcacctg	gaaggaggct	gcagtgtgcc	agtagccgtg	catacagcta	tgaaggatgg	900
<del>geaaetgtac</del>	<del>ctgactggag</del>	<del>gagtcctggag</del>	<del>tctagacggc</del>	<del>tcagatagca</del>	<del>tacaagagac</del>	960
catgcaggct	accatccatg	tccttgccca	gcatgaagat	ggccctgagg	atgaccacaca	1020
gttggtaggc	atcactgctc	gtaacattcc	acgagggccc	cagttggctg	cccagaactt	1080
gggcatcagc	ctggccaact	tgttgctgag	caaaggagcc	aaaaacatcc	tggatgttgc	1140
acggcaattg	aacgatgccc	attaataagc	ttatcgatac	cgtcgacctc	gagggggggc	1200
ccggtaccca	attcgcccta	tagtgagtcg	tattacaatt	cactggccgt	cgttttacaa	1260






Fig. 1

2/22<sup>4</sup>




Fig. 2

3/22<sup>4</sup>




Fig. 3

4/22




Fig. 4

5/22




Fig. 5

6/22<sup>4</sup>




Fig. 6

7/22




Fig. 7

8/22





Fig. 8



4  
9/22



**PLASMID FEATURES:**

Start	End	Name
33	1067	rhPBGD (open reading frame)
1593	2453	amp <sup>R</sup> (open reading frame)
5105	3915	tet <sup>R</sup> (open reading frame)
5376	1	ptac (promoter)
1075	1501	Term. (terminator region)
3214	2519	Rep. (replication region)
3214		Ori (origin of replication)

**Fig. 9**

10/22




Fig. 10

11/22<sup>4</sup>




Fig. 11

12/22




Fig. 12

13/22





Fig. 13

14/22




Chromatography on DEAE-Sephacrose FF (DEAE1). Peak a flow through the gel 40 mM KCl, Peak b 120 mM KCl Peak c 300 mM KCl Peak d NaOH 1 M.

Fig. 14

15/22


4



Chromatography on DEAE-Sephrose FF (DEAE2). Peak a flow through the gel 40 mM KCl, Peak b 150 mM KCl Peak c NaOH 1 M.

Fig. 15

4  
16/22




Chromatography on Butyl-Sepharose 4 FF. Peak a flow through the gel, Peak b water Peak c NaOH 1 M.

Fig. 16



17/22



**PLASMID FEATURES :**

Start	End	Name
7	1056	rhPBGD-His
1064	1490	terminator region
1582	2442	amp <sup>R</sup>
3820	3629	rop
5362	1490	pBR322
5544	1	ptac (promoter)

**Fig. 17**

18/22




Fig. 18

19/22<sup>4</sup>




Fig. 19

# DEAE Sepharose Column Fractions:




Fig. 20

21/22





Fig. 21

22/22<sup>4</sup>



1	Mark 12 molecular weight standards (Novex)
2	Cobalt load #1 (DEAE fractions 9 -> 12)
3	Flowthrough from cobalt load #1
4	50 mM imidazole eluate from cobalt run #1
5	Concatamerized nickel purified rhPBGD-His
6	Flowthrough from cobalt load #2
7	10 mM imidazole eluate from cobalt run #2
8	50 mM imidazole eluate from cobalt run #2

Fig. 22

23/24




Fig 23: PBGD activity related to protein concentration in HeLa cells.

Fig. 23

Fig 24/24




Figure 24: PBGD activity related to protein concentration in NIH 3T3 cells.